



九天化工集团有限公司
JIUTIAN CHEMICAL GROUP LIMITED

ANNUAL REPORT
2023



**ROOTED
IN STRENGTH**



OUR MISSION STATEMENT

To Be A Key Player In
China's Coal-Based Fine
Chemical Industry


This annual report has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this annual report, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.



CONTENTS

02	Corporate Profile	62	Consolidated Statement of Changes in Equity
04	Our Products	63	Statement of Changes in Equity
07	Chairman's Statement	64	Consolidated Statement of Cash Flows
10	主席致辞	66	Notes to the Financial Statements
11	Financial Highlights	115	Statistics of Shareholdings
12	Review of Operations	117	Appendix I in Relation to the Proposed Renewal of the Shareholders' General Mandate for Interested Person Transactions
14	Board of Directors	144	Appendix II in Relation to the Proposed Renewal of the Share Buyback Mandate
17	Key Management	167	Notice of the Nineteenth Annual General Meeting Proxy Form
18	Corporate Information		
19	Corporate Governance Report		
50	Directors' Statement		
55	Independent Auditor's Report		
59	Consolidated Statement of Profit or Loss and Other Comprehensive Income		
60	Statements of Financial Position		



CORPORATE PROFILE

A SPECIALIST IN FINE CHEMICAL INDUSTRY

Jiutian Chemical Group Limited (“Jiutian Chemical” or the “Group”), incorporated in Singapore on 30 November 2004, was listed on the mainboard of the Singapore Exchange Securities Trading Limited (“SGX-ST”) on 4 May 2006, and transferred to the Catalist of SGX-ST in 2016. We are engaged in the manufacturing and production of dimethylformamide (“DMF”), methylamine, sodium hydrosulfate and dimethylacetamide (DMAC). We are also involved in the processing and sale of consumable carbon dioxide.



CORPORATE PROFILE

We are located in Henan, with a population of 96 million, which together with surrounding provinces have a combined population of 450 million. Whilst economic development and industrialisation in China began on the eastern and southern coast, this process has begun to spread rapidly inland, including to Henan and its surrounding regions, where cost of labour, land and raw materials are significantly lower.

In addition, our location in China's Coal Belt allow us to enjoy a cost advantage over other PRC DMF producers due to our secure and low-cost access to the coal-based raw materials that are used in the manufacture of our products. Our production efficiency and cost-effective supply chain management strategy, which include direct piping-in of raw materials from our main supplier, has provided us a relative cost advantage against our competitors.

Henan Province is also on the Beijing-Guangzhou railway and its capital Zhengzhou, has one of Asia's largest railway stations and network. Zhengzhou has been developed into a logistics central station for cargo transportation. This will further reduce the transportation costs of our products. Our customer base in China consists of customers in Henan, the surrounding provinces adjacent to Henan, namely Hebei, Shaanxi, Shanxi, Hubei, Shandong, and Anhui, and provinces in the Yangtze Delta Region, namely, Jiangsu and Zhejiang.

The Group's wholly owned subsidiary company, Anyang Jiutian Fine Chemical Co., Ltd. ("Anyang Jiutian") is engaged in the manufacturing and production of DMF and methylamine. Anyang Jiutian has emerged as one of the world's largest manufacturers of DMF with a total annual capacity of 150,000 tons of DMF and methylamine.

The Group has a 49% equity interest in Anyang Jiulong Chemical Co., Ltd. ("Anyang Jiulong") with Henan's largest enterprise and one of China's most significant coal mining companies, Henan Energy and Chemical Industry Group Co., Ltd. ("HNEC"). To date, Anyang Jiulong has completed the construction of two 130 tons per hour steam boilers, two 10,000 tons methanol storage tanks, a 400 tons per hour distilled water station, two 25,000 kilo watts per hour power station and a 20,000 tons DMAC plant. The partnership with HNEC and investment in Anyang Jiulong will strengthen the integration of our operations and diversify our earnings base.

The Group's 74% owned associated company, Anyang Jiujiu Chemical Technology Co., Ltd. is undertaking the Project Sodium Hydrosulfite (the "Project"). The facilities in the Project will enable us to produce 140,000 tons of sodium hydrosulfite annually and together with the ancillary facilities, 45,000 tons of sodium formate, 45,000 tons of sodium metabisulfite and 45,000 tons of liquid sulphur dioxide which are main feedstock of sodium hydrosulfite. This will make us the most integrated and the second largest manufacturer of sodium hydrosulfite in China.



OUR PRODUCTS

DIMETHYLFORMAMIDE (DMF)



DMF, which is our main product, uses methylamine (another of the Group's secondary products) as a feedstock. DMF has a diversified range of applications. It is in turn used as a feedstock in the production of Polyurethane ("PU"), a key component in the manufacture of consumer goods such as leather products and shoe soles, as well as feedstock in the production for pharmaceutical and agro chemical products. DMF is also a universal industrial solvent that can be used as an absorbing agent mainly in electronics, acrylic fibre and pharmaceutical products.

DMF PRODUCTION PROCESSES

We have a fully integrated production process in our 150,000 tons DMF plant where methylamine manufactured is sold independently as well as used as feedstock in DMF production. This flow-through production process provides operational flexibility, as it allows management to change product mix to suit market conditions. We consistently optimise our cost structure through various measures including minimising transportation costs and ensuring regular supply of our high quality products to the customers.

PU - DMF AS A KEY FEEDSTOCK

One of the most important applications of DMF is its use as a feedstock in the production of PU, an important chemical used in a wide range of consumer related applications. PU products can be found everywhere and is one of the most versatile materials today that offers the elasticity of rubber combined with the toughness and durability of metal. PU absorbs weight, improves durability, enhances insulation in the products and provides added comfort and resiliency.



OUR PRODUCTS

KEY USES OF PU INCLUDE:

CONSUMER GOODS

PU is often used for its insulation and cushioning capabilities. Over three quarters of the global consumption of PU products is in the form of foams with flexible and rigid types being roughly equal in market size. Flexible foams are used in the upholstery of commercial and domestic furniture as well as in automobiles, while rigid foams are found on the insides of metal and plastic walls of most refrigerators and freezers; or behind paper, metals and other surface materials in the case of thermal insulation panels in the construction sector.

SHOE SOLE

DMF is commonly used in manufacturing extremely versatile PU elastomers. With the properties of high levels of elasticity, tensile strength, elongation and shock absorbing abilities, it can be used in manufacturing shoe soles.

PU LEATHER

DMF is also widely used in the manufacture of PU leather, or synthetic leather. Due to its lightweight, classy-looking and comfortable properties, PU leather is easily maintained, water-resistant, abrasion-resistant and can be dry-cleaned. Synthetic leather is a lower cost alternative to real leather that can be used in manufacturing sofas, handbags, shoes and belts.

DMF AS UNIVERSAL SOLVENTS

PETROCHEMICAL

DMF can be used as an industrial solvent to produce petrochemical products, including butadiene. When combined with other chemicals, end products include synthetic rubber, nylon and automobile tyres. With the surging consumer and industrial demand for petrochemical products in China, large-scale increases in production capacity of petrochemical products are expected in the coming decade.

ACRYLIC FIBRE/NATURAL LEATHER

DMF is also used as an industrial solvent to produce acrylic fibre. Driven by the global fashion market, acrylic fibre has become a lower cost alternative to cashmere due to its similar soft fabric feeling. It is extensively used in knitwear, carpet, toys, blanket and apparel industries. DMF is also used to remove hair from natural leather.

PHARMACEUTICAL

In China, DMF is used as an industrial solvent to produce antibiotics and other type of consumable drugs - new uses of DMF as an ingredient of pharmaceutical products are being developed constantly.

ELECTRONICS

DMF is also used to dissolve the catalyst in the epoxy laminated printed circuit boards ("PCB") in the electronics industry. Driven by the influx of investment in the electronics sector, along with the rapid development of the communications industry, China is amongst the world's largest producer of PCB boards, thus demand for DMF in China is expected to remain significant as well.

DMF AS OTHER CHEMICAL FEEDSTOCK

AGROCHEMICAL

DMF and methylamine, used as chemical feedstock to produce agrochemicals such as fertilisers, soil conditioners, pesticides and antibiotics, are critical in raising crops for food. The PRC Government has pledged to improve the living standards of farmers by increasing local agricultural productivity and new investments in the countryside. The use of agrochemicals in Henan Province, which has one of China's largest agricultural sectors, is expected to increase in the coming decades due to this initiative.



OUR PRODUCTS

METHYLAMINE

Methylamine is an important chemical feedstock in the organic chemical industry. It is widely used in various areas, such as agricultural chemicals, medicine, fuel, synthetic resin, leather making, production of the solvent used for chemical fibres, activating agents and photography. Methylamine is produced by the reaction of methanol with ammonia. Most of the methylamine produced by the Group is used as a feedstock for the production of DMF.



CONSUMABLE CARBON DIOXIDE

Carbon dioxide can be broadly classified as industrial carbon dioxide and consumable carbon dioxide. The Group's focus will be the higher margin consumable carbon dioxide due to the increasing demand for the product for use in aerated beverages, tobacco and preservation of vegetables.

SODIUM HYDROSULFITE

Sodium hydrosulfite is a white crystalline powder with a weak sulfurous odor. Its low toxicity makes it suitable for a wide variety of uses. These include water treatment, gas purification, cleaning, stripping, and the industrial processing of textiles, leather, foods, polymers, photography and others.



CHAIRMAN'S STATEMENT



XU AIJUN

Non-Executive and Non-Independent Chairman

“ WE HAVE OPTIMISED OUR OPERATIONS, STREAMLINED PROCESSES, AND ENHANCED COST-EFFICIENCY MEASURES TO MITIGATE THE IMPACT OF ADVERSE MARKET CONDITIONS. DESPITE THESE MEASURES, THE GROUP SUFFERED A NET LOSS OF RMB346.7 MILLION IN FY2023, ENDING OUR THREE CONSECUTIVE YEARS OF RECORD PROFITABILITY FROM FY2020. ”



CHAIRMAN'S STATEMENT



DEAR SHAREHOLDERS,

On behalf of the Board of Directors, I am pleased to present to you the Group's performance for the financial year ended 31 December 2023 ("FY2023").

The past year has been marked by a confluence of unprecedented hurdles, testing our resilience and fortitude like never before. Despite our best efforts, we have experienced significant setbacks, culminating in a substantial financial loss.

The operating environment we faced was undeniably tough, characterised by a combination of economic headwinds, global uncertainties, and dampened demand in China. The volatility in our product prices, intensified competition, and geopolitical tensions further exacerbated our challenges.

In response to these challenges, we have taken decisive actions to navigate through these turbulent waters. We have optimised our operations, streamlined processes, and enhanced cost-efficiency measures to mitigate the impact of adverse market conditions. Despite these measures, the Group suffered a net loss of RMB346.7 million in FY2023, ending our three consecutive years of record profitability from FY2020.

This sharp turn in performance was mainly due to a significant downward correction of prices of our main products namely Dimethylformamide ("DMF") and Methylamine, with average selling prices declining 54% and 58% respectively in FY2023 as compared to the prices in FY2022. These were triggered by a twin impact of industry-wide softening of demand due to slower than expected economic recovery in China, as well as the addition of new capacity by our new main competitor, Jiangxi Xinlianxin Chemical Industry Co., Ltd., which has a total DMF capacity of 200,000 tonnes per year, as compared to the Group's 150,000 tonnes per year. This resulted in a 75% drop in our revenue to RMB598.6 million in FY2023.

ROOTED IN STRENGTH

While we acknowledge the magnitude of the loss incurred, we are steadfast in our belief that adversity breeds opportunity. We are leveraging this experience as a catalyst for transformation and renewal, re-evaluating our strategies, and realigning our priorities to emerge stronger and more resilient. Our dedication to innovation, product excellence, and customer satisfaction remains unwavering, driving us forward on the path to recovery and growth.

CHAIRMAN'S STATEMENT

As part of the Group's corporate strategy to its road to recovery, we seek to diversify and expand our existing core business to include the manufacturing, production and sale of synthetic ammonia and urea, as well as explore strategic investments to construct new production facilities to carry out these activities.

We believe that this diversification of our product portfolio can contribute positively to the Group's new revenue and earning streams, which will in turn provide long-term growth and enhance shareholders' value. Through this diversification, the Group will not only be able to better control prices of our raw materials, but also sell any excess synthetic ammonia manufactured that it does not require for its own manufacturing processes, thereby elevating our synergy and growth prospects, while mitigating our risks for price fluctuations.

With this diversification strategy, the Group is embarking on the Synthetic Ammonia Project and the lease of the Urea Production Facility previously owned by Anyang Chemical Industry Group Co., Ltd. in Henan, China. We believe that the manufacturing, production and sale of synthetic ammonia and urea would be of merit to the Group and presents future business opportunities.

In addition, it will also be complementary to the Group's existing business and allows us to reduce our reliance on suppliers for synthetic ammonia and maintain a greater degree of control over the quality of the synthetic ammonia.

POISED FOR GROWTH

As we look to the future, we remain cautiously optimistic, recognising that challenges may persist in the near term. However, we are confident in the underlying strength of our business, the dedication of our employees, and the enduring support of our strategic partners and loyal customers.

We will continue to monitor the market condition closely and adapt our business strategies to cater to the evolving business environment. These include constantly adjusting our production volume according to market dynamics to achieve optimal financial performance, while strategically supplying to long-term customers and defending our market share.

Through embarking on the Synthetic Ammonia Project, we can become a more fully integrated producer of DMF and Methylamine, and go into the production of urea for wider product offering and a more diversified earning base. Correspondingly, with our new 100,000-tonne Methylamine plant adjacent to our current 120,000-tonne Methylamine/DMF facility ready for commercial production in the upcoming months, we are poised for recovery and sustainable growth.

Additionally, we will remain committed to upholding the standards of safety, environmental sustainability, and corporate responsibility, despite the uphill obstacles in our path. The Group will continue to stay prudent and vigilant, assessing and considering the necessary financing and technical expertise before engaging in future investments and acquisitions.

IN APPRECIATION

In closing, I would like to take this opportunity to express my heartfelt appreciation for Mr Han Lianguo for his invaluable contributions and stewardship during his tenure as the Non-Executive and Non-Independent Chairman of the Group. At the same time, our Independent Directors namely Mr Chan Kam Loon, Mr Wu Yu Liang, Mr Gao Guoan and Mr Chen Mingjin will also be stepping down from the Board at the conclusion of the Annual General Meeting ("AGM") to facilitate Board renewal as they have served as Directors for more than 9 years and pursuant to Listing Rule 210(5)(d)(iv), they will not be considered independent. I would like to extend my deepest gratitude for their commitment and contributions to the Group and wish them all the best for their future endeavours.

Last but not least, my sincere gratitude also goes to our shareholders, employees, customers, and partners for their continued support and commitment during these trying times. Your resilience, dedication, and perseverance will continue to inspire us to face the challenges ahead with confidence and determination.

XU AIJUN

Non-Executive and Non-Independent Chairman

主席致辞

尊敬的股东，

我很高兴代表董事会向您介绍集团截至2023年12月31日止的财政年度（“2023财年”）的业绩。

过去的一年充满了前所未有的障碍，前所未有地考验着我们的韧性和毅力。尽管我们尽了最大努力，但我们还是经历了重大挫折，最终造成了巨大的财务损失。

无可否认，我们面临的经营环境非常艰难，经济逆风、全球不确定性以及中国需求下降等因素综合作用。产品价格波动、竞争加剧以及地缘政治紧张局势进一步加剧了我们的挑战。

为了应对这些挑战，我们采取了果断行动，渡过这片汹涌的水域。我们优化了运营、简化了流程并增强了成本效益措施，以减轻不利市场条件的影响。尽管采取了这些措施，集团在2023财年仍造成人民币3.467亿元的净亏损，结束了自2020财年以来连续三年创纪录的盈利水平。业绩大幅转变主要是由于我们的主要产品二甲基甲酰胺（“DMF”）和甲胺的价格大幅下调，2023财年平均售价较2022财年分别下降54%和58%。这是由于中国经济复苏慢于预期导致全行业需求疲软以及我们的新主要竞争对手江西连心化工有限公司新增产能（DMF产能为每年20万吨，而本集团的年产能为15万吨）的双重影响引发的。这导致我们2023财年的收入下降75%至人民币5.99亿元。

植根于实力

虽然我们承认损失的严重性，但我们坚信逆境孕育机遇。我们正在利用这一经验作为转型和更新的催化剂，重新评估我们的战略，并重新调整我们的优先事项，以变得更强、更有弹性。我们对创新、卓越产品和客户满意度的奉献始终坚定不移，推动我们在复苏和增长的道路上前进。

作为集团复苏之路企业战略的一部分，我们寻求多元化和扩展现有核心业务，将合成氨和尿素的制造、生产和销售纳入其中，并探索战略投资建设新生产设施，以实现企业盈利。

我们相信，产品组合的多元化可以为集团的新收入和盈利来源做出积极贡献，从而带来长期增长并提高股东价值。通过这种多元化，集团不仅能够更好地控制原材料价格，还能出售其自身生产过程中多余的合成氨，从而提高我们的协同效应和增长前景，同时减轻我们的成本。价格波动的风险。

凭借这一多元化战略，本集团正着手建设合成氨项目以及租赁原安阳化工集团有限公司位于中国河南的尿素生产设施。我们相信，合成氨及尿素的制造、生产及销售将为本集团带来优势并带来未来商机。

此外，这亦将与本集团现有业务形成互补，让我们减少对合成氨供应商的依赖，并保持对合成氨质量的更大程度的控制，以保证我们产品DMF/甲胺的质量，提高产品竞争力。



蓄势待发

展望未来，我们保持谨慎乐观，认识到挑战可能在短期内持续存在。我们对我们的业务的潜在实力、员工的奉献精神以及战略合作伙伴和忠实客户的持久支持充满信心。

我们将继续密切关注市场状况并调整我们的业务策略以适应不断变化的业务环境。其中包括根据市场动态不断调整我们的产量，以实现最佳的财务业绩，同时战略性地向长期客户供货并捍卫我们的市场份额。

通过开展合成氨项目，我们可以成为更全面一体化的DMF和甲胺生产商，并进入尿素生产，以提供更广泛的产品范围和更多元化的盈利基础。相应地，我们新的10万吨甲胺工厂毗邻我们目前的12万吨甲胺/DMF设施，准备在未来几个月进行商业生产，我们已做好复苏和可持续发展的准备。

此外，尽管我们的道路上存在艰巨的障碍，我们仍将继续致力于维护安全、环境可持续性发展和企业责任的标准。本集团将继续保持审慎和警惕，在进行未来投资和收购之前评估和考虑必要的融资和技术专长。

感谢

最后，我谨借此机会对韩联合国先生在担任本集团非执行和非独立主席期间做出的宝贵贡献和领导表示感谢。与此同时，我们的独立董事陈锦纶先生、吴幼良先生、高国安先生和陈明今先生也将在年度股东大会结束时辞去董事会职务，以方便董事会变更，主要是由于他们担任董事超过9年，并且根据上市规则第210(5)(d)(iv)条，他们将不被视为独立。我谨对他们对集团的承诺和贡献表示最深切的感谢，并祝愿他们在未来的工作中一切顺利。


最后但同样重要的一点是，我真诚感谢我们的股东、员工、客户和合作伙伴在这些艰难时期的持续支持和承诺。你们的韧性、奉献精神和毅力将继续激励我们充满信心和决心地面对未来的挑战。

徐爱军
非执行及非独立主席


FINANCIAL HIGHLIGHTS

	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue (RMB'000)	598,563	2,434,843	2,173,310	1,146,253	1,054,460
Gross (Loss)/Profit (RMB'000)	(260,178)	708,413	675,621	274,770	74,889
(Loss)/Profit Attributable to Equity Holders (RMB'000)	(344,643)	490,497	324,901	173,685	(248,418)
(Loss)/Earnings per share (RMB cents)	(17.33)	24.67	16.34	9.39	(13.66)


REVENUE (RMB'000)




GROSS (LOSS)/PROFIT (RMB'000)



(LOSS)/PROFIT ATTRIBUTABLE TO EQUITY HOLDERS (RMB'000)



(LOSS)/EARNINGS PER SHARE RMB Cents



REVIEW OF OPERATIONS



THE YEAR IN REVIEW

FY2023 has been a year fraught with intense challenges. The overall business environment was clouded by impact from trade tensions, geopolitical conflicts and other uncertainties. Burdened by the protracted property crisis, weak consumer and business confidence, mounting local government debts, and weak global growth, the China's economy also experienced slower than expected recovery from the post-COVID pandemic, dampening demand within the country.

Adding to the woes, there was a significant downward correction of product prices across our main products, namely Dimethylformamide ("DMF") and Methylamine, resulting in average selling prices of DMF and Methylamine declining 54% and 58% from prices in FY2022, to RMB5,153 per tonne and RMB6,497 per tonne respectively.

The decline in prices started in the fourth quarter ended 31 December 2022 ("4Q2022"), and continued to worsen throughout FY2023. Furthermore, the twin impact of industry-wide softening of demand due to slow economic recovery in China, coupled with the addition of new capacity by our new main competitor, Jiangxi Xinlianxin Chemical Industry Co., Ltd., which has a total DMF capacity of 200,000 tonne per year, as compared to Jiutian's 150,000 tonnes per year, has inevitably contributed to significantly lower average selling prices.

Against the backdrop of these difficult market conditions, the Group had adjusted our production

volumes and balancing production mix to minimise the losses from low selling prices so as to achieve optimal financial performance, while continuing to supply strategically to our long-term customers to defend our market share. This had resulted in 55% and 36% lower sales volumes in our DMF and Methylamine in FY2023, as compared to that for FY2022 respectively, triggering a 75% drop in our overall revenue from RMB2.4 billion in FY2022 to RMB598.6 million in FY2023.

Year on year, the capacity utilisation of our DMF plant decreased from 67% to 32% whilst capacity utilisation rate of our Methylamine plant decreased from full capacity to 64%.

Consequently, the Group suffered a gross loss of RMB260.2 million in FY2023, as compared to a gross profit of RMB708.4 million in FY2022.

Other income increased to RMB24.2 million in FY2023 from RMB22.4 million in the preceding year, mainly due to gain on liquidation of subsidiaries arising from the liquidation of Henan Herunsheng Isotope Technology Co., Ltd. ("Herunsheng"), a 45% indirectly-owned subsidiary of the Group and partially offset by loss on liquidation of Changzhou Jiutian Xiean Chemical Co., Ltd. ("Changzhou Jiutian"), a 80% directly-owned subsidiary of the Group which took place in 4Q2023. Share of results of associated companies was attributable to the Group's 49% associated company, Anyang Jiulong Chemical Co., Ltd. and its subsidiary, Anyang Jiujiu Chemical Technology Co., Ltd. (together "Anyang Jiulong

REVIEW OF OPERATIONS

Group"). Share of losses in FY2023 was mainly due to provision of impairment loss for Anyang Jiulong Group's property, plant and equipment.

In our best efforts to contain costs, our operating expenses decreased significantly with a 39% decline in distribution expenses to RMB11.5 million in FY2023 as compared to RMB18.7 million, while administrative expenses fell by 15% to RMB37.6 million in FY2023 from RMB44.0 million in FY2022. Other expenses of RMB7.0 million was incurred due to loss on disposal of property, plant and equipment and inventories written off.

Impairment loss on financial assets increased to RMB25.8 million in FY2023 from RMB5.1 million in FY2022, as there was a further provision of impairment loss for receivable from associated company, Anyang Jiujiu Chemical Technology Co., Ltd. of the above amount.

The marginal increase in finance costs to RMB2.6 million in FY2023 from RMB2.5 million in FY2022 was mainly due to higher bank borrowings during the year under review.

As a result of the above, the Group recorded a net loss of RMB346.7 million attributable to Shareholders for FY2023.

STATEMENT OF FINANCIAL POSITION

As at 31 December 2023, the Group's non-current assets increased to RMB365.9 million from RMB287.4 million as at 31 December 2022, mainly due to the acquisition of property, plant and equipment related to the construction of the new 100,000-tonne Methylamine plant which was partially offset by a decrease in investment in associated companies due to the share of loss from associated companies in FY2023, as well as the further impairment on financial assets and hence reducing the other receivables.

Meanwhile, the Group's current assets decreased to RMB923.2 million as at 31 December 2023 from RMB1.7 billion as at 31 December 2022, largely attributed to a decrease in cash and cash equivalents mainly due to cash used in operating activities and investing activities as presented in the statement of cash flows below, a decrease in trade and other receivables as lower revenue was generated during the financial year, and a decrease in inventories due to fewer inventories kept as at 31 December 2023.

Looking at the other side, the Group's current liabilities also decreased in FY2023 to RMB457.2 million as at 31 December 2023 from RMB706.0 million as at

31 December 2022. This was the result of a decrease in gross trade and other payables due to fewer repayment to suppliers using trade bills received from customers with longer credit repayment period, a decrease in contract liabilities mainly due to decrease in selling price in 4Q2023 and fewer sales orders received for 1Q2024, and an absence of income tax payables due to net losses generated in the financial year. These were partially offset by increase in bank borrowings due to increase in bill payables to banks as more bill payables to bank was issued as repayment to trade bill payables and a reclassification of bank borrowings of RMB49.94 million from non-current liabilities to current liabilities.

Non-current liabilities increased to RMB66.0 million as at 31 December 2023 as compared to RMB58.7 million as at 31 December 2022, largely attributed to an increase in bank borrowings due to a drawdown of RMB66.01 million in related to the construction of new 100,000-tonne Methylamine plant and partially offset by a reclassification of bank borrowings of RMB49.9 million from non-current liabilities to current liabilities.

WORKING CAPITAL

As at 31 December 2023, the Group maintained a net current assets position of RMB466.0 million. We will remain vigilant and strengthen our cost optimisation strategy, while constantly looking out for opportunities. With our expansion plans in the pipeline, we believe that we can continue to reap greater benefits and value for all stakeholders in time to come.

STATEMENT OF CASH FLOWS

In FY2023, net cash used in operating activities amounted to RMB385.7 million mainly due to net losses generated in the financial year of RMB346.9 million.

Net cash used in investing activities in FY2023 was RMB125.7 million, mainly due to purchase of property, plant and equipment related to the construction of the new 100,000-tonne Methylamine plant of RMB187.3 million.

Net cash of RMB0.7 million was used in financing activities in FY2023, mainly due to dividend paid of RMB 111.9 million and repayment of bill payables to banks of RMB 226.2 million, partially offset by drawdown of bank borrowings of RMB66.0 million and drawdown of bill payables to bank of RMB301.4million.

BOARD OF DIRECTORS



MR XU AIJUN

*Non-Executive and
Non-Independent Chairman*

Mr Xu Aijun was appointed as the Non-Executive and Non-Independent Chairman of the Group on 29 February 2024. Mr Xu graduated from the China University of Petroleum with a bachelor's degree in Chemical engineering and technology. He is currently also the Chairman of Anyang Chemical Industry Group Co., Ltd. ("Anhua"). Prior to these appointments, Mr Xu also held various managerial and supervisory positions in Anhua across a span of over 20 years.



MR LEE CHEE SENG

Executive Director

Mr Lee Chee Seng, Executive Director, is responsible for corporate finance and strategic planning for the Group. Mr Lee graduated from the National University of Singapore obtaining First Class Honours degree in Bachelor of Civil Engineering in 1987. Upon graduation, Mr Lee joined the Monetary Authority of Singapore as a central banking officer. Mr Lee has been a qualified Chartered Financial Analyst (CFA) since 1990. Mr Lee joined Morgan Grenfell (Asia) Limited in 1988 and was promoted in 1993 to become the Managing Director of Deutsche Morgan Grenfell (Malaysia) to run its investment banking business in Malaysia. Mr Lee returned to Singapore in 1994 to become Head of Corporate Finance for South-East Asia for Deutsche Morgan Grenfell Asia. Between April 2001 and November 2003, Mr Lee served as non-executive director of Malaysian Plantations Berhad, a Malaysian holding company for Alliance Bank Malaysia, and as exco member on the boards of its banking and finance subsidiaries.



MR WU YU LIANG

*Non-Executive and
Lead Independent Director*

Mr Wu Yu Liang is an Independent Director. On 28 February 2008, Mr Wu was appointed by the Board as the Lead Independent Director of the Company. He graduated in 1985 from the National University of Singapore with a degree in Bachelor of Laws with Second Class Honours (Upper Division). He was admitted as an Advocate and Solicitor of the Supreme Court of Singapore in 1986. Mr Wu is currently the Managing Director of the Law Corporation WU LLC. His main areas of practice are corporate and commercial laws as well as litigation.

BOARD OF DIRECTORS



MR CHAN KAM LOON

*Non-Executive and
Independent Director*

Mr Chan Kam Loon is an Independent Director. He holds a degree in Accounting and Finance from the London School of Economics and Political Science and is a Chartered Accountant with the Institute of Chartered Accountants in England and Wales. Between 1990 and 1996, Mr Chan worked at Morgan Grenfell Asia Ltd. and HG Asia Securities Ltd. in their corporate finance teams. From 1996 to 2001, Mr Chan was a Director of Investments at a private equity fund, Suez Asia Holdings Pte Ltd. From July 2001 to July 2004, Mr Chan headed up the Listings Function within the Markets Group at the Singapore Exchange Securities Trading Limited.



MR GAO GUOAN

*Non-Executive and
Independent Director*

Mr Gao Guoan was appointed as a Non-Executive and Independent Director on 26 April 2013. Mr Gao was the secretary of the Party Committee of Henan Coal Mine Design Institute and the secretary of Party Committee and director of Henan Coal Industrial Department (Bureau). He also served as a member of Henan CPPCC Standing Committee and the deputy head of its Human Resources and Environment Committee. Mr Gao was also the president of Henan Province Coal Industrial Association.



MR SONG FUDONG

*Non-Executive and
Non-Independent Director*

Mr Song Fudong was appointed as the Non-Executive and Non-Independent Director of the Group on 23 June 2022. Mr Song graduated from the Henan University with a Bachelor's Degree in Economics. He is currently also the Chief Financial Officer of Anyang Chemical Industry Group Co., Ltd. Prior to these appointments, Mr Song also held various managerial and supervisory positions in Anyang Chemical Industry Group Co., Ltd. across a span of over 30 years.



BOARD OF DIRECTORS



MR WANG GANG

*Non-Executive and
Non-Independent Director*

Mr Wang Gang was appointed as a Non-Executive and Non-Independent Director on 1 February 2018. Mr Wang specialises in accounting and has a Bachelor Degree in Accounting from the Henan University of Finance and Economics. He is currently the Deputy General Manager of Financial Business Department of HNEC. Prior to his current appointment in HNEC, Mr Wang was the Chief Financial Officer of Anyang Chemical Industry Group Co Ltd. from July 2017 to June 2021 and Department Head of Finance of Henan Province Gas (Group) Co., Ltd. from December 2012 to December 2016.



MR CHEN MINGJIN

*Non-Executive and
Independent Director*

Mr Chen Mingjin was appointed as a Non-Executive and Independent Director on 1 February 2018. Mr Chen graduated from Northeast Forestry University of China with a Bachelor Degree in Forestry Economy. Subsequently, he obtained a Master's Degree in Economic Management from Heilongjiang Academy of Social Sciences. Between 2001 and 2012, he was the Vice Mayor of Anyang City, Henan Province. He also served as Deputy Secretary of the municipal Government and Municipal Standing Committee.



MR KOH ENG KHENG VICTOR

*Non-Executive and
Independent Director*

Mr Koh Eng Kheng Victor was appointed as a Non-Executive and Independent Director on 1 February 2018. Mr Koh graduated from the National University of Singapore in 1986 with a Bachelor of Business Administration (Honours). He was awarded the designation of Chartered Financial Analyst in 1992, and is a member of CFA Society Singapore. Mr Koh has over 26 years of experience with Asia ex-Japan equity markets, principally in the area of asset allocation and portfolio management. He was 18 years with AIG Global Investment Corporation (Singapore) Ltd. (subsequently renamed PineBridge Investments Singapore Limited) where he served as Managing Director of Asia ex-Japan equities and subsequently as Chairman and Chief Executive Officer of the company. Mr Koh had also previously served as a member of Commercial Affairs Department Panel of Experts on Security offences.

KEY MANAGEMENT

MR WEI HONGGUANG

Acting CEO and General Manager of Subsidiaries

Mr Wei Hongguang graduated from Anyang Institute of Technology with a Bachelor Degree in Chemical Engineering and Technology. Mr Wei was appointed as the General Manager of the China Subsidiaries in May 2017. He is responsible for taking care of the daily operations of the subsidiaries. Prior to joining the Group, Mr Wei was a Manager in Anyang Chemical Industry Group Co., Ltd., where he held a number of supervisor and manager positions spanning over 10 years.

MR NG HAN KIAT

Group Financial Controller

Mr Ng Han Kiat is responsible for the accounting, financial and taxation matters of the Jiutian Chemical Group Limited. He is experienced in the accounting and finance industries and has substantially been involved in public and private company audits whilst working at accounting and business advisory firms in Singapore.

MR HE QINGWU

Head of Marketing

Mr He Qingwu is responsible for directing market research, planning, market analysis and forecast, monitoring national and international development and changes in the product market, formulating marketing strategy and brand strategy. Mr He joined the group in August 2017 as Deputy Head of Marketing and was promoted to the current position in July 2019. Mr He obtained a Bachelor Degree from Xi'an Jiaotong University.

MR XING LULIANG

Vice General Manager of Subsidiaries - Production and Technology

Mr Xing Luliang is responsible for the management and deployment of our production personnel, setting of the Group's technical targets, ensuring stable production and energy conservation. Mr Xing joined Anyang Jiutian in December 2002. Mr Xing graduated from Anyang Institute of Technology with a Bachelor Degree in Chemical Engineering and Technology.

MR ZONG HU

Financial Controller of Subsidiaries

Mr Zong Hu graduated from Henan University of Economics and Law with a Bachelor of Business Administration. He worked in the Finance Department of Anhua from 2006 to 2020 and participated in the production costing, project financial management and manages the company's finances. Mr Zong joined Anyang Jiutian in 2021 as the financial controller and is responsible for the financial management, financial budget, financial statements and taxation of the subsidiaries in China.

MR LI NAN

*Vice General Manager of Subsidiaries
- Safety and Environmental Protection*

Mr Li Nan is responsible for safety, environmental protection, worker's health, fire protection, security and other related work. Mr Li joined Anyang Jiutian in December 2002. Mr Li graduated from Anyang Institute of Technology with a Bachelor Degree in Chemical Engineering and Technology.

MR QI HONGLIANG

*Vice General Manager of Subsidiaries
- Equipment Management*

Mr Qi Hongliang is responsible for equipment management and other related work. Mr Qi graduated from Anyang Institute of Technology with a Bachelor Degree in Mechanical Design, Manufacturing and Automation.

CORPORATE INFORMATION

BOARD OF DIRECTORS

Xu Aijun
Lee Chee Seng
Wu Yu Liang
Chan Kam Loon
Gao Guoan
Song Fudong
Wang Gang
Chen Mingjin
Koh Eng Kheng Victor

AUDIT COMMITTEE

Chan Kam Loon (Chairman)
Wu Yu Liang
Koh Eng Kheng Victor

NOMINATING COMMITTEE

Gao Guoan (Chairman)
Koh Eng Kheng Victor
Xu Aijun

REMUNERATION COMMITTEE

Wu Yu Liang (Chairman)
Chan Kam Loon
Gao Guoan

COMPANY SECRETARIES

Lee Wei Hsiung, ACIS
Pan Mi Keay, ACIS

REGISTERED OFFICE

9 Raffles Place
#26-01 Republic Plaza
Singapore 048619
Telephone number: 6536 3738
Fax number: 6536 3898

COMPANY REGISTRATION NUMBER

200415416H

PRINCIPAL PLACE OF BUSINESS ADDRESS

350 Orchard Road
#21-03 Shaw House
Singapore 238868
Telephone number: 6536 3738
Fax number: 6536 3898

Zhangwu Street, Long An District
Anyang City, Henan Province
People's Republic of China

SHARE REGISTRAR

Tricor Barbinder Share Registration Services
(a business division of Tricor Singapore Pte. Ltd.)
9 Raffles Place
#26-01 Republic Plaza
Singapore 048619

PRINCIPAL BANKER

Industrial and Commercial Bank of China
Anhua Branch
Zhangwu Street, Long An District,
Anyang City, Henan Province,
People's Republic of China

INDEPENDENT AUDITOR

Baker Tilly TFW LLP
Chartered Accountants of Singapore
600 North Bridge Road
#05-01 Parkview Square
Singapore 188778
Partner-in-charge: Mr Lim Kok Heng
Appointed since financial year ended 31 December 2023

CONTINUING SPONSOR

PrimePartners Corporate Finance Pte. Ltd.
16 Collyer Quay
#10-00 Collyer Quay Centre
Singapore 049318

CORPORATE GOVERNANCE REPORT

JIUTIAN CHEMICAL GROUP LIMITED (“**Jiutian Chemical**” or the “**Company**”) is committed to maintaining high standards of corporate governance within the Company and its subsidiaries (the “**Group**”) to advance its mission to create value for the Group’s customers and shareholders. The Board recognises the importance of practicing good corporate governance as a fundamental part of its responsibilities to protect and enhance shareholders’ value and the financial performance of the Group.

This report outlines the Company’s corporate governance processes and activities in respect of the financial year ended 31 December 2023 (“**FY2023**”) that were in place, with specific reference to the Code of Corporate Governance 2018 (the “**Code**”) and the disclosure guide (the “**Guide**”) developed by Singapore Exchange Securities Trading Limited (the “**SGX-ST**”).

The Group is generally in compliance with the principles and provisions as set out in the Code and the Guide. Appropriate explanations have been provided in relevant sections where there are deviations.

BOARD MATTERS

Principle 1 – THE BOARD’S CONDUCT OF AFFAIRS

The Company is led by an effective Board, working closely with the Management for the long-term success of the Company. The composition of the Board as at the date of this report is as follows:

Mr Xu Aijun ⁽¹⁾	Non-Executive and Non-Independent Chairman
Mr Lee Chee Seng	Executive Director
Mr Wang Gang	Non-Executive and Non-Independent Director
Mr Song Fudong	Non-Executive and Non-Independent Director
Mr Wu Yu Liang	Non-Executive and Lead Independent Director
Mr Chan Kam Loon	Non-Executive and Independent Director
Mr Gao Guoan	Non-Executive and Independent Director
Mr Chen Mingjin	Non-Executive and Independent Director
Mr Koh Eng Kheng Victor	Non-Executive and Independent Director

(1) Mr Xu Aijun has been appointed as a Director of the Company with effect from 29 February 2024. Mr Han Lianguo has resigned as a director of the Company with effect from 29 February 2024.

All Directors objectively discharge their duties and responsibilities at all times in the interest of the Company. The principal functions of the Board apart from its statutory responsibilities are to:

- a) set values and standards of the Company and ensure that obligations to shareholders are understood and met;
- b) provide entrepreneurial leadership, approve the strategic and financial objectives, corporate policies and authorisation matrix of the Company;
- c) align the interests of the Board and Management with that of shareholders and balance the interests of all stakeholders;
- d) oversee the processes for risk management, financial reporting and compliance and evaluate the adequacy of internal controls; approve annual budget, key operational matters, major acquisition and divestment proposals and major funding proposals of the Company;
- e) review management performance;
- f) ensure compliance with all laws and regulations as may be relevant to the business;

CORPORATE GOVERNANCE REPORT

- g) approve the nominations to the Board of Directors and appointment of key management personnel, as may be recommended by the Nominating Committee;
- h) identifying the key stakeholder groups and recognise that their perceptions affect the Company's reputation;
- i) formulate and put in place corporate governance framework of the Company; and
- j) considering sustainability issues including environmental and social factors in the formulation of Group's strategies.

The Board meets at least four times a year. Ad-hoc meetings are convened as warranted by circumstances or deemed appropriate by the Board members. Non-Executive Directors are encouraged to meet regularly without management present.

Where Board Meetings are not convened, the Board may use circular resolution in writing to sanction certain decisions. Directors facing conflict of interest will recuse themselves from discussions and decisions involving the issues of conflict.

The Group has adopted and documented internal guidelines setting forth the matters that require Board's prior approval. Matters which are specifically reserved for the decision of the entire Board include:

- Approval of quarterly results announcements, annual reports and audited financial statements;
- Convening of shareholders' meetings;
- Group strategy, business plan and annual budget;
- Material acquisition and disposal of assets;
- Capital-related matters including financial re-structure, market fund-raising;
- Share issuances, dividends release or changes in capital;
- Material interested person transactions; and
- Any investment or expenditures.

While matters relating to the Group's objectives, strategies and policies require the Board's decision and approval, Management is responsible for the day-to-day operation and administration of the Group.

To facilitate effective management, certain functions of the Board have been delegated to various Board Committees, namely Audit Committee ("**AC**"), Nominating Committee ("**NC**") and Remuneration Committee ("**RC**"). Further information regarding the function and details of the terms of reference of the Board Committees are set out in the later part of the report.

CORPORATE GOVERNANCE REPORT

The number of the Board and Board Committee meetings held during FY2023 and the attendance of each Board member are shown below:

Name	Board	AC ⁽¹⁾	NC ⁽²⁾	RC ⁽³⁾
	Number of Meetings held: 5	Number of Meetings held: 4	Number of Meetings held: 1	Number of Meetings held: 1
	Number of Meetings Attended	Number of Meetings Attended	Number of Meetings Attended	Number of Meetings Attended
Mr Han Lianguo ⁽⁴⁾	5	n.a.	1 (Member)	n.a.
Mr Xu Aijun ⁽⁵⁾	n.a.	n.a.	n.a.	n.a.
Mr Lee Chee Seng	5	n.a.	n.a.	n.a.
Mr Wang Gang	4	n.a.	n.a.	n.a.
Mr Song Fudong	5	n.a.	n.a.	n.a.
Mr Wu Yu Liang	5	4 (Member)	n.a.	1 (Chairman)
Mr Chan Kam Loon	5	4 (Chairman)	n.a.	1 (Member)
Mr Gao Guoan	5	n.a.	1 (Chairman)	1 (Member)
Mr Chen Mingjin	5	n.a.	n.a.	n.a.
Mr Koh Eng Kheng Victor	5	4 (Member)	1 (Member)	n.a.

n.a.: not applicable

For FY2023

- (1) The AC comprises 3 members, all of whom, including the Chairman, are independent. All members of the AC are Non-Executive Directors.
- (2) The NC comprises 3 members, the majority of whom, including the Chairman, are independent.
- (3) The RC comprises 3 members, all of whom, including the Chairman, are independent. All members of the RC are Non-Executive Directors.
- (4) Mr Han Lianguo has resigned as a Director of the Company with effect from 29 February 2024.
- (5) Mr Xu Aijun has been appointed as a Director of the Company with effect from 29 February 2024.

The Board values on-going professional development and recognises that it is important that all Directors receive regular training so as to be able to serve efficiently on and contribute to the Board. Each Director is entitled a certain budget to their training needs, to keep abreast with the latest developments such as updates on the relevant laws and regulations, changes in technology and industrial practice relating to the Group's business. The Group has an open policy for professional training for all Board members. The Company endorses the Singapore Institute of Directors ("SID") training programs and sets a budget for such training and professional development programs. All Board members are encouraged to attend relevant trainings organised by the SID or any other organisation which provides relevant training courses for directors. The cost of such training will be borne by the Company.

CORPORATE GOVERNANCE REPORT

The Company will arrange for all newly appointed directors (if any) to meet with the Company's senior management to familiarise themselves with the business, operations and governance practices of the Company and its subsidiaries. Newly appointed Directors will be provided a formal letter setting out their duties and obligations. Existing directors of the Company are encouraged to participate in seminars and/or briefing sessions to be kept abreast of latest developments, such as regulatory changes which applicable to the Group.

A new Director who has no prior experience as a director of an issuer listed on the SGX-ST must undergo mandatory training in his roles and responsibilities as prescribed by the SGX-ST. Mr Xu Aijun who was appointed as Non-Executive and Non-Independent Chairman on 29 February 2024, the Company will be enrolling him for the mandatory training courses in the roles and responsibilities of a director of a listed company as prescribed by SGX-ST.

In addition, with effect from 1 January 2022, all Directors are required to undergo training on sustainability matters. In this connection, all the Board members have completed the mandated sustainability training course as required by the enhanced SGX sustainability reporting rules.

Furthermore, there are briefings and updates for the Directors during FY2023 include:

- The independent auditors had briefed the AC on changes or amendments to accounting standards.
- The Company Secretary has briefed the Board on regulatory changes, such as changes to the Companies Act and/or the SGX-ST Listing Manual Section B: Rules of Catalyst ("**Catalist Rules**").
- The Executive Director briefed the Board on the business activities and updates of the Group.

Under the existing Constitution of the Company, the Directors may participate in a meeting of the Directors by means of a conference via telephone or similar communications. Timely communication with the Board can be achieved through electronic means.

From time to time, the directors are furnished with detailed information concerning the Group to enable them to be fully aware and understand the decisions and actions of the management of the Group. The Board has unrestricted access to the Group's records and information. As a general rule, the Board papers are required to be sent to directors at least five (5) working days before Board meeting so that members may better understand the matters before the Board meeting and discussion may be focused on questions that the Board has about the Board papers. The Board papers include sufficient information from the management on financial, business and corporate issues to enable the directors to be properly briefed on issues to be considered at Board meetings. Directors with multiple board representations (if any) will ensure that sufficient time and attention are given to the affairs of the Company.

The independent directors have separate and independent access to the Group's senior management and Company Secretary at all times. The appointment and removal of the company secretary are subject to the approval of the Board. The Board also takes independent professional advice as and when necessary to enable them to discharge their responsibilities effectively. Subject to the approval of the Chairman, Directors, whether as a group or individually, may seek and obtain independent professional advice to assist them in their duties, at the Company's expense.

CORPORATE GOVERNANCE REPORT

Principle 2 – Board Composition and Guidance

The Board comprises nine (9) Directors: one (1) Executive Director (“**ED**”), five (5) Non-Executive and Independent Directors (“**ID**”) and three (3) Non-Executive and Non-Independent Directors (“**NENID**”) as at the date of this report. The profiles of the Directors are set out on pages 14, 15 and 16 of this Annual Report.

In view of the fact that the Chairman is not an Independent Director, the majority of the Board are independent. The majority of the Board also make up of non-executive directors. In the event of any retirement, resignation or redesignation which renders the Company unable to meet these requirement, the Company would endeavor to fill the vacancy within two months, but in any case not later than three months.

The Board assesses the effectiveness of the Board and Board Committee as a whole and the contribution by each Director to the effectiveness of the Board annually. It is of the view that the current composition and board size is appropriate for effective decision making. The Board will continue to review the size of the Board on an ongoing basis. In addition, each Director has been appointed on the strength of his calibre and experience which brings about a valuable range of experience and expertise to contribute to the development of the strategy and performance of the Company. As a team, the Board collectively provides core competencies in the areas of accounting, finance, legal, business and management, as well as industry knowledge.

The IDs have confirmed that they are independent in conduct, character and judgement, and have no relationship with the Company, its related corporations, its substantial shareholders or its officers that could interfere, or be reasonably perceived to interfere, with the exercise of the directors’ independent business judgement in the best interests of the Company as stipulated in Principle 2.1 of the Code as well as Rule 406(3)(d) of the Catalist Rules. Annually, each ID is required to complete the Director’s Independence confirmation checklist in their assessment of independence. The NC has reviewed, determined and confirmed the independence of the IDs in accordance with the Code and the Catalist Rules.

The NC has affirmed that Mr Wu Yu Liang, Mr Chan Kam Loon, Mr Gao Guoan, Mr Chen Mingjin and Mr Koh Eng Kheng Victor are independent. Each ID has abstained from the NC/Board’s determination of his independence. There is no Director who is deemed independent by the Board, notwithstanding the existence of a relationship as stated in the Code.

The Board recognises that IDs may over time develop significant insights into the Group’s business and operations, and can continue to objectively provide significant and valuable contributions to the Board as a whole.

Mr Chan Kam Loon, Mr Wu Yu Liang and Mr Gao Guoan were appointed as an Independent Director on 19 April 2006 and 26 April 2013 respectively. They have served the Board for more than nine (9) years. The NC has conducted a rigorous review of their continuing contribution, character, background and independence.

The NC considered that Mr Wu Yu Liang, Mr Chan Kam Loon and Mr Gao Guoan continued to demonstrate a strong spirit of professionalism, independence of conduct at the Board and Board Committee meetings. They have been consistent and diligent in discharging their duties and exercise sound independent business judgment in the deliberation for the best interest of the Company and objectivity which did not diminish over time. The length of their services on the Board didn’t affect their independence from the Management and the Board as they continue to express their independent views and debate the issues in the Meetings.

CORPORATE GOVERNANCE REPORT

However, on 11 January 2023, Singapore Exchange Regulation (SGX RegCo) announced the change of Catalyst Rules to limit to nine years the tenure of IDs serving on the boards of listed companies and to remove with immediate effect the two-tier vote mechanism for listed companies to retain long-serving IDs who have served for more than nine years. A transition period is given to find new IDs, as such, existing IDs whose tenure exceeds the nine-year limit can continue to serve as IDs until the listed companies' AGM held for the financial year ending on or after 31 December 2023.

In view of the above revised Catalyst Rules, Mr Chan Kam Loon, Mr Wu Yu Liang and Mr Gao Guoan will be retiring as a Director of the Company upon the conclusion of the forthcoming AGM. The Company has commenced its search process for suitable ID candidates to replace Mr Chan Kam Loon, Mr Wu Yu Liang and Mr Gao Guoan and would endeavor to fill the vacancies within two months, but in any case not later than three months.

Additionally the Board is of the opinion that it would be most effective to draw on the wealth of experience from the long serving directors while concurrently taking progressive steps to review and consider opportunities to refresh the Board as and when deemed required. To meet the changing challenges in the industry, such review includes considering factors such as the expertise, skills and perspectives which the Board needs against the existing competencies would be done on an annual basis to ensure that the Board dynamics remain optimal.

Under the Board Diversity Policy, the NC is responsible for reviewing and assessing the composition of the Board and making recommendations to the Board on the appointment of new Directors. To achieve an optimally balanced composition of the Board, the NC will consider candidates based on merit and the nature and scope of the Company's operation and business requirements.

The current Board composition reflects the Company's commitment to Board diversity. The NC will continue to review the Board Diversity Policy, as appropriate, to ensure its effectiveness, and will recommend appropriate revisions to the Board for consideration and approval.

The Company prioritizes diversity in experience, encompassing professional, industry, cultural, and social backgrounds, regardless of gender.

The NC and the Board is of the view that the aims and target of the Company towards achieving board diversity has currently been met and sufficiently addressed, after taking consideration in the various aspect aforementioned, and having considered the existing needs, direction and overall strategy of the Company. The NC and the Board recognizes that board diversity matters are an ongoing process, and the Company will continuously monitor its diversity initiatives to ensure that it maintains its commitment to promoting board diversity.

The NC and the Board is cognizant of the guidance provided in Provision 2.4 and Practice Guidance 2 of the Code and believe that the practices implemented by the Company align with the principles outlined in Principle 2 of the Code and compliance with the Rule 710A of the Catalyst Rules.

Any updates or progress made towards implementing the Board Diversity Policy will be disclosed in the Corporate Governance Report, as appropriate.

CORPORATE GOVERNANCE REPORT

The current Board composition provides a diversity of skills, experience, and knowledge to the Company as follows:

Table 2.6 – Balance and Diversity of the Board

	Number of Directors	Proportion of Board
Core Competencies		
- Accounting or finance	5	56%
- Business management	9	100%
- Legal or corporate governance	3	33%
- Relevant industry knowledge or experience	5	56%
- Strategic planning experience	9	100%

The Board has taken the following steps to maintain or enhance its balance and diversity:

- Annual review by the NC to assess if the existing attributes and core competencies of the Board are complementary and enhance the efficacy of the Board; and
- Annual evaluation by the Directors of the skill sets the other Directors possess, with a view to understand the range of expertise which is lacking by the Board.

The NC will consider the results of these exercises in its recommendation for the appointment of new directors and/or the re-appointment of incumbent directors.

The Board and management recognise the benefits of open and constructive debates, Non-Executive Directors may challenge and help to develop proposals on strategy and guidance to the management in the best interest of the Company.

The Non-Executive Directors and/or Independent Directors are scheduled to meet regularly, and as warranted, in the absence of key management personnel to discuss concerns or matters such as the effectiveness of Management. For FY2023, the Non-Executive Directors and Independent Directors have met once in the absence of key management personnel.

Principle 3 – Chairman and Chief Executive Officer

To ensure a balance of power and authority within the Company, the role of the Non-Executive and Non-Independent Chairman ("**Chairman**") and the Acting Chief Executive Officer ("**Acting CEO**") of the Company are undertaken by separate persons, Mr Xu Aijun and Mr Wei Hongguang respectively as at the date of this report.

Mr Xu Aijun was appointed as the Non-Executive and Non-Independent Chairman, plays a key role in developing a strong leadership and vision of the Group. The Chairman is responsible for the workings of the Board, ensuring the integrity and effectiveness of its governance process. He works closely with the Board to implement the policies set by the Board to realise the Company's vision. He also promotes a culture of openness and debate at the Board, facilitate the effective contribution of the Board and encourages constructive relations within the Board and between the Board and the Management. All major decisions made by the Chairman are reviewed by the Board.

CORPORATE GOVERNANCE REPORT

As the Acting CEO, Mr Wei Hongguang's responsibility includes overseeing the business operations of the Group with the assistance of key management personnel and takes a leading role in developing the business of the Group. He also oversees the execution of the business and corporate strategy decision made by the Board.

The Chairman of the Company and Acting CEO are not related to each other.

Mr Lee Chee Seng is the Executive Director of the Company who is responsible for the day-to-day operations of the Company, with the support of Management to ensure the implementation of policies and strategy across the Group. Mr Lee has collaborated closely with the NENID and leads the development of the Company's future strategy.

Mr Wu Yu Liang, has also been appointed as the Lead Independent Director of the Company and make himself available to the shareholders if they have concerns relating to matters which the Chairman or Acting CEO or Group Financial Controller have failed to resolve or contact through which is inappropriate. The Lead Independent Director makes himself available to shareholders at the Company's general meetings.

Led by the Lead Independent Director, the IDs will meet in the absence of the other Directors as and when circumstances warrant.

Principle 4 – Board Membership

Nominating Committee

The NC comprises the following three (3) members, majority of whom, including the Chairman are independent:

Gao Guoan	(NC Chairman, ID)
Koh Eng Kheng Victor	(Member, ID)
Xu Aijun	(Member, NENID)

The NC has written terms of reference that describe the responsibilities of its members. The duties of the NC, among others, are as follows:

- (a) review and make recommendations to the Board on all candidates nominated for appointment and re-appointment to the Board as well as to the senior management positions in the Company, taking into account the Board's diversity policy, candidate's track record, age, experience, capabilities and other relevant factors;
- (b) identify and make recommendations to the Board as to the Directors who are to retire by rotation and to be put forward for re-election;
- (c) determine annually and as when circumstances require whether or not a Director is independent in accordance with the Provision 2.1 of the Code and other salient factors;
- (d) decide, in relation to a Director who has multiple board representations, whether or not such Director is able to and has been adequately carrying out his duties as Director of the Company;
- (e) put in place plans for succession, in particular, of the chairman of the Board and the key management personnel of the Company;
- (f) make recommendations to the Board on matters relating to the review of training and professional development programs for the Board;

CORPORATE GOVERNANCE REPORT

- (g) the process and criteria to evaluate the effectiveness of the Board as a whole and assess the contribution by each Director, to the effectiveness of the Board; and
- (h) procure that at least one-third (1/3) of the Board shall comprise of IDs. (or such other minimum proportion and criteria as may be specified in the CG Code from time to time.)

The NC has in place formal written procedures for making recommendations to the Board on the selection and appointment of Directors. Such procedures would be activated when a vacancy on the Board arises or when the Board is considering making a new Board appointment either to enhance the core competency of the Board or for purpose of progressive renewal of the Board.

In identifying suitable candidates, the NC may:

1. Advertise or use services of external advisers to facilitate a search.
2. Approach alternative sources such as the SID.
3. Consider candidates from a wide range of backgrounds from internal or external sources.
4. After short listing the candidates, the NC shall:
 - (a) consider and interview all candidates on merit against objective criteria, taking into consideration that appointees have enough time available to devote to the position; and
 - (b) evaluate and agree to a preferred candidate for recommendation to and appointment by the Board.

The NC and Board has also taken into consideration whether a director had served on the board with an adverse track record before his appointment as a director of the Company. In addition, the NC will review the directorship of each director and assess whether the resignation from any company casts any doubt on his qualification and ability to act as a director of the Company. The Board is satisfied the existing directors who had served the Board did not have any adverse track record in FY2023.

The NC has also reviewed the Company's succession plan for all directors, Acting CEO and Key Management Personnel including the mechanisms for identifying the suitable and potential candidates for the Company.

The Company currently does not have any alternate director.

The following non-executive and non-independent Directors are not part of the Management. They do not participate in the Company's day-to-day operation and did not receive the director's fee from the Company. They are nominees of Henan Energy and Chemical Industry Group Co., Ltd. being the ultimate holding company of Anyang Longyu (HK) Development Co., Ltd. and Anyang Chemical Industry Group Co., Ltd. (Controlling Shareholder of the Company):

- (1) Mr Xu Aijun , Chairman of Anyang Chemical Industry Group Co., Ltd., the holding company of the Anyang Longyu (HK) Development Co., Ltd., being the Controlling Shareholder of the Company;
- (2) Mr Wang Gang, Deputy General Manager of Financial Business Department of Henan Energy and Chemical Industry Group Co., Ltd.; and
- (3) Mr Song Fudong, Chief Financial Officer of Anyang Chemical Industry Group Co., Ltd..

CORPORATE GOVERNANCE REPORT

In accordance with the provisions of the Company's Constitution and Rule 720(4) of the Catalist Rules, one-third of the Directors will retire by rotation and being eligible, submit for re-election at every Annual General Meeting ("**AGM**"). No Director can stay in office for more than 3 years without being re-elected by the shareholders in the Company. Any new director appointed prior to the AGM, is also required to seek re-election by shareholders at the forthcoming AGM.

The tabulation of the Company's assessment processes for re-election of incumbent Directors are shown below:

1.	Assessment of director	<ul style="list-style-type: none"> The NC would assess the performance of the director in accordance with the performance criteria set by the Board; and The NC would also consider the current needs of the Board. The NC member would recuse from his own assessment.
2.	Re-appointment of director	<ul style="list-style-type: none"> Subject to the NC's satisfactory assessment, the NC would recommend the proposed re-appointment of the director to the Board for its consideration and approval.

The NC has recommended and the Board has agreed for the following Directors to stand for re-election as Director at the forthcoming AGM of the Company to be convened on 25 April 2024:

(i) Pursuant to Regulation 91 of the Company's Constitution

- (a) Mr Koh Eng Kheng Victor, upon re-election as a director of the Company, will remain as a Non-Executive and Independent Director as well as a member of Audit Committee and Nominating Committee. Upon the retirement of Mr Wu Yu Liang as Director of the Company, Mr Koh will serve as the Chairman of Remuneration Committee. He is considered independent for the purposes of Rule 704(7) of the Catalist Rules.
- (b) Mr Chan Kam Loon and Mr Gao Guoan will be retiring as Directors of the Company pursuant to Regulation 91 of the Company's Constitution and will not be seeking for re-election at the forthcoming AGM. Accordingly, they will be retiring as Directors of the Company upon the conclusion of the forthcoming AGM.

(ii) Pursuant to Regulation 97 of the Company's Constitution

Mr Xu Aijun, upon re-election as a director of the Company, will remain as a Non-Executive and Non-Independent Chairman and member of Nominating Committee.

- (iii) To note the voluntary retirement of Mr Wu Yu Liang and Mr Chen Mingjin as Directors of the Company upon the conclusion of the forthcoming AGM.

CORPORATE GOVERNANCE REPORT

Pursuant to Rule 720(5) of the Catalist Rules, the information relating to the retiring Directors as set out in Appendix 7F of the Catalist Rules is disclosed below:

Name of Director	Koh Eng Kheng Victor ("Mr Koh")	Xu Aijun ("Mr Xu")
Date of Appointment	1 February 2018	29 February 2024
Date of last re-appointment (if applicable)	28 April 2021	N.A.
Age	64	52
Country of principal residence	Singapore	People's Republic of China ("PRC")
The Board's Comments on the appointment (including rationale, selection criteria, and the search and nomination process)	The re-election of Mr Koh as the Non-Executive and Independent Director was recommended by the NC and the Board has accepted the recommendation, after taking into consideration his qualifications, past experience and overall contribution since he was appointed as a Director of the Company.	The re-election of Mr Xu as the Non-Executive and Non-Independent Chairman was recommended by the NC and the Board has accepted the recommendation, after taking into consideration his qualifications and past experience since he was appointed as a Director of the Company.
Whether appointment is executive, and if so, the area of responsibility	Non-Executive	Non-Executive
Job title (e.g. Lead ID, AC Chairman, AC Member etc)	Non-Executive and Independent Director, NC member and AC member	Non-Executive and Non-Independent Chairman and NC member
Professional Qualifications	Bachelor of Business Administration (Honours) from National University of Singapore. Mr Koh holds a Chartered Financial Analyst designation and a member of CFA Society Singapore	Diploma in Chemical Engineering and Technology Bachelor Degree in Chemical Engineering and Technology

CORPORATE GOVERNANCE REPORT

Name of Director	Koh Eng Kheng Victor ("Mr Koh")	Xu Aijun ("Mr Xu")
Working experience and occupation(s) during the past 10 years	<p>2013 to December 2014: Managing Director, Fund Management, Aglaia Investment Management Pte Ltd.</p> <p>Retired in December 2014.</p> <p>July 2023 to Present: Executive Director/Chief Executive Officer, VI Capital Pte Ltd.</p>	<p>December 2023 to present: Chairman of Anyang Chemical Industry Group Co., Ltd.</p> <p>October 2020 to December 2023: General Manager of Anyang Chemical Industry Group Co., Ltd.</p> <p>May 2017 to October 2020: Vice General Manager of Anyang Chemical Industry Group Co., Ltd.</p> <p>January 2015 to May 2017: Vice General Manager of Henan Energy Chemical Group Fine Chemical Co., Ltd.</p> <p>August 2014 to January 2015: Head of production operation department cum Manager of purification department of Anyang Chemical Industry Group Co., Ltd.</p> <p>October 2010 to August 2014: Manager of purification department of Anyang Chemical Industry Group Co., Ltd.</p>
Shareholding interest in the listed issuer and its subsidiaries	None	None
Any relationship (including immediate family relationship) with any existing director, existing executive officer the issuer and/or substantial shareholder of the listed issuer or of any of its principal subsidiaries	None	Mr Xu is the Chairman of Anyang Chemical Industry Group Co., Ltd., the controlling shareholder having a deemed interest in approximately 25.27% of the Company.
Conflict of interest (including any competing business)	None	None
Other principal commitment (including any competing Directorship)	None	<p>Present Principal Commitment: Chairman of Anyang Chemical Industry Group Co., Ltd.</p> <p>Present Directorship: Anyang Chemical Industry Group Co., Ltd. Anyang Longyu Investment Management Co., Ltd. Anyang Jiulong Chemical Co., Ltd.</p>

CORPORATE GOVERNANCE REPORT

Name of Director	Koh Eng Kheng Victor ("Mr Koh")	Xu Aijun ("Mr Xu")
Undertaking (in the format set out in Appendix 7H) under Rule 720 (1) has been submitted to the listed issuer	Yes	Yes
Information required pursuant to Catalist Rules 704 (6) and/or 704(7)		
(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?	No	No
(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?	No	No
(c) Whether there is any unsatisfied judgment against him?	No	No

CORPORATE GOVERNANCE REPORT

Name of Director	Koh Eng Kheng Victor ("Mr Koh")	Xu Aijun ("Mr Xu")
(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?	No	No
(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?	No	No
(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?	No	No

CORPORATE GOVERNANCE REPORT

Name of Director	Koh Eng Kheng Victor ("Mr Koh")	Xu Aijun ("Mr Xu")
(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?	No	No
(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?	No	No
(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?	No	No
(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of- (i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or (ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or	No	No

CORPORATE GOVERNANCE REPORT

Name of Director	Koh Eng Kheng Victor ("Mr Koh")	Xu Aijun ("Mr Xu")
(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or (iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?		
(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?	No	No

In making the recommendations, the NC considered the Directors' overall contribution and performance. Their profiles are shown on pages 14, 15 and 16 of the Annual Report.

All Directors are required to declare their board appointments. The NC has reviewed the time spent and attention given by each Director to the Company's affairs, taking into account the multiple directorships and other principal commitments of each of the Directors (if any), and is satisfied that all Directors have adequately discharged their duties for FY2023.

CORPORATE GOVERNANCE REPORT

The Board has not capped the maximum number of listed company board representations each Director may hold. The NC is of the view that the effectiveness of each Director is best assessed by a qualitative assessment of the Director's contributions, after taking into account his other listed company board directorships and other principal commitments, not guided by a numerical limit. The NC also believes that it is for each Director to assess his own capacity and ability to undertake other obligations or commitments together with serving on the Board effectively. The NC does not wish to omit from consideration outstanding individuals who, despite the demands on their time, have the capacity to participate and contribute as members of the Board.

Key information regarding the Directors of the Company as at the report is disclosed as follows:

Name of Directors	Date of first appointment	Date of last re-election	Nature of Appointment	Membership of Board Committee	Directorship/ Chairmanship both present and those held over the preceding three years in other listed company	Other Principal Commitments
Xu Aijun	29 February 2024	N.A.	Non-Executive and Non-Independent Chairman	1. Nominating Committee	<u>Present</u> – <u>Past three years</u> –	Chairman of Anyang Chemical Industry Group Co., Ltd.
Lee Chee Seng	30 November 2004	28 April 2022 (Regulation 91)	Executive Director	–	<u>Present</u> – <u>Past three years</u> –	–
Wang Gang	1 February 2018	28 April 2022 (Regulation 91)	Non-Executive and Non-Independent Director	–	<u>Present</u> – <u>Past three years</u> –	Deputy General Manager of Financial Business Department of Henan Energy and Chemical Industry Group Co., Ltd.
Wu Yu Liang	19 April 2006	26 April 2023 (Regulation 91)	Non-Executive and Lead Independent Director	1. Remuneration Committee (Chairman) 2. Audit Committee	<u>Present</u> 1. AusGroup Limited <u>Past three years</u> 1. Seven Atelier Limited	Managing Director of Wu LLC
Chan Kam Loon	19 April 2006	28 April 2021 (Regulation 91)	Non-Executive and Independent Director	1. Audit Committee (Chairman) 2. Remuneration Committee	<u>Present</u> 1. Megachem Limited 2. Uni-Asia Group Ltd. 3. Tee International Limited 4. Alpha DX Group Limited 5. Southern Packaging Group Limited <u>Past three years</u> 1. Sarine Technology Ltd. 2. OIO Holdings Limited	–
Gao Guoan	26 April 2013	28 April 2022 (Regulation 91)	Non-Executive and Independent Director	1. Nominating Committee (Chairman) 2. Remuneration Committee	<u>Present</u> – <u>Past three years</u> –	–

CORPORATE GOVERNANCE REPORT

Name of Directors	Date of first appointment	Date of last re-election	Nature of Appointment	Membership of Board Committee	Directorship/ Chairmanship both present and those held over the preceding three years in other listed company	Other Principal Commitments
Chen Mingjin	1 February 2018	26 April 2023 (Regulation 91)	Non-Executive and Independent Director	–	Present – <u>Past three years</u> –	–
Koh Eng Kheng Victor	1 February 2018	28 April 2021 (Regulation 91)	Non-Executive and Independent Director	1. Audit Committee 2. Nominating Committee	Present – <u>Past three years</u> –	Executive Director/ Chief Executive Officer of VI Capital Pte Ltd.
Song Fudong	23 June 2022	26 April 2023 (Regulation 97)	Non-Executive and Non-Independent Director	–	Present – <u>Past three years</u> –	Chief Financial Officer of Anyang Chemical Industry Group Co., Ltd.

Principle 5 – Board Performance

A review of the performance and effectiveness of the Board as a whole and the contribution by each Director to the effectiveness of the Board are conducted by the NC annually. On the recommendation of the NC, the Board has adopted an internal process for evaluating the effectiveness of the Board as a whole. Each Board member will be required to complete an evaluation form to be returned to the NC Chairman for evaluation. Based on the evaluation results, the NC Chairman will present his recommendations to the Board. The key objective of the evaluation exercise is to obtain constructive feedback on the various aspects of the Board's performance from each Director to continually improve the Board's performance and assess the overall effectiveness of the Board.

The NC had decided on the evaluation form for the Board's performance and the objective performance criteria. Such performance criteria allow the comparison with industry peers which are required to be approved by the Board in order to enhance the shareholders' value in long term. The NC did not propose any changes to the performance criteria for FY2023 as compared to the previous financial year as the Board composition and the Group's principal business activities remained the same.

The NC will at the relevant time look into adopting guidelines for annual assessment of the contribution of each individual Director to the effectiveness of the Board and also the assessment of Board Committees. The NC is of the view that the Board is able to exercise objective judgement on corporate affairs independently and no individual or small group of individuals dominates the Board's decision making process. In addition, the evaluation exercise also assists the NC in determining whether to re-nominate Directors who are resigning or in appointing new directors in order to improve the performance and contributions of the Board.

All NC members have abstained from the voting or review process of any matters in connection with the assessment of his performance.

The Board has not engaged any external facilitator in conducting the assessment of the Board's performance. The Board has met its performance objectives in FY2023.

CORPORATE GOVERNANCE REPORT

Management provides the Board with key information that is complete, adequate and timely, pertaining to areas such as budget forecast, funding positions and cash flow projections of the Group to help them carry out their responsibilities effectively. The following tabulates the information provided and the frequency in FY2023:

Information	Frequency
1. Board papers (with background or explanatory information relating to the matters brought before the Board, where necessary)	Quarterly
2. Updates to the Group's operations and the markets in which the Group operates in	Quarterly
3. Budgets and/or forecasts (with variance analysis) and management accounts (with financial ratios analysis)	Monthly
4. Reports on on-going or planned corporate actions	Quarterly
5. Enterprise risk framework and internal auditors' ("IA") report(s)	Quarterly
6. Research report(s)	Quarterly
7. Shareholding statistics	Quarterly
8. Regulatory updates and implications	Quarterly
9. Significant project updates	Quarterly
10. Independent auditor's report(s)	Annually

Management will also on best endeavours, encrypt documents which bear material price sensitive information when circulating documents electronically.

All Board members are provided with the contact details of senior management personnel in order to facilitate separate and independent access to these personnel, when required.

REMUNERATION MATTERS

Principle 6 – Procedures for Developing Remuneration Policies

Remuneration Committee

In FY2023, the RC comprises the following three (3) members, all of whom are independent:

Wu Yu Liang	(RC Chairman, ID)
Chan Kam Loon	(Member, ID)
Gao Guoan	(Member, ID)

The RC has written terms of reference that describe the responsibilities of its members. The duties of the RC, among others, are as follows:

- (a) recommend to the Board a framework of remuneration for the Board and determine the specific remuneration package for each ED and the key management personnel of the Company, if he is not an ED;
- (b) consider whether Directors and key management personnel should be eligible for benefits under long-term incentive schemes; and
- (c) recommend to the Board the fees of Non-Executive Directors.

CORPORATE GOVERNANCE REPORT

In preparation for the extent of termination of executive directors' and key management personnel's contract of service, the RC reviews such contracts of services and institutes safeguards for fair and reasonable termination clauses which are not overly generous.

The Company did not appoint an external remuneration consultant during the financial year.

The Directors did not participate in any decision concerning their own remuneration.

Principle 7 – Level and Mix of Remuneration

The RC recommends to the Board a framework of remuneration for the Directors and key management personnel and determines specific remuneration packages for each Executive Director. The recommendations of the RC on the remuneration of Directors would be submitted for endorsement by the entire Board. All aspects of remuneration, including but not limited to Directors' fees, salaries, allowances, bonuses and benefits-in-kind shall be reviewed by the RC to ensure that they are fair.

In its review, the RC's objective is to establish and maintain a level of remuneration that is in alignment with the long-term interest and risk policies of the Company to ensure that it is competitive to attract, retain and motivate the Directors and key management personnel to run the Company successfully. The framework of remuneration policies for its Directors and key executives is largely guided by the financial performance of the Company as well as prevailing market conditions. The RC also ensures that the remuneration policies and systems of the Group support the Group's objectives and strategies.

The Company currently does not have any contractual provisions which allow it to reclaim incentives from the Executive Director and key management personnel in certain circumstances. The Board is of the view that as the Group pays performance bonuses based on the actual performance of the Group and/or Company (and not on forward-looking results) as well as the actual results of its Executive Director and key management personnel, "claw back" provisions in the service agreements may not be relevant or appropriate.

For the remuneration packages of Non-Executive Directors, the effort, time spent, and responsibilities of the Non-Executive Directors are taken into account. None of Non-Executive Directors decides his own remuneration. Directors' fees to be paid to Directors are subject to the approval of shareholders at the forthcoming AGM.

The Company has no share-based compensation schemes or any long-term scheme involving the offer of shares or option in places.

Principle 8 – Disclosure on Remuneration

In setting the remuneration packages of the ED, the Company makes a comparative study of the packages of ED in comparable industries and takes into account the performance of the Company.

Non-Executive Directors are paid a basic fee. The chairman of each of Board Committee is compensated for his additional responsibilities. Such fees are approved by the shareholders of the Company at the annual general meetings of the Company.

During FY2023, NENID who are the nominee director for HNEC were not paid any remuneration.

CORPORATE GOVERNANCE REPORT

During the financial year, the RC met once to review and recommend the remuneration of the ED, NENIDs and IDs. The RC had recommended the directors' fee for the IDs of S\$209,000 for FY2023 to be paid quarterly in arrears.

The aggregate amount of the retirement and post-employment benefits to the Directors, the Acting CEO and top 5 key management personnel (who are not directors or Acting CEO) is approximately S\$90,107. Details of the said benefits can be found on pages 72 to 73 and 78 of the Annual Report.

The remuneration band of the Directors and key management personnel for FY2023 and the various components of their remuneration in percentage terms are set out below in compliance with the recommendation of the Code.

For FY2023, the details of the annual remuneration of the Directors and top 5 key management personnel are as follows:

	Fees	Salary	Bonus	Other Benefits	Total
	%	%	%	%	%
EXECUTIVE DIRECTOR					
<u>S\$250,000 – S\$500,000</u>					
Lee Chee Seng	–	72%	18%	10%	100%
NON-EXECUTIVE DIRECTORS					
<u>Below S\$250,000</u>					
Han Lianguo ⁽¹⁾	–	–	–	–	–
Wang Gang	–	–	–	–	–
Song Fudong	–	–	–	–	–
INDEPENDENT DIRECTORS					
<u>Below S\$250,000</u>					
Chan Kam Loon	100%	–	–	–	100%
Wu Yu Liang	100%	–	–	–	100%
Gao Guoan	100%	–	–	–	100%
Chen Mingjin	100%	–	–	–	100%
Koh Eng Kheng Victor	100%	–	–	–	100%

Note:

(1) Mr Han Lianguo has resigned as a Director of the Company with effect from 29 February 2024.

CORPORATE GOVERNANCE REPORT

	Fees	Salary	Bonus	Other Benefits	Total
	%	%	%	%	%
KEY MANAGEMENT PERSONNEL					
<u>Below S\$250,000</u>					
Wei Hongguang	–	73%	–	27%	100%
Ng Han Kiat	–	71%	18%	11%	100%
Zong Hu	–	68%	–	32%	100%
Li Nan	–	69%	–	31%	100%
He Qingwu	–	69%	–	31%	100%

Due to a highly competitive environment where industry poaching of executives is commonplace, and for confidentiality reasons, the Company is therefore not disclosing the exact remuneration of Directors and key management personnel. The Company is instead disclosing the remuneration in bands of S\$250,000.

For FY2023, the aggregate amount of the remuneration paid to the top 5 key management personnel is approximately S\$358,000.

There is no employee of the Group who is substantial shareholder of the Company or an immediate family member of the Director, the Acting CEO or a substantial shareholder of the Company whose remuneration exceeded S\$100,000 in FY2023.

The Company does not adopt any Employee Share Options or Share Schemes.

The remuneration received by the Executive Directors and key management personnel takes into consideration his performance and contribution towards the overall performance of the Group for FY2023. Their remuneration was made up of fixed and variable compensations. The fixed compensation consists of an annual base salary and fixed allowances. The variable compensation is determined based on the level of achievement of individual performance objectives.

The following performance conditions are used by the Group to remain competitive and to motivate the Executive Director and key management personnel to work in alignment with the goals of all stakeholders:

1. Financial performance of the Group
2. Leadership
3. People development
4. Commitment

The RC has reviewed and is satisfied that the qualitative and quantitative performance conditions of the key management personnel and Executive Director were met for FY2023.

CORPORATE GOVERNANCE REPORT

ACCOUNTABILITY AND AUDIT

Principle 9 – Risk Management and Internal Controls

The Board is responsible for the overall risk governance, risk management and internal control framework of the Group and is fully aware of the need to put in place a system of internal controls within the Group to safeguard shareholders' interest and the Group's assets and to manage risk. The Group maintains a system of internal controls for all companies within the Group, but recognises that no internal control system will preclude all errors and irregularities. The system is designed to manage rather than to eliminate the risk of failure to achieve business objectives. The controls are to provide reasonable, but not absolute, assurance to safeguard shareholders' investments and the Group's assets. The Board regularly reviews the effectiveness of all internal controls including operational controls. The role of risk management has been delegated to the AC.

Risk Management

The AC assisted the Board to review the adequacy and effectiveness of the Company's risk management and internal audit function annually based on the report of the internal and independent auditors. The Company had engaged Crowe Horwath First Trust Risk Advisory Pte. Ltd. to perform a review on its internal controls and enterprise risk management (the "**Reviews**"). During the financial year, the AC had reviewed and based on the internal auditors' reports of the Reviews, internal controls and risk management system established and maintained by the Group, work performed by independent auditors and reviews performed by Management, the Board with the concurrence of the AC is of the opinion that the Company's internal controls (including financial, operational, compliance, information technology and sanctions-related risks) and risk management are adequate and effective for FY2023.

The independent auditor has, during their audit, carried out a review of the effectiveness of key internal controls within the audit scope. Material non-compliance and internal control weaknesses noted during the audit and their accompanying recommendations are reported to the AC. It was noted that there were no systemic issues to be highlighted. The AC has reviewed the internal auditor and independent auditor's comments and findings to ensure that there are adequate internal controls in the Group and follow up on actions required to be implemented before the next audit review.

In line with the Code, the Board has received assurance from the Acting CEO and the Group Financial Controller that the financial records as at 31 December 2023 have been properly maintained and the financial statements give a true and fair view of the Group's operations and finances. The Board has also received assurance from the Acting CEO and Group Financial Controller that the Group's risk management and internal control systems are adequate and effective.

Principle 10 – Audit Committee

In FY2023, the AC comprises the following three (3) members, all of whom are independent:

Chan Kam Loon	(AC Chairman, ID)
Wu Yu Liang	(Member, ID)
Koh Eng Kheng Victor	(Member, ID)

The AC has written terms of reference that describe the responsibilities of its members. The AC meets at least four (4) times a year to perform the following main functions:

- (a) to review with the independent auditors their audit plan, their evaluation of the system of internal accounting controls relevant to their statutory audit and their report on the financial statements;

CORPORATE GOVERNANCE REPORT

- (b) reviewing the assurance from the CEO and CFO (or their equivalents) on the financial records and financial statements;
- (c) to review quarterly and full year financial statements of the Company and of the Group, including announcements in relation thereto before their recommendation to the Board of Directors for approval to be released to SGX-ST;
- (d) to review the assistance given by management to the independent auditors;
- (e) to review any significant unresolved differences between the independent auditors, internal auditors and management;
- (f) to review the scope and results of the audit and its cost effectiveness. The independence of independent auditors should be reviewed annually;
- (g) to review annually the nature and extent of non-audit services (where these are substantial) provided by the independent auditors to the Company to ensure that these are provided objectively, on a value-for-money basis;
- (h) to review the significant financial reporting issues and judgments so as to ensure the integrity of the financial statements of the Company and any formal announcements relating to the Company's financial performance;
- (i) to consider the appointment/re-appointment and removal of the independent auditors, the remuneration, terms of engagement and matters relating to the resignation or dismissal of the independent auditors for the purpose of making recommendations to the Board;
- (j) to commission and review the findings of internal investigations into matters where there is any suspected fraud or irregularity or failure of internal controls or suspected infringement of any law, rule and regulation (whether of Singapore or elsewhere) which has or is likely to have a material impact on the Groups and the Company's operating results and/or financial position, and management's response;
- (k) to review the adequacy and effectiveness of the Group's and the Company's internal controls, including financial, operational, compliance, information technology controls, sanctions-related risk and risk management policies and systems established by the management at least once a year;
- (l) to review Whistle-Blowing Policy and to ensure that arrangements are in place for independent investigation of such matters and for appropriate follow up action;
- (m) to review the adequacy, independence, scope, results and cost-effectiveness of internal audit procedures as well as the effectiveness of the Group's and Company's internal audit and external audit function;
- (n) to review interested person transactions periodically to ensure that they comply with the internal control procedures;
- (o) to undertake such other reviews and projects as may be requested by the Board of Directors; and
- (p) to undertake such other functions and duties as may be required by the Catalist Rules or by law, and by such amendments made thereto from time to time.

CORPORATE GOVERNANCE REPORT

The AC has full access to, and cooperation from the Management including the independent auditors, and has full discretion to invite any director and executive officer to attend its meetings. The AC also has power to investigate any matter brought to its attention, within its terms of reference, with the power to retain professional advice at the Company's expense.

The Board considers Mr Chan Kam Loon, who has extensive and practical accounting and financial management knowledge and experience, well qualified to chair the AC. Mr Wu Yu Liang is legally trained and he has attended the training of accounting and financial management and Mr Koh Eng Kheng Victor is also trained in accounting and financial management.

The members of the AC collectively have over 10 combined years of strong accounting and related financial management expertise and experience and are appropriately qualified to discharge their responsibilities.

During the financial year, AC met once with the internal auditors and independent auditors, without the presence of the management to discuss, amongst others, audit finding and evaluations of the Group's internal controls.

The AC had reviewed the scope and quality of audit by the independent auditors and the independence and objectivity of the independent auditors as well as the cost effectiveness, and is satisfied that the nature and extent of such services would not prejudice the independence of the independent auditors. The AC will report to the Board of Directors immediately if there are any significant issues found by Independent Auditors while performing the audit review of the Company's year end financial statements. Meantime, the AC will provide the financial updates and recommendation for Board of Director for improvement the quality of financial statements of the Company. The AC also reviewed the audit fees paid to the independent auditors. The audit fees for the Group and its associated companies for the financial year ended 31 December 2023 was S\$300,000. The independent auditors did not render any non-audit services to the Group during the financial year.

No former Partner or Director of the Company's existing auditing firm or auditing corporation has acted as a member of the Company's AC: (a) within a period of two years commencing on the date of his/her ceasing to be a Partner of the auditing firm or Director of the auditing corporation; and in any case (b) for as long as he/she has any financial interest auditing firm or auditing corporation.

The Company is in compliance with Rules 712 and 715 of the Catalist Rules in relation to its independent auditors, as the subsidiary and associated companies of the Company were audited by Baker Tilly China Certified Public Accountants (an independent member firm of the Baker Tilly International network) for the purpose of preparation of the consolidated financial statements of the Group.

The AC is also satisfied that the independent auditors, Baker Tilly TFW LLP is able to meet the audit obligations of the Company and is pleased to recommend to the Board, the nomination of Baker Tilly TFW LLP for re-appointment as independent auditor of the Company at the forthcoming Annual General Meeting.

The independent auditor provides regular updates and briefing to the AC on changes or amendments to accounting standards to enable the members of the AC to keep abreast of such changes and its corresponding impact on the financial statements, if any.

CORPORATE GOVERNANCE REPORT

Internal Audit

The Board recognises the importance of the internal audit function which, being independent of Management is one of the principal means by which the AC is able to carry out its responsibilities effectively. The internal audit function is currently outsourced to Crowe Horwath First Trust Risk Advisory Pte. Ltd. ("**Crowe Horwath**") as the internal auditors of the Group. Crowe Horwath primarily reports to the AC.

The internal auditors' carry out their function in accordance to the Standards for the Professional Practice of Internal Auditing set by the Institute of Internal Auditors.

The AC ensures that management provides good support to the internal auditors and provides them with access to documents, records, properties and personnel when requested in order for the internal auditors to carry out their function accordingly.

To ensure the adequacy of the internal audit function, the AC reviews and approves, on an annual basis, the internal audit plans and the resources required to adequately perform this function.

The AC is satisfied that Crowe Horwath is effective, independent and adequately resourced with the relevant qualifications and experience as Crowe Horwath is able to discharge its duties effectively as the internal auditor has the appropriate standing in the Company, given, inter alia, its involvement in certain AC meetings and its unfettered access to all the Group's documents, records, properties and personnel, including direct access to the AC. The AC also satisfied that the internal audit function is stated by suitably qualified and experienced professionals with the relevant experience.

Whistle-Blowing Policy

The Company has developed a Whistle-Blowing policy. This policy provides well-defined and accessible channels in the Group through which employees may raise concerns about improper conduct within the Group. The Whistle-Blowing policy sets out procedures to keep identity of whistleblower confidential as the Company is committed to protect the whistleblower against detrimental or unfair treatment. The AC is responsible for the oversight and monitoring of whistleblowing. There was no Whistle-Blowing report received during the financial year.

SHAREHOLDER RIGHTS AND ENGAGEMENT

Principle 11 – Shareholder Rights and Conduct of General Meetings

The reports or circulars of the Company including Notice of general meeting are announced through SGXNET.

All registered shareholders are invited to participate and given the right to vote on resolutions at AGM. Every matter requiring shareholders' approval is proposed as a separate resolution. Where the resolutions are "bundled", the Company will explain the reasons and material implications in the notice of meeting.

Each item of special business included in the notice of the AGM is accompanied, where appropriate, by an explanation for the proposed resolution. Proxy forms are enclosed with the notice of AGM to all shareholders.

The Company's Constitution allow a member of the Company to appoint not more than two (2) proxies to attend and vote on his behalf at general meeting through proxy forms deposited 72 hours before the AGM. However, as the authentication of shareholder identity information and other related security issues still remain a concern, the Company has decided, for the time being, not to implement voting in absentia by mail, email or fax.

CORPORATE GOVERNANCE REPORT

All Directors, Management, Company Secretary, independent auditors and legal advisors (if necessary), attend the AGM. The procedures of AGM provides shareholders the opportunity to ask questions relating to each resolution tabled for approval and open communication are encouraged by the shareholders with the Director on their views on matters relating to the Company. To enhance shareholder participation, the Company will put all resolutions at the AGM to vote by poll and announces the results by showing the number of votes cast for and against each resolution and the respective percentage to the audience at the AGM. The polling results are also announced to the SGX-ST after the meetings.

The forthcoming AGM in respect of FY2023 will be held physically with no option for shareholders to participate virtually, at Royal Plaza on Scotts, Balmoral Hall, Level 5, 25 Scotts Road, Singapore 228220 on 25 April 2024 ("**AGM 2024**"). Arrangements relating to attendance at the AGM 2024, submission of questions to the Chairman of the Meeting in advance of, or at, the AGM 2024, and voting at the AGM 2024 by shareholders or their duly appointed proxy(ies), are set out in the notice of AGM dated 9 April 2024.

At general meetings of the Company, shareholders are given the opportunity to communicate their views and are encouraged to ask the directors and the Management questions regarding matters affecting the Company and the Group. The shareholders are invited to submit their questions for the AGM in advance of the meeting, and the Company will provide its responses via SGXNET and the corporate website at least 48 hours prior to the closing date and time of the lodgement of the proxy forms .

All directors will endeavour to be present at the AGM 2024 to address shareholders' questions relating to the work of the Board and the Board Committees. The Company's external auditors, Baker Tilly TFW LLP, will also be present and are available to assist the directors in addressing any relevant queries by the shareholders relating to the conduct of the audit and the preparation and content of the auditors' report.

The Company Secretary prepares minutes of AGM that include substantial and relevant comments or queries from shareholders relating to the agenda of the meetings, and responses from the Board and Management. These minutes are made available to shareholders on SGXNET within one month after the AGM.

For FY2023, the Company will publish the minutes of the AGM to be held on 25 April 2024 on SGXNet within one month after the AGM.

The Company does not have a specific dividend policy. Nonetheless, the Management after reviewing the performance of the Company in the relevant financial year will make appropriate recommendation to the Board.

The Company had declared a tax-exempt (1-tier) interim dividend of SGD0.009 per ordinary share to the shareholders on 8 June 2023 and paid on 16 June 2023. The relevant announcement had been released through SGXNET on 12 May 2023.

Principle 12 – Engagement with the Shareholders

The AGM of the Company is the principal forum for dialogue and interaction with all shareholders to gather views or inputs, and address shareholders' concern. The Board welcome shareholders to voice their views and ask the Board questions regarding the Company and the Group.

Information is disseminated / made available to shareholders through:

- (i) SGXNET announcements and news releases; and
- (ii) Annual Reports.

CORPORATE GOVERNANCE REPORT

The Company treats all shareholders fairly and equitably, and recognises, protects and facilitates the exercise of shareholders' rights and continually reviews and updates such governance arrangements. The Group strives for timeliness and transparency in its disclosures to the shareholders and the public. The Board provides shareholders with an assessment of the Company's performance, position and prospects on a quarterly basis and other ad hoc announcements as required by the SGX-ST. In addition to the regular dissemination of information through SGXNET, the Company also responds to enquiries from investors, analysts, fund managers and the press. However, the Company does not practise selective disclosure as all price-sensitive information are disclosed in a comprehensive, accurate and timely manner via SGXNET. The Company also communicates through its corporate website at <http://www.jiutianchemical.com.sg> which provides shareholders with corporate announcements, press releases, annual reports and profile of the Group.

All shareholders are accorded their rights in accordance with the Companies Act 1967 of Singapore and the Company's Constitution.

The Company currently does not have an investor relations policy but considers advice from its corporate lawyers and professionals on appropriate disclosure requirements before announcing material information to shareholders. The Company will consider the appointment of a professional investor relations officer to manage the function should the need arises.

Shareholders may also provide any feedback they may have about the Company to the Company's email at info@jiutianchemical.com.

To promote a better understanding of shareholders' views, the Board actively encourages shareholders to participate during the Company's general meeting. These meetings provide excellent opportunities for the Company to obtain shareholders' view on value creation.

The Company has been conducting voting by poll during the Company's general meeting. An announcement of the detailed results showing the number of vote cast for and against each resolution and the respective percentages will be made immediately after AGM is concluded.

The Company will review its Constitution from time to time and make such amendments to the Constitution to be in line with the applicable requirements or rules and regulations governing the Continuing Listing obligations of the Catalist Rules.

Managing Stakeholders Relationships

Principle 13 – Engagement with Stakeholders

The Company is poised to take a leading role in the environmental, health and safety aspects in order to ensure the sustainability of the operations and fulfil the responsibility of the Company towards the stakeholders. The Company has engaged in constructive dialogue with the stakeholders and focus on the Quality Management, Production Safety, Environmental Protection and Employee Well-being.

The Company also emphasises on the environmentally-friendly industrial operations to keep abreast of related regulatory developments and consequently improving the operations to comply with these changes.

In addition, the Board has considered sustainability issues as part of its strategic formulation. The Board has determined the material environmental, social and governance ("ESG") factors and overseen the management in monitoring these material ESG factors.

The Company updates shareholders on its corporate developments through SGXNet announcements and its annual report. All materials presented in general meetings are uploaded on the SGXNet.

CORPORATE GOVERNANCE REPORT

For enquires and all other matters, Shareholders and all other parties can contact the Company at info@jiutianchemical.com.

Dealing in Securities

The Board is aware of the guidelines of the corporate disclosure policy and the requirements for continuing disclosure as set out in the Catalist Rules. The Board has the responsibility to ensure that the Directors and employees are prohibited from securities dealings on short-term consideration and while they are in possession of price-sensitive information.

The Company issues regular circulars to its Directors, principal officers and relevant officers who have access to unpublished material price-sensitive information to remind them of the aforementioned prohibition and the requirement to report their dealings in shares of the Company. The Directors and employees are also prohibited from dealing in the securities of the Company during the period commencing two weeks before the announcement of the Company's quarterly and half yearly results and one month before the announcement of the Company's full year results and ending on the date of the particular announcement.

Interested Person Transactions ("IPT")

The AC is satisfied that the review procedures for IPTs and the reviews to be made periodically by the AC in relation thereto are adequate to ensure that the IPTs, if any, will be transacted on normal terms and will not be prejudicial to the interests of the Company and its minority shareholders.

In compliance with Rule 920 of the Catalist Rules, the aggregate value of the IPT, including recurrent interested persons transactions of revenue or trading in nature conducted during the financial year ended 31 December 2023 by the Company in accordance with the shareholders' mandate are as follows:

Name of interested person/ Nature of relationship	Aggregate value of all interested person transactions during the financial period under review (excluding transactions less than S\$100,000 and transactions conducted under shareholders' mandate pursuant to Rule 920)	Aggregate value of all interested person transactions conducted under shareholders' mandate pursuant to Rule 920 (excluding transactions less than S\$100,000)
	FY2023	FY2023
Anyang Chemical Industry Group Co., Ltd. ("Anhua") ⁽¹⁾	Security and fire protection service fees RMB 5.23 million	Sales of Repair Material, industrial steams and electricity RMB 14.47 million
	Purchase of Property, plant and equipment RMB 1.74 million	Purchase of Raw Materials I and II RMB 24.93 million
	Project consultation fees RMB 3.50 million	Purchase of Repair Materials RMB 12.09 million
	Transportation fees RMB 1.30 million	Rental income of equipment RMB 1.36 million
		Rental expense of equipment RMB 21.22 million

CORPORATE GOVERNANCE REPORT

Name of interested person/ Nature of relationship	Aggregate value of all interested person transactions during the financial period under review (excluding transactions less than S\$100,000 and transactions conducted under shareholders' mandate pursuant to Rule 920)	Aggregate value of all interested person transactions conducted under shareholders' mandate pursuant to Rule 920 (excluding transactions less than S\$100,000)
	FY2023	FY2023
Anyang Jiulong Chemical Co., Ltd. ("Anyang Jiulong") ⁽²⁾	Nil	Sale of Dimethylamine, repair material and electricity RMB 62.11 million
		Purchase of Raw Materials I and II RMB 274.61 million
		Rental of equipment RMB 1.22 million
Anyang Jiujiu Chemical Technology Co., Ltd. ("Anyang Jiujiu") ⁽³⁾	Advances given for working capital purposes RMB 0.47 million	Nil
Total	RMB 12.24 million	

Notes:

- (1) Anhua is the holding company of Anyang Longyu (HK) Development Co., Ltd. ("Anyang Longyu"), a controlling shareholder of the Company. Anyang Longyu holds approximately 25.27% of the issued share capital of the Company.
- (2) Anyang Jiulong is a joint venture between Jiutian Chemical Group Limited and Anhua and Henan Energy and Chemical Industry Group Co., Ltd. ("HNEC") pursuant to which Anhua holds 15.9% and HNEC holds 35.1% and Jiutian Chemical Group Limited holds 49% of the registered capital of Anyang Jiulong. HNEC is the parent of Anhua.
- (3) Anyang Jiujiu is a joint venture between Jiutian Chemical Group Limited and Anyang Jiulong pursuant to which Anyang Jiulong holds 51% and Jiutian Chemical Group Limited holds 49% of the registered capital of Anyang Jiujiu. The effective interest of the Group in Anyang Jiujiu is therefore approximately 74%. However, it was assessed and concluded that the Group has no control but only significant influence over Anyang Jiujiu as the majority voting rights and representative of the board of the directors in Anyang Jiujiu are held by Anyang Jiulong. As Anyang Jiulong is a subsidiary company of HNEC, the parent of Anhua who is in turn the holding company of the controlling shareholder, Anyang Longyu. HNEC would have control over Anyang Jiujiu through Anyang Jiulong.

The Advances were made for Anyang Jiujiu's working capital and were provided by the joint venture partners, namely the Company and Anyang Jiulong, in proportion to their respective equity interest in Anyang Jiujiu and on the same terms and conditions.

Pursuant to Rule 916(3) of the Singapore Exchange Securities Trading Limited Listing Manual Section B: Rules of Catalyst, the Audit Committee of the Company, having considered the terms of the Advances and the joint venture, is of the view that (i) the provision of the Advances is not prejudicial to the interest of the Company and its minority shareholders, and (ii) the risk and rewards of the joint venture are in proportion to the equity of each joint venture partner and the terms of the joint venture are on normal commercial terms and are not prejudicial to the interest of the Company and its minority shareholders

Save as disclosed above, there are no other IPTs of S\$100,000 and above in FY2023.

CORPORATE GOVERNANCE REPORT

Material Contracts

Save as disclosed in the IPT section above, there were no material contracts entered into by the Group involving the interests of the Chairman, Directors or controlling shareholders, which are either still subsisting at the end of FY2023 or if not then subsisting, entered into since the end of the previous financial year.

Sustainability Report

The Sustainability report is released by the Company on the SGXNet on 09 April 2024, together with the release of the Annual Report.

Such report will highlight the key economic, environmental, social and governance (ESG) factors, such as quality management, production safety, environmental protection and employee well-being. Please refer to the Sustainability Report for FY2023 released by the Company on the SGXNet on 09 April 2024 for further details.

Non-sponsor fees

For FY2023, the Company paid to its sponsor, PrimePartners Corporate Finance Pte. Ltd. non sponsor fees of S\$5,000.

Use of Net Proceeds

The following relates to the net proceeds of S\$9.97 million raised from the Placement that was completed on 27 October 2020:

Purpose	Amount allocated (S\$'000)	Net proceeds utilised as 31.03.2024 (S\$'000)	Balance unutilised (S\$'000)
Working Capital			
Wages and staff related cost	–	2,766	–
Directors' fee	–	748	–
Office rental	–	295	–
Professional fees	–	899	–
Other office expenses	–	535	–
Total	9,967	5,243	4,724

The use of proceeds is consistent with the Company's proposed use of funds as set out in the announcement dated 27 October 2020.

DIRECTORS' STATEMENT

For the financial year ended 31 December 2023

The directors hereby present their statement to the members together with the audited consolidated financial statements of Jiutian Chemical Group Limited (the "Company") and its subsidiary companies (the "Group") and the statement of financial position and statement of changes in equity of the Company for the financial year ended 31 December 2023.

Opinion of the directors

In the opinion of the directors:

- (i) the consolidated financial statements of the Group and the statement of financial position and statement of changes in equity of the Company as set out on pages 59 to 114 are properly drawn up so as to give a true and fair view of the financial position of the Group and the Company as at 31 December 2023 and of the financial performance, changes in equity and cash flows of the Group and changes in equity of the Company for the financial year then ended in accordance with the provisions of the Companies Act 1967 (the "Act") and Singapore Financial Reporting Standards (International) ("SFRS(I)"); and
- (ii) at the date of this statement, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due.

Directors

The directors of the Company in office at the date of this statement are:

Xu Aijun (Appointed on 29 February 2024)
Lee Chee Seng
Wu Yu Liang
Chan Kam Loon
Gao Guoan
Wang Gang
Song Fudong
Chen Mingjin
Koh Eng Kheng Victor

Arrangement to enable directors to acquire benefits

Neither at the end of nor at any time during the financial year was the Company a party to any arrangement whose objects are, or one of whose objects is, to enable the directors of the Company to acquire benefits by means of the acquisition of shares in or debentures of the Company or any other body corporate.

DIRECTORS' STATEMENT

For the financial year ended 31 December 2023

Directors' interests in shares or debentures

The directors of the Company holding office at the end of the financial year had no interests in the shares and debentures of the Company and related corporations as recorded in the Register of Directors' Shareholdings kept by the Company under Section 164 of the Act except as follows:

Name of directors and company in which interest are held	Number of ordinary shares			
	Shareholdings registered in the name of the director		Shareholdings in which a director is deemed to have an interest	
	At 1.1.2023	At 31.12.2023	At 1.1.2023	At 31.12.2023
The Company				
Lee Chee Seng	11,250,000	11,250,000	22,419,000	22,419,000
Wu Yu Liang	300,000	300,000	–	–

The directors' interests in the ordinary shares of the Company as at 21 January 2024 were the same as those as at 31 December 2023.

Share options

No options to take up unissued shares of the Company or its subsidiary corporations were granted during the financial year.

There were no shares issued during the financial year by virtue of the exercise of options to take up unissued shares of the Company or its subsidiary corporations whether granted before or during the financial year.

There were no unissued shares of the Company or its subsidiary corporations under option at the end of the financial year.

DIRECTORS' STATEMENT

For the financial year ended 31 December 2023

Audit Committee ("AC")

The members of the Audit Committee during the financial year and at the date of this statement are:

Chan Kam Loon (Chairman)	(Non-Executive and Independent Director)
Koh Eng Kheng Victor	(Non-Executive and Independent Director)
Wu Yu Liang	(Non-Executive and Lead Independent Director)

The AC has written terms of reference that describe the responsibilities of its members. The AC meets at least four (4) times a year to perform the following main functions:

- (a) to review with the independent auditors their audit plan, their evaluation of the system of internal accounting controls relevant to their statutory audit and their report on the financial statements;
- (b) to review the assurance from the CEO and CFO (or their equivalents) on the financial records and financial statements;
- (c) to review quarterly and full year financial statements of the Company and of the Group, including announcements in relation thereto before their recommendation to the Board of Directors for approval to be released to Singapore Exchange Securities Trading Limited ("SGX-ST");
- (d) to review the assistance given by management to the independent auditors;
- (e) to review any significant unresolved differences between the independent auditors, internal auditors and management;
- (f) to review the scope and results of the audit and its cost effectiveness. The independence of independent auditors should be reviewed annually;
- (g) to review annually the nature and extent of non-audit services (where these are substantial) provided by the independent auditors to the Company to ensure that these are provided objectively;
- (h) to review the significant financial reporting issues and judgments so as to ensure the integrity of the financial statements of the Company and any formal announcements relating to the Company's financial performance;
- (i) to consider the appointment/re-appointment and removal of the independent auditors, the remuneration, terms of engagement and matters relating to the resignation or dismissal of the independent auditors for the purpose of making recommendations to the Board of Directors;
- (j) to commission and review the findings of internal investigations into matters where there is any suspected fraud or irregularity or failure of internal controls or suspected infringement of any law, rule and regulation (whether of Singapore or elsewhere) which has or is likely to have a material impact on the Group's and the Company's operating results and/or financial position, and management's response;
- (k) to review the adequacy and effectiveness of the Group's and the Company's internal controls, including financial, operational, compliance, information technology controls and risk management policies and systems established by the management at least once a year;
- (l) to review Whistle-Blowing Policy and to ensure that arrangements are in place for independent investigation of such matters and for appropriate follow up action;

DIRECTORS' STATEMENT

For the financial year ended 31 December 2023

Audit Committee (cont'd)

- (m) to review the adequacy, independence, scope, results and cost-effectiveness of internal audit procedures as well as the effectiveness of the Group's and Company's internal audit function;
- (n) to review interested person transactions periodically to ensure that they comply with the internal control procedures;
- (o) to undertake such other reviews and projects as may be requested by the Board of Directors; and
- (p) to undertake such other functions and duties as may be required by the SGX-ST Listing Manual Section B: Rule of Catalist ("Catalist Rules") or by law, and by such amendments made thereto from time to time.

The AC has full access to, and cooperation from the Management including the independent auditors, and has full discretion to invite any director and executive officer to attend its meetings. The AC also has power to investigate any matter brought to its attention, within its terms of reference, with the power to retain professional advice at the Company's expense.

The Board of Directors considers Mr Chan Kam Loon, who has extensive and practical accounting and financial management knowledge and experience, well qualified to chair the AC. Mr Wu Yu Liang is legally trained and he has attended the training of accounting and financial management and Mr Koh Eng Kheng Victor is also trained in accounting and financial management.

The members of the AC collectively have over 10 combined years of strong accounting and related financial management expertise and experience and are appropriately qualified to discharge their responsibilities.

During the financial year, the AC had met once with the internal auditors and independent auditors, without the presence of the management to discuss, amongst others, audit finding and evaluations of the Group's internal controls.

The AC had reviewed the scope and quality of audit by the independent auditors and the independence and objectivity of the independent auditors as well as the cost effectiveness, and is satisfied that the nature and extent of such services would not prejudice the independence of the independent auditors. The AC also reviewed the audit fees paid to the independent auditors. The audit fees for the Group and its associated companies for the financial year ended 31 December 2023 is S\$300,000 (2022: S\$300,000). The independent auditors did not render any non-audit services to the Group during the financial year.

No former Partner or Director of the Company's existing auditing firm or auditing corporation has acted as a member of the Company's AC: (a) within a period of two years commencing on the date of his/her ceasing to be a Partner of the auditing firm or Director of the auditing corporation; and in any case (b) for as long as he/she has any financial interest in the auditing firm or auditing corporation.

The Company is in compliance with Rules 712 and 715 of the Catalist Rules in relation to its independent auditors, as the subsidiary and associated companies of the Company were audited by Baker Tilly China Certified Public Accountants (an independent member firm of the Baker Tilly International network) for the purpose of preparation of the consolidated financial statements of the Group.

The AC is satisfied with the independence and objectivity of the independent auditors, and has recommended to the Board that Baker Tilly TFW LLP be nominated for re-appointment as independent auditor of the Company at the forthcoming Annual General Meeting.

DIRECTORS' STATEMENT

For the financial year ended 31 December 2023

Independent auditor

The independent auditor, Baker Tilly TFW LLP, has expressed its willingness to accept re-appointment.

On behalf of the Board of Directors

Xu Aijun
Director

Song Fudong
Director

5 April 2024

INDEPENDENT AUDITOR'S REPORT

To the Members of Jiutian Chemical Group Limited

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of Jiutian Chemical Group Limited (the "Company") and its subsidiary companies (the "Group") as set out on pages 59 to 114, which comprise the statements of financial position of the Group and the Company as at 31 December 2023, and the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows of the Group and the statement of changes in equity of the Company for the financial year then ended, and notes to the financial statements, including material accounting policy information.

In our opinion, the accompanying consolidated financial statements of the Group and the statement of financial position and statement of changes in equity of the Company are properly drawn up in accordance with the provisions of the Companies Act 1967 (the "Act") and Singapore Financial Reporting Standards (International) ("SFRS(I)") so as to give a true and fair view of the consolidated financial position of the Group and the financial position of the Company as at 31 December 2023 and of the consolidated financial performance, consolidated changes in equity and consolidated cash flows of the Group and of the changes in equity of the Company for the financial year ended on that date.

Basis for Opinion

We conducted our audit in accordance with Singapore Standards on Auditing ("SSAs"). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Group in accordance with the Accounting and Corporate Regulatory Authority ("ACRA") *Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities* ("ACRA Code") together with the ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matter

Key audit matter is the matter that, in our professional judgement, was of most significance in our audit of the financial statements of the current period. This matter was addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on this matter.

INDEPENDENT AUDITOR'S REPORT

To the Members of Jiutian Chemical Group Limited

Report on the Audit of the Financial Statements (cont'd)

Key Audit Matter (cont'd)

Amount due from associated company

Description of key audit matter:

As disclosed in Note 12 to the financial statements, the carrying amount of amount due from associated company, Anyang Jiujiu Chemical Technology Co., Ltd. ("Anyang Jiujiu") is RMBNil (2022: RMB25,640,000) as at 31 December 2023. An impairment loss of RMB25,840,000 (2022: RMB5,000,000) was recognised in the Group's profit or loss during the current financial year. Management performed an impairment assessment for the amount due from associated company using the expected credit loss model. The impairment assessment involves estimations of the amount the Group expects to recover from the associated company to determine the difference between the contractual cash flows due and those that the Group would expect to receive.

In assessing the impairment loss allowance, management evaluated the financial status and credit risk of the associated company, the Group's historical experience with the associated company, forward-looking information of the associated company including the realisation of the associated company's business resumption plans, the regulatory environment of the associated company, the proceeds recoverable from selling the Group's security collateral from the associated company, as well as the timing of expected cash flows for recovery of the receivable.

The impairment assessment of the amount due from associated company is considered a key audit matter as it requires the application of significant estimates and judgement in the measurement of expected credit loss by the management and details are as disclosed in Notes 3 and 12 to the financial statements.

Component auditor's and our procedures to address the key audit matter:

We obtained an understanding of management's impairment assessment of the amount due from associated company. We reviewed management's impairment assessment of the amount due from associated company using the expected credit loss model. We compared management's impairment assessment performed in the current financial year to that in the prior financial year to identify any significant changes in circumstances or key estimates. We assessed the reasonableness of management's estimates and judgement applied in its impairment assessment. We obtained an understanding from management on the current and future outlook of the associated company. We reviewed the adequacy and appropriateness of the disclosures made in the financial statements.

Other Information

Management is responsible for the other information. The other information comprises the information included in the Annual Report 2023, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

INDEPENDENT AUDITOR'S REPORT

To the Members of Jiutian Chemical Group Limited

Report on the Audit of the Financial Statements (cont'd)

Responsibilities of Management and Directors for the Financial Statements

Management is responsible for the preparation of the financial statements that give a true and fair view in accordance with the provisions of the Act and SFRS(I), and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets.

In preparing the financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The directors' responsibilities include overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

INDEPENDENT AUDITOR'S REPORT

To the Members of Jitian Chemical Group Limited

Report on the Audit of the Financial Statements (cont'd)

Auditor's Responsibilities for the Audit of the Financial Statements (cont'd)

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

In our opinion, the accounting and other records required by the Act to be kept by the Company have been properly kept in accordance with the provisions of the Act.

The engagement partner on the audit resulting in this independent auditor's report is Lim Kok Heng.

Baker Tilly TFW LLP
Public Accountants and
Chartered Accountants
Singapore

5 April 2024

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the financial year ended 31 December 2023

	Note	Group	
		2023	2022
		RMB'000	RMB'000
Revenue	4	598,563	2,434,843
Cost of sales		(858,741)	(1,726,430)
Gross (loss)/profit		(260,178)	708,413
Other income			
- Interest income from deposits with banks		15,362	15,025
- Others	5	8,882	7,329
Distribution costs		(11,526)	(18,747)
Administrative expenses		(37,559)	(44,012)
Other expenses	6	(6,951)	(1,560)
Impairment loss on financial assets		(25,840)	(5,097)
Finance costs	6	(2,615)	(2,496)
Share of results of associated companies		(26,499)	13,139
(Loss)/profit before tax	7	(346,924)	671,994
Tax credit/(expense)	9	195	(181,621)
(Loss)/profit and total comprehensive (loss)/income for the financial year		(346,729)	490,373
(Loss)/profit and total comprehensive (loss)/income for the financial year attributable to:			
Equity holders of the Company		(344,643)	490,497
Non-controlling interests		(2,086)	(124)
		(346,729)	490,373
Earnings per share for (loss)/profit for the financial year attributable to equity holders of the Company (in RMB cents per share)			
Basic and diluted	10	(17.33)	24.67

The accompanying notes form an integral part of these financial statements.

STATEMENTS OF FINANCIAL POSITION

As at 31 December 2023

	Note	Group		Company	
		2023	2022	2023	2022
		RMB'000	RMB'000	RMB'000	RMB'000
ASSETS					
Current assets					
Cash and cash equivalents	11	684,026	1,172,325	70,495	55,495
Trade and other receivables	12	207,382	483,065	301	315
Inventories	13	31,775	42,787	–	–
Total current assets		923,183	1,698,177	70,796	55,810
Non-current assets					
Property, plant and equipment	14	315,576	183,233	–	34
Land use rights	15	1,405	2,049	–	–
Investment in subsidiary companies	16	–	–	257,570	257,736
Investment in associated companies	17	48,898	75,397	48,898	75,397
Other receivables	12	–	25,640	–	–
Deferred tax assets	18	–	1,100	–	–
Total non-current assets		365,879	287,419	306,468	333,167
Total assets		1,289,062	1,985,596	377,264	388,977
LIABILITIES AND EQUITY					
Current liabilities					
Bank borrowings	19	199,874	84,702	–	–
Trade and other payables	20	245,242	511,560	1,481	1,812
Contract liabilities	21	12,099	22,207	–	–
Income tax payables		–	87,488	–	–
Total current liabilities		457,215	705,957	1,481	1,812
Non-current liabilities					
Bank borrowings	19	66,010	49,940	–	–
Deferred income	22	–	2,000	–	–
Deferred tax liabilities	18	–	6,750	–	–
Total non-current liabilities		66,010	58,690	–	–
Total liabilities		523,225	764,647	1,481	1,812

The accompanying notes form an integral part of these financial statements.

STATEMENTS OF FINANCIAL POSITION

As at 31 December 2023

	Note	Group		Company	
		2023	2022	2023	2022
		RMB'000	RMB'000	RMB'000	RMB'000
Capital and reserves					
Share capital	23	709,977	709,977	709,977	709,977
(Accumulated losses)/ retained earnings		(54,846)	401,655	(334,194)	(322,812)
Statutory reserve fund	24	110,706	110,706	–	–
Equity attributable to equity holders of the Company		765,837	1,222,338	375,783	387,165
Non-controlling interests		–	(1,389)	–	–
Total equity		765,837	1,220,949	375,783	387,165
Total liabilities and equity		1,289,062	1,985,596	377,264	388,977

The accompanying notes form an integral part of these financial statements.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the financial year ended 31 December 2023

		Share capital	Retained earnings/ (accumulated losses)	Statutory reserve fund	Equity attributable to equity holders of the Company	Non-controlling interests	Total equity
Note	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Group							
	Balance at 1 January 2022	709,977	58,089	48,142	816,208	(2,265)	813,943
	Profit and total comprehensive income for the financial year	–	490,497	–	490,497	(124)	490,373
	Capital injected by non-controlling interest	–	–	–	–	1,000	1,000
	Dividends	25	(84,367)	–	(84,367)	–	(84,367)
	Transfer to statutory reserve fund	24	(62,564)	62,564	–	–	–
	Balance at 31 December 2022	709,977	401,655	110,706	1,222,338	(1,389)	1,220,949
	Loss and total comprehensive loss for the financial year	–	(344,643)	–	(344,643)	(2,086)	(346,729)
	Liquidation of subsidiary companies	16	–	–	–	3,475	3,475
	Dividends	25	(111,858)	–	(111,858)	–	(111,858)
	Balance at 31 December 2023	709,977	(54,846)	110,706	765,837	–	765,837

The accompanying notes form an integral part of these financial statements.

STATEMENT OF CHANGES IN EQUITY

For the financial year ended 31 December 2023

		Share capital	Accumulated losses	Total equity
	Note	RMB'000	RMB'000	RMB'000
Company				
Balance at 1 January 2022		709,977	(340,101)	369,876
Profit and total comprehensive income for the financial year		–	101,656	101,656
Dividends	25	–	(84,367)	(84,367)
Balance at 31 December 2022		709,977	(322,812)	387,165
Profit and total comprehensive income for the financial year		–	100,476	100,476
Dividends	25	–	(111,858)	(111,858)
Balance at 31 December 2023		709,977	(334,194)	375,783

The accompanying notes form an integral part of these financial statements.

CONSOLIDATED STATEMENT OF CASH FLOWS

For the financial year ended 31 December 2023

	Note	Group	
		2023 RMB'000	2022 RMB'000
Cash flows from operating activities			
(Loss)/profit before tax		(346,924)	671,994
Adjustments for:			
Amortisation of land use rights	7	644	643
Depreciation of property, plant and equipment	7	22,536	21,669
Financing bank charges	6	632	197
Gain on liquidation of subsidiary companies	5, 16(c)	(796)	–
Impairment loss on financial assets		25,840	5,097
Interest expenses on bank borrowings	6	1,983	2,299
Interest income		(15,362)	(15,025)
Inventories written down	13	9,686	–
Loss on disposal of property, plant and equipment	6	3,380	1,451
Share of results of associated companies		26,499	(13,139)
Unrealised gain on foreign exchange		(2,473)	(5,269)
Operating cash flows before movements in working capital		(274,355)	669,917
Changes in operating assets and liabilities:			
Inventories		1,326	18,334
Receivables		254,601	131,356
Payables and contract liabilities		(289,642)	(175,622)
Cash (used in)/generated from operations		(308,070)	643,985
Interest received		15,362	15,025
Income tax paid		(92,943)	(225,004)
Net cash (used in)/generated from operating activities		(385,651)	434,006
Cash flows from investing activities			
Advances to associated company, net		(200)	(177)
Liquidation of subsidiary companies	16(c)	(318)	–
Purchases of property, plant and equipment	A	(125,578)	(9,961)
Proceeds from disposal of property, plant and equipment		394	285
Net cash used in investing activities		(125,702)	(9,853)

The accompanying notes form an integral part of these financial statements.

CONSOLIDATED STATEMENT OF CASH FLOWS

For the financial year ended 31 December 2023

	Note	Group	
		2023 RMB'000	2022 RMB'000
Cash flows from financing activities			
Capital injected by non-controlling interest		–	1,000
Dividends paid	25	(111,858)	(84,367)
Drawdown of bank borrowings	19	66,010	10,000
Financing bank charges paid	19	(632)	(197)
Drawdown of bills payables to banks	19	301,397	248,412
Repayment of bills payables to banks	19	(226,165)	(341,951)
(Increase)/decrease in pledged fixed deposits		(21,258)	83,882
Interest expenses on bank borrowings paid	19	(3,226)	(2,299)
Refund of deposit paid to secure bank borrowings		5,000	–
Repayment of bank borrowings	19	(10,000)	(10,000)
Net cash used in financing activities		(732)	(95,520)
Net (decrease)/increase in cash and cash equivalents			
Cash and cash equivalents at beginning of the financial year		1,107,623	773,550
Effect of exchange rate changes on cash and cash equivalents		2,528	5,440
Cash and cash equivalents at end of the financial year	11	598,066	1,107,623
Note A:			
<u>Purchases of property, plant and equipment ("PPE")</u>			
Aggregate cost of PPE acquired	14	187,303	8,997
Add: Outstanding payables at 1 January	20	29,415	30,379
Less: Outstanding payables related to former subsidiary companies that liquidated during the financial year		(27,289)	–
Less: Outstanding payables at 31 December	20	(62,608)	(29,415)
Less: Capitalised borrowing costs	14	(1,243)	–
Net cash outflow for purchases of PPE		125,578	9,961

The accompanying notes form an integral part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

These notes form an integral part of and should be read in conjunction with the accompanying financial statements.

1 Corporate information

The Company (Co. Reg. No. 200415416H) is incorporated and domiciled in Singapore and is listed on the Singapore Exchange Securities Trading Limited ("SGX-ST").

The registered office and principal place of business of the Company are located at 9 Raffles Place, #26-01 Republic Plaza, Singapore 048619 and 350 Orchard Road #21-03 Shaw House, Singapore 238868, respectively. The principal place of business of the Group is located at Zhangwu Street, Long An District, Anyang City, Henan Province, the People's Republic of China ("PRC").

The principal activity of the Company is that of investment holding. The principal activities of the subsidiary companies are disclosed in Note 16.

2 Material accounting policies

a) Basis of preparation

The financial statements are presented in Chinese Renminbi ("RMB"), which is the Company's functional currency and all financial information presented in RMB have been rounded to the nearest thousand (RMB'000), unless otherwise stated. The financial statements have been prepared in accordance with the provisions of the Companies Act 1967 and Singapore Financial Reporting Standards (International) ("SFRS(I)"). The financial statements have been prepared under the historical cost convention except as disclosed in the accounting policies below.

The preparation of financial statements in conformity with SFRS(I) requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the financial year. Although these estimates are based on management's best knowledge of current events and actions and historical experiences and various other factors that are believed to be reasonable under the circumstances, actual results may ultimately differ from those estimates.

Use of estimates and judgements

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The areas involving a higher degree of judgement in applying accounting policies, or areas where assumptions and estimates have a significant risk of resulting in material adjustment within the next financial year are disclosed in Note 3.

The carrying amounts of cash and cash equivalents, trade and other receivables and payables and current bank borrowings approximate their respective fair values due to the relatively short-term maturity of these financial instruments.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

2 Material accounting policies (cont'd)

a) Basis of preparation (cont'd)

New and revised standards that are adopted

In the current financial year, the Group has adopted all the new and revised SFRS(I) and SFRS(I) Interpretations ("SFRS(I) INT") that are relevant to its operations and effective for the current financial year. Changes to the Group's accounting policies have been made as required, in accordance with the transitional provisions in the respective SFRS(I) and SFRS(I) INT.

The adoption of these new and revised SFRS(I) and SFRS(I) INT did not have any material effect on the financial results or position of the Group and the Company except as disclosed below:

Amendments to SFRS(I) 1-1 and SFRS(I) Practice Statement 2: Disclosure of Accounting Policies

The amendments to SFRS(I) 1-1 and SFRS(I) Practice Statement 2 *Making Materiality Judgements* provide guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments require entities to disclose their material accounting policies rather than their significant accounting policies, and provide guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures.

The Group has adopted the amendments to SFRS(I) 1-1 on disclosures of accounting policies. The amendments have no impact on the measurement, recognition and presentation of any items in the Group's and the Company's financial statements.

New and revised standards not yet effective

New standards, amendments to standards and interpretations that have been issued at the end of the reporting period but are not yet effective for the financial year ended 31 December 2023 have not been applied in preparing these financial statements. None of these are expected to have a significant effect on the financial statements of the Group and the Company.

b) Subsidiary companies

Subsidiary companies are entities controlled by the Group. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity.

In the Company's statement of financial position, investment in subsidiary companies are accounted for at cost less accumulated impairment losses, if any. On disposal of the investments, the difference between disposal proceeds and the carrying amounts of the investments are recognised in profit or loss.

c) Basis of consolidation

The consolidated financial statements comprise the financial statements of the Company and its subsidiary companies at the end of the reporting period. Subsidiary companies are consolidated from the date on which the Group obtains control, and continue to be consolidated until the date that such control ceases.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

2 Material accounting policies (cont'd)

c) Basis of consolidation (cont'd)

The financial statements of the subsidiary companies are prepared for the same reporting date as the parent company. Consistent accounting policies are applied for like transactions and events in similar circumstances.

Intragroup balances and transactions, including income, expenses and dividends, are eliminated in full. Profits and losses resulting from intragroup transactions that are recognised in assets, such as inventory and property, plant and equipment, are eliminated in full.

Consolidation of the subsidiary companies in PRC are based on the subsidiary companies' financial statements prepared in accordance with SFRS(I). Profits reflected in the financial statements prepared in accordance with SFRS(I) may differ from those reflected in the PRC statutory financial statements of the subsidiary companies, prepared for PRC reporting purposes. In accordance with the relevant laws and regulations, profits available for distribution by the PRC subsidiary companies are based on the amounts stated in the PRC statutory financial statements.

d) Associated companies

An associated company is an entity over which the Group has significant influence but not control or joint control, over the financial and operating policies of the entity.

Investment in associated companies are accounted for in the consolidated financial statements using the equity method of accounting, less impairment losses, if any.

Investment in associated companies are initially recognised at cost. Subsequent to initial recognition, the consolidated financial statements include the Group's share of the post-acquisition profit or loss and other comprehensive income of equity-accounted investees, after adjustments to align the accounting policies with those of the Group, from the date that significant influence commences until the date that significant influence ceases.

Distributions received from associated companies are adjusted against the carrying amount of the investment. When the Group's share of losses in an associated company equals or exceeds its interest in the associated company, including any other unsecured non-current receivables, the Group does not recognise further losses, unless it has obligations or has made payments on behalf of the associated company.

Where a group entity transacts with an associated company of the Group, unrealised gains and losses are eliminated to the extent of the Group's interest in the relevant associated company. Unrealised losses are also eliminated unless the transactions provide evidence of impairment of the assets transferred.

In the Company's statement of financial position, investment in associated companies are carried at cost less accumulated impairment losses. On disposal of investment in associated companies, the difference between the disposal proceeds and the carrying amount of the investment is recognised in profit or loss.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

2 Material accounting policies (cont'd)

e) Property, plant and equipment

Property, plant and equipment are initially recognised at cost and subsequently carried at cost less accumulated depreciation and any impairment in value.

Depreciation is calculated on a straight-line method to allocate the depreciable amounts of property, plant and equipment over their estimated useful lives. The estimated useful lives are as follows:

Leasehold buildings	15 to 40 years (over the terms of lease)
Machinery and equipment	3 to 28 years
Motor vehicles	8 years

Construction work-in-progress represents assets in the course of construction for production, or administrative purposes, or for purposes not yet determined, are carried at cost, less any recognised impairment loss until construction or development is completed. Cost includes professional fees and, for qualifying assets, borrowing costs capitalised in accordance with the Group's accounting policies (Note 2(m)). Depreciation of these assets, on the same basis as other property assets, commences when the assets are ready for their intended use.

f) Land use rights

Land use rights are initially recognised at cost and subsequently carried at cost less accumulated amortisation and any impairment in value. Land use rights are amortised on a straight-line basis over the operation period of 18.5 years.

g) Impairment of non-financial assets excluding goodwill

At the end of each reporting period, the Group assesses the carrying amounts of its non-financial assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs of disposal and value-in-use. In estimating value-in-use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss.

Where an impairment loss subsequently reverses, the carrying amount of the asset (cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (cash-generating unit) in prior years. A previously recognised impairment loss for an asset other than goodwill is only reversed if there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognised. A reversal of an impairment loss is recognised immediately in profit or loss.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

2 Material accounting policies (cont'd)

h) Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined on a weighted average basis. The cost of finished goods comprises raw materials, direct labour, other direct costs and related production overheads based on normal operating capacity but excludes borrowing costs. Net realisable value is the estimated selling price in the ordinary course of business, less the costs of completion and selling expenses.

i) Financial assets

Recognition and derecognition

Regular way purchases and sales of financial assets are recognised on trade date - the date on which the Group commits to purchase or sell the asset. Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all risks and rewards of ownership.

Financial assets are initially measured at fair value. Transaction costs that are directly attributable to the acquisition of financial assets (other than financial assets at fair value through profit or loss) are added to the fair value of the financial assets on initial recognition. Transaction costs directly attributable to acquisition of financial assets at fair value through profit or loss are recognised immediately in profit or loss. Trade receivables without a significant financing component is initially measured at transaction prices.

Classification and measurement

All financial assets are subsequently measured in their entirety at either amortised cost or fair value, depending on the classification of the financial assets.

The Group classifies its financial assets at amortised cost. The classification is based on the Group's business model for managing the financial asset and the contractual cash flow characteristics of the financial assets.

The Group reclassifies financial assets when and only when its business model for managing those assets changes.

Subsequent measurement

Debt instruments include cash and cash equivalents and trade and other receivables (excluding prepayments, value-added tax recoverable and advance payments to suppliers). The subsequent measurement category is dependent on the Group's business model for managing the asset and cash flow characteristics of the asset.

The Group measures financial assets at amortised cost if both of the following conditions are met:

- The financial asset is held within a business model with the objective to hold financial assets in order to collect contractual cash flows; and
- The contractual terms of the financial asset give rise on specific dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

2 Material accounting policies (cont'd)

i) Financial assets (cont'd)

Subsequent measurement (cont'd)

Financial assets at amortised cost are subsequently measured using the effective interest rate ("EIR") method and are subject to impairment. Gains and losses are recognised in profit or loss when the asset is derecognised, modified or impaired. Interest income from these financial assets is included in interest income using the EIR method.

Impairment

The Group recognises an allowance for expected credit losses ("ECLs") for financial assets carried at amortised cost. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate.

The impairment methodology applied depends on whether there has been a significant increase in credit risk. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a "12-month ECL"). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a "lifetime ECL").

For trade receivables that do not have a significant financing component, the Group applies a simplified approach to recognise a loss allowance based on lifetime ECLs at each reporting date.

If the Group has measured the loss allowance for a financial asset at an amount equal to lifetime ECL in the previous reporting period, but determines at the current reporting date that the conditions for lifetime ECL are no longer met, the Group measures the loss allowance at an amount equal to 12-month ECL at the current reporting date.

The Group recognises an impairment gain or loss in profit or loss for all financial assets with a corresponding adjustment to their carrying amount through a loss allowance account.

Offset

Financial assets and liabilities are offset and the net amount presented on the statement of financial position when, and only when the Group has a legal right to offset the amounts and intends either to settle on a net basis or to realise the asset and settle the liability simultaneously.

j) Financial liabilities

Financial liabilities include trade and other payables (excluding value-added tax payables) and bank borrowings. Trade bills payables represent trade bills receivables that have been endorsed as payments to the suppliers and yet to mature at the end of the reporting period.

Financial liabilities are recognised on the statement of financial position when, and only when, the Group becomes a party to the contractual provisions of the financial instruments.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

2 Material accounting policies (cont'd)

j) Financial liabilities (cont'd)

Financial liabilities are initially recognised at fair value plus directly attributable transaction costs and subsequently measured at amortised costs using the effective interest method.

A financial liability is derecognised when the obligation under the liability is extinguished. Gains and losses are recognised in profit or loss when the liabilities are derecognised and through the amortisation process.

k) Revenue recognition

Sales of goods

The Group sells chemical-based products, methylamine and dimethylformamide ("DMF"). The Group transfers control and recognises a sale when they deliver goods to their customers. The amount of revenue recognised is the amount of the transaction price allocated to the satisfied performance obligation. Transaction price is the amount of consideration in the sales invoice and sales contract to which the Group expects to be entitled in exchange for transferring the promised goods. No element of financing is deemed present as the sales are made with an average credit period of 90 days which is consistent with market practice. A receivable is recognised when the goods are delivered as this is the point in time that the consideration is unconditional because only the passage of time is required before the payment is due.

For protective reasons, a portion of the contract consideration is received upfront, and the remaining consideration is received from customers when goods are delivered to the customers. As such, no financing component has been recognised as the payment terms are for reasons other than financing.

Interest income

Interest income is recognised using the effective interest method.

Rental income

Lease payments from operating leases are recognised on a straight-line basis over the lease term.

l) Employee benefits

Employee leave entitlement

Employee entitlements to annual leave are recognised when they accrue to employees. A provision is made for the estimated liability for annual leave as a result of services rendered by employees up to the end of the reporting period.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

2 Material accounting policies (cont'd)

l) Employee benefits (cont'd)

Defined contribution plans

Defined contribution plans are post-employment benefit plans under which the Group pays fixed contributions into separate entities such as the Central Provident Fund in Singapore, and will have no legal or constructive obligation to pay further contributions once the contributions have been paid. Contributions to defined contribution plans are recognised as an expense in the period in which the related service is performed.

Pursuant to the relevant regulations in the PRC, the Group's subsidiaries in the PRC (the "PRC subsidiaries") participate in central pension schemes (the "Schemes") operated by local municipal governments whereby the PRC subsidiaries are required to contribute a certain percentage of the basic salaries of their employees to the Schemes to fund their retirement benefits. The local municipal governments undertake to assume the retirement benefit obligations of all existing and future retired employees of the PRC subsidiaries. The only obligation of the PRC subsidiaries with respect to the Schemes is to pay the ongoing required contributions under the Schemes mentioned above. Contributions under the Schemes are recognised as an expense in the period in which the related service is performed.

m) Borrowing costs

Borrowing costs, which comprise interest and other costs incurred in connection with the borrowing of funds, are capitalised as part of the cost of a qualifying asset if they are directly attributable to the acquisition, construction or production of that asset. Capitalisation of borrowing costs commences when the activities to prepare the asset for its intended use or sale are in progress and the expenditures and borrowing costs are incurred. Borrowing costs are capitalised until the assets are substantially completed for their intended use or sale. All other borrowing costs are recognised in profit or loss using the effective interest method.

n) Foreign currencies

Functional and presentation currency

Items included in the financial statements of each entity in the Group are measured using the currency of the primary economic environment in which that entity operates (the "functional currency"). The financial statements of the Group and the Company are presented in the Renminbi, which is the functional currency of the Company, its subsidiary companies and associated companies.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

3 Critical accounting judgements and key sources of estimation uncertainty

Critical judgements in applying the Group's accounting policies

In the process of applying the Group's accounting policies, which are described in Note 2, management has made the following judgements that have the most significant effect on the amounts recognised in the financial statements (apart from those involving estimations, which are dealt with below):

Investment in associated company

As disclosed in Note 17, the Group's effective interest in Anyang Jiujiu Chemical Technology Co., Ltd. ("Anyang Jiujiu") is 74%. However, management has assessed and concluded that the Group has no control but only significant influence over Anyang Jiujiu as the majority voting rights and representative of the board of the directors in Anyang Jiujiu are held by Anyang Jiulong Chemical Co., Ltd. ("Anyang Jiulong"). Anyang Jiulong is in turn a subsidiary company of Henan Energy and Chemical Industry Group Co., Ltd. ("HNEC"). As such, HNEC has control over Anyang Jiujiu through Anyang Jiulong. Accordingly, the Group has accounted for this investment as its associated company in the consolidated financial statements using the equity method of accounting.

Key sources of estimation uncertainty

The key assumptions concerning the future, and other key sources of estimation uncertainty at the end of the reporting period, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are discussed below.

Useful lives and residual values of property, plant and equipment

Property, plant and equipment are depreciated on a straight-line basis over their estimated useful lives, after taking into account their estimated residual values. The Group reviews the useful lives and residual values of property, plant and equipment at the end of each reporting period in accordance with the accounting policy in Note 2(e). The estimation of the useful lives and residual values involves assumptions concerning the future and estimation of the assets' common life expectancies and expected level of usage. Any changes in the expected useful lives of these assets would affect the carrying amounts of property, plant and equipment and the depreciation charges for the financial year. The carrying amounts of property, plant and equipment and the depreciation charges for the financial year are disclosed in Note 14.

Impairment review of property, plant and equipment and land use rights

The Group assesses whether there are any indicators of impairment for property, plant and equipment and land use rights in accordance with the accounting policy in Note 2(g). The Group also assesses whether there is any indication that an impairment loss recognised in prior periods for property, plant and equipment may no longer exist or may have decreased. An impairment loss recognised in prior periods shall be reversed if there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognised. An impairment loss exists when the carrying value of the property, plant and equipment and land use rights exceeds their recoverable amount, which is the higher of its fair value less costs of disposal and its value-in-use.

The carrying value of the Group's property, plant and equipment and land use rights are disclosed in Note 14 and Note 15 respectively.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

3 Critical accounting judgements and key sources of estimation uncertainty (cont'd)

Key sources of estimation uncertainty (cont'd)

Impairment review of investment in associated companies

Management exercises their judgement in estimating recoverable amounts of its investment in associated companies.

The recoverable amounts of the investments are reviewed at the end of each reporting period to determine whether there is any indication that these investments have suffered an impairment loss. If any such indication exists, the recoverable amount is estimated in order to determine the extent of the impairment loss (if any). An impairment exists when the carrying value of an asset or cash generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value-in-use.

When value-in-use calculations are undertaken, management is required to estimate the expected future cash flows from the asset or cash-generating unit and a suitable discount rate, in order to determine the present value of those cash flows. The carrying values of the Company's investment in associated companies are disclosed in Note 17. Further details of the key assumptions applied in the impairment assessment of the Company's investment in associated companies are disclosed in Note 17. Changes in assumptions made and discount rate applied could affect the carrying value of the investments in associated companies.

Calculation of loss allowance

When measuring ECL, the Group uses reasonable and supportable forward-looking information, which is based on assumptions and forecasts of future economic conditions with consideration of the impact of the current macroeconomic uncertainties and how these conditions will affect the Group's ECL assessment. Loss given default is an estimate of the loss arising on default. It is based on the difference between the contractual cash flows due and those that the lender would expect to receive, taking into account cash flows from collateral and integral credit enhancements.

Probability of default constitutes a key input in measuring ECL. Probability of default is an estimate of the likelihood of default over a given time horizon, the calculation of which includes historical data, assumptions and expectations of future conditions.

As the calculation of loss allowance on trade and other receivables is subject to assumptions and forecasts, any changes to these estimations will affect the amounts of loss allowance recognised and the carrying amounts of trade and other receivables. Details of ECL measurement and carrying value of trade and other receivables at the reporting date are disclosed in Note 27(b) and Note 12 respectively.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

4 Revenue

Revenue represents the amount received or receivable from sales of goods, net of sales related taxes. Revenue are predominantly attributable from the PRC. All revenue are recognised at a point in time.

The following table provides a disaggregation disclosure of the Group's revenue by major product of the Group.

	Group	
	2023	2022
	RMB'000	RMB'000
Methylamine	380,440	1,430,176
DMF	206,568	993,311
Others	11,555	11,356
	598,563	2,434,843

Revenue recognised during the financial year from amounts included in contract liabilities at the beginning of the financial year amounted to RMB18,008,000 (2022: RMB36,765,000) (Note 21).

The Group applies the practical expedient in SFRS(I) 15 *Revenue from Contracts with Customers* and does not disclose information about its remaining performance obligation as the performance obligation is part of contracts that have original expected duration of one year or less.

5 Other income - others

	Group	
	2023	2022
	RMB'000	RMB'000
Gain on liquidation of subsidiary companies (Note 16(c))	796	–
Government grant income	30	44
Net gain on foreign exchange	5,550	5,083
Rental income	882	826
Commission fee	–	486
Outsourcing services income	886	–
Sundry income	738	890
	8,882	7,329

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

6 Other expenses and finance costs

	Group	
	2023	2022
	RMB'000	RMB'000
Other expenses		
Loss on disposal of property, plant and equipment	3,380	1,451
Inventories written down (Note 13)	3,571	–
Others	–	109
	6,951	1,560
Finance costs		
Interest expenses on bank borrowings	1,983	2,299
Financing bank charges	632	197
	2,615	2,496

7 (Loss)/profit before tax

(Loss)/profit before tax is arrived at after charging:

	Group	
	2023	2022
	RMB'000	RMB'000
Amortisation of land use rights (Note 15)	644	643
Audit fees paid/payable to:		
- independent auditor of the Company	945	908
- other auditors – Baker Tilly International network firms	330	40
Depreciation of property, plant and equipment (Note 14)	22,536	21,669
Directors' fees	1,112	981
Inventories written down (Note 13)	6,115	–
Staff costs (Note 8)	46,915	56,653
Lease expenses	4,795	4,745
Transportation charges	5,770	13,435

In 2023 and 2022, there are no fees for non audit services paid/payable to the auditors of the Company and other auditors of the Group.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

8 Staff costs

	Group	
	2023	2022
	RMB'000	RMB'000
<i>Directors of the Company</i>		
- Salaries, bonus and other benefits	2,591	2,566
- Defined contribution benefits	62	70
<i>Directors of the subsidiary companies</i>		
- Salaries and bonus	217	294
- Defined contribution benefits	80	75
<i>Key management personnel (non-directors)</i>		
- Salaries and bonus	1,570	1,893
- Defined contribution benefits	392	408
<i>Other personnel</i>		
- Salaries, bonus and other benefits	27,157	39,644
- Defined contribution benefits	14,846	11,703
	46,915	56,653

9 Tax (credit)/expense

	Group	
	2023	2022
	RMB'000	RMB'000
Income tax		
- Current year	-	166,436
- Withholding tax	6,750	4,750
- (Over)/under provision in respect of prior years	(1,295)	10,305
Deferred tax		
- Current year (Note 18)	(5,650)	130
	(195)	181,621

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

9 Tax (credit)/expense (cont'd)

The tax (credit)/expense on the results of the financial year differs from the amount of income tax determined by applying the domestic rates applicable to profit in the countries where the Group operates due to the following factors:

	Group	
	2023	2022
	RMB'000	RMB'000
(Loss)/profit before tax	(346,924)	671,994
Share of results of associated companies	26,499	(13,139)
	(320,425)	658,855
Tax at the domestic rates in the countries where the Group operates	(79,957)	162,852
Income not subject to tax	(1,203)	–
Expenses not deductible for tax purposes	8,701	1,709
(Over)/under provision of income tax expenses in prior years	(1,295)	10,305
Deferred tax asset not recognised	73,560	–
Effect of withholding tax on the distributable profits of the Group's PRC subsidiary companies	–	6,750
Others	(1)	5
	(195)	181,621

The above tax reconciliation is prepared by aggregating separate reconciliations for each national jurisdiction.

The statutory income tax rate applicable to the Company is 17% (2022: 17%).

Pursuant to the relevant laws and regulations in the PRC, the subsidiary companies of the Group which were incorporated in the PRC are required to pay the PRC enterprise income tax at a uniform rate of 25% (2022: 25%).

Pursuant to the PRC Corporate Income Tax Law, a 10% withholding tax is levied on dividends declared to foreign investors from the foreign investment enterprises established in Mainland China. The requirement is effective from 1 January 2008 and applies to earnings after 31 December 2007. A lower withholding tax rate may be applied if there is a tax treaty between Mainland China and the jurisdiction of the foreign investors. For the Group, the applicable rate is 5%. The Group is therefore liable for withholding taxes on dividends distributed by those subsidiary companies established in Mainland China in respect of earnings generated from 1 January 2008. At the end of the reporting period, deferred tax liability of RMBNil (2022: RMB6,750,000) has been recognised on the undistributed earnings of the subsidiary companies (Note 18).

There are no income tax consequences attaching to the payment of dividends by the Company to its shareholders.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

10 Earnings per share

The calculation of the basic and diluted earnings per share attributable to the ordinary equity holders of the Company is based on the following:

	Group	
	2023	2022
(Loss)/profit for the financial year attributable to equity holders of the Company (RMB'000)	(344,643)	490,497
Weighted average number of ordinary shares ('000)	1,988,444	1,988,444
Earnings per share (RMB cents per share)	(17.33)	24.67

Diluted earnings per share are the same as basic earnings per share as there were no potential dilutive ordinary shares for the financial years ended 31 December 2023 and 31 December 2022.

11 Cash and cash equivalents

	Group		Company	
	2023	2022	2023	2022
	RMB'000	RMB'000	RMB'000	RMB'000
Cash on hand and at bank	529,620	1,107,623	2,049	55,495
Fixed deposits	154,406	64,702	68,446	–
	684,026	1,172,325	70,495	55,495
Pledged fixed deposits	(85,960)	(64,702)	–	–
Cash and cash equivalents in the consolidated statement of cash flows	598,066	1,107,623	70,495	55,495

Fixed deposits earn interest rates ranging from 1.30% to 3.35% (2022: 1.30%) per annum.

Fixed deposits of RMB85,960,000 (2022: RMB64,702,000) are pledged to secure bills payables to banks (Note 19). The pledged fixed deposits will be released upon the settlement of the bills payables to banks on maturity date. The carrying amounts of these assets approximate their fair values.

The Group's and the Company's cash and cash equivalents that are not denominated in the functional currencies of the respective entities are as follows:

	Group		Company	
	2023	2022	2023	2022
	RMB'000	RMB'000	RMB'000	RMB'000
Singapore dollar	70,393	55,396	70,393	55,396
United States dollar	102	99	102	99

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

12 Trade and other receivables

	Group		Company	
	2023	2022	2023	2022
	RMB'000	RMB'000	RMB'000	RMB'000
<i>Current</i>				
Trade receivables:				
- Former subsidiary company (Note 16(c))	14,970	–	–	–
- Related party	6,262	6,257	–	–
- Third parties	638	1,220	–	–
Trade bills receivables (i)	135,065	469,119	–	–
	156,935	476,596	–	–
Less: Allowance for expected credit loss (Note 27(b))				
- Former subsidiary company	(14,970)	–	–	–
- Related party	(6,252)	(6,252)	–	–
Total trade receivables, net	135,713	470,344	–	–
Advance payments to suppliers:				
- Associated company	22,088	–	–	–
- Related party	13	419	–	–
- Third parties	57	5,731	–	–
Total advance payments to suppliers	22,158	6,150	–	–
Value-added tax recoverable	49,210	20	–	–
Prepayments	61	79	61	79
Refundable deposits	240	236	240	236
Other receivables:				
- Former subsidiary company (Note 16(c))	466	–	–	–
- Third parties	–	1,236	–	–
Security deposits paid to secure corporate guarantee of the bank borrowing (Note 19)	–	5,000	–	–
	72,135	12,721	301	315
Less: Allowance for expected credit loss – former subsidiary company (Note 27(b))	(466)	–	–	–
Total other receivables, net	71,669	12,721	301	315
	207,382	483,065	301	315

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

12 Trade and other receivables (cont'd)

	Group		Company	
	2023	2022	2023	2022
	RMB'000	RMB'000	RMB'000	RMB'000
<i>Non-current</i>				
Amount due from associated company (ii)	173,310	173,110	–	–
Less: Accumulated impairment loss (Note 27(b))	(173,310)	(147,470)	–	–
Net amount due from associated company	–	25,640	–	–
	207,382	508,705	301	315

The Group's and the Company's trade and other receivables that are not denominated in the functional currencies of the respective entities are as follows:

	Group		Company	
	2023	2022	2023	2022
	RMB'000	RMB'000	RMB'000	RMB'000
Singapore dollar	301	315	301	315

(i) Trade bills receivables

The average credit period on sales of goods is 90 days (2022: 90 days). No interest is charged on the overdue trade receivables. The Group's trade bills receivables are non-interest bearing and are normally settled on terms of 90 to 365 days (2022: 90 to 365 days).

Included in the Group's trade bills receivables are trade bills receivables amounting to RMB103,954,000 (2022: RMB383,265,000) that have been endorsed as payments made to the suppliers. The Group has retained the substantial risks and rewards, which include default risks relating to the trade bills receivables and the Group continued to recognise the full carrying amounts of the trade bills receivables and the associated trade bills payables accordingly. These trade bills receivables have yet to mature at the end of the reporting period (Note 20).

(ii) Amount due from associated company

The non-current amount due from associated company represents advances to Anyang Jiujiu and is interest-free.

Management estimated the impairment loss on the amount due from associated company using the expected credit loss model. In determining the impairment loss, management considered the pledge on a portion of Anyang Jiujiu's property, plant and equipment as security collateral of the amount due to the Group (the "Arrangement"), assessed the latest financial performance and financial position of Anyang Jiujiu, the realisation of Anyang Jiujiu's business resumption plans, the regulatory environment of Anyang Jiujiu, Anyang Jiujiu's historical ability in fulfilling the established repayment plan with the Group and the timing of expected cash flows for recovery of the receivable.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

12 Trade and other receivables (cont'd)

(ii) *Amount due from associated company (cont'd)*

In view of the recent amendments to PRC's legislature, Anyang Jiujiu's ongoing legal proceedings and the expected time and costs to be incurred to execute the Arrangement, management estimated that the expected cash flows for recovery of the receivable to be approximately RMBNil (2022: RMB25,640,000) and an impairment loss of RMB25,840,000 (2022: RMB5,000,000) was recognised in the Group's profit or loss during the financial year.

13 Inventories

	Group	
	2023	2022
	RMB'000	RMB'000
Raw materials, at cost	17,484	26,909
Finished goods, at cost and net realisable value	14,291	15,878
	31,775	42,787
Inventories written down recognised as an expense in cost of sales	6,115	–
Inventories written down recognised as an expense in other expenses - prolonged cessation of an operation	3,571	–
	9,686	–
Cost of inventories recognised as an expense in cost of sales	807,585	1,684,087

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

14 Property, plant and equipment

	Leasehold buildings	Machinery and equipment	Motor vehicles	Construction work-in- progress	Total
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Group					
Cost					
At 1 January 2022	91,273	534,681	3,281	97,389	726,624
Additions	–	3,969	421	4,607	8,997
Disposals	–	(8,840)	–	–	(8,840)
At 31 December 2022	91,273	529,810	3,702	101,996	726,781
Additions	–	14,665	3	172,635	187,303
Disposals	(7,488)	(27,158)	–	–	(34,646)
Liquidation of subsidiary companies (Note 16(c))	(2,391)	(5,558)	(140)	(77,729)	(85,818)
At 31 December 2023	81,394	511,759	3,565	196,902	793,620
Accumulated depreciation and impairment losses					
At 1 January 2022	42,940	433,440	2,396	50,207	528,983
Depreciation charge (Note 7)	2,618	18,935	116	–	21,669
Disposals	–	(7,104)	–	–	(7,104)
At 31 December 2022	45,558	445,271	2,512	50,207	543,548
Depreciation charge (Note 7)	2,527	19,896	113	–	22,536
Disposals	(4,918)	(25,954)	–	–	(30,872)
Liquidation of subsidiary companies (Note 16(c))	(1,263)	(5,558)	(140)	(50,207)	(57,168)
At 31 December 2023	41,904	433,655	2,485	–	478,044
Carrying amount					
At 31 December 2022	45,715	84,539	1,190	51,789	183,233
At 31 December 2023	39,490	78,104	1,080	196,902	315,576

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

14 Property, plant and equipment (cont'd)

- (i) Included in accumulated depreciation and impairment losses is accumulated impairment losses of RMBNil (2022: RMB50,207,000).
- (ii) Capitalisation of borrowing costs

During the financial year, borrowing costs capitalised as cost of property, plant and equipment amounted to RMB1,243,000 (2022: RMBNil). The borrowing costs capitalised are the actual borrowing costs incurred on funds borrowed specifically for the construction work-in-progress.

- (iii) Impairment review

During the financial year, management performed an impairment test for the Group's property, plant and equipment and land use rights as the Group incurred a net loss for the financial year. The recoverable amount of the Group's property, plant and equipment and land use rights was determined based on value-in-use calculations. The Group's value-in-use calculations used cash flow forecasts derived from the most recent financial budgets approved by management covering a five-year period. Cash flows at terminal year was forecasted using zero growth rate. The forecasted sales growth (average over next five years) and pre-tax discount rate is 9% and 14.9% respectively. The forecasted gross profit margin averaged at -23% over the first two years and 8% over the remaining three years of the five years cash flow forecast.

Based on management's assessment, no impairment loss is required on the Group's property, plant and equipment and land use rights as at 31 December 2023.

Sensitivity to changes in assumptions

Sensitivity analysis indicates that a slight deviation of the forecasted sales, pre-tax discount rate or forecasted average gross profit margin of approximately 1% lower, 1% higher or 1% lower respectively from management's estimates, would result in the Group recognising an impairment loss on the Group's property, plant and equipment and land use rights as at 31 December 2023.

	Office equipment	
	2023	2022
	RMB'000	RMB'000
Company		
Cost		
At 1 January and 31 December	411	411
Accumulated depreciation		
At 1 January	377	239
Additions	34	138
At 31 December	411	377
Carrying amount		
At 31 December	–	34

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

15 Land use rights

	Group	
	2023	2022
	RMB'000	RMB'000
Cost		
At 1 January	14,936	14,936
Liquidation of subsidiary companies (Note 16(c))	(2,897)	–
At 31 December	12,039	14,936
Accumulated amortisation		
At 1 January	12,887	12,244
Amortisation charge (Note 7)	644	643
Liquidation of subsidiary companies (Note 16(c))	(2,897)	–
At 31 December	10,634	12,887
Carrying amount		
At 31 December	1,405	2,049

The Group has made an upfront payment to secure the right-of-use for 47-50 years of leasehold land.

The details of the land use rights as at 31 December 2023 are as follows:

Location	Lease period	Land area (square metre)
Zhangwu Street, Long An District, Anyang City, Henan Province, PRC	50 years from August 2001	20,833
Dabai Highway West, Tianchi Village, Shuiye Town, Anyang City, Henan Province, PRC	50 years from December 2007	10,487
Zhangwu Street, Long An District, Anyang City, Henan Province, PRC	47 years from December 2007	49,875

During the financial year, management performed an impairment test for the Group's land use rights as disclosed in Note 14(iii).

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

16 Investment in subsidiary companies

	Company	
	2023	2022
	RMB'000	RMB'000
Unquoted equity shares, at cost		
At beginning of the financial year	265,724	265,724
Less: Liquidation	(8,154)	–
At end of the financial year	257,570	265,724
Less: Allowance for impairment loss	–	(7,988)
Total	257,570	257,736

Movement in allowance for impairment loss during the financial year are as follows:

	Company	
	2023	2022
	RMB'000	RMB'000
At beginning of the financial year	7,988	7,988
Allowance for impairment loss	166	–
Liquidation	(8,154)	–
At end of the financial year	–	7,988

(a) The details of the subsidiary companies are as follows:

Name of subsidiary company	Principal activities (Place of establishment/operation)	Proportion of ownership interest	
		2023	2022
		%	%
Held by the Company			
Anyang Jiutian Fine Chemical Co., Ltd. (“Anyang Jiutian”)	Production, sale and service of industrial methanol, methylamine, DMF and gas (PRC)	100	100
Changzhou Jiutian Xiean Chemical Co., Ltd. (“Changzhou Jiutian”)	Sale of methylamine, DMF, polyurethane and downstream products (PRC)	–	80
Held by Anyang Jiutian			
Henan Herunsheng Isotope Technology Co., Ltd. (“Herunsheng”)	Research and development of isotope technology and, manufacturing and trading of Oxygen 18 and deuterium depleted water (PRC)	–	45

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

16 Investment in subsidiary companies (cont'd)

(a) The details of the subsidiary companies are as follows: (cont'd)

Management has assessed and concluded that the Group had control over Herunsheng on the basis that another investor with 35% of the voting rights in Herunsheng is acting in concert with the Group, although the Group owns 45% of the voting rights in Herunsheng. The investor with 35% of the voting rights in Herunsheng has signed an agreement to vote in accordance with the decision as voted by the Group about relevant activities of Herunsheng including but are not limited to operating, financing and investing activities. The aggregate shareholding and voting rights in Herunsheng of the Group and its concert party is 80%. The sole director of Herunsheng is appointed by the Group. Accordingly, the Group has accounted for this investment as its subsidiary company. During the financial year ended 31 December 2023, Herunsheng commenced liquidation proceedings and accordingly, consolidation of Herunsheng ceased on the day the Group lost control over Herunsheng (Note 16(c)(i)).

The subsidiary companies are audited by Baker Tilly China Certified Public Accountants ("Baker Tilly China") (an independent member firm of the Baker Tilly International network) for the purpose of preparation of the consolidated financial statements of the Group.

(b) Significant restrictions

Cash and cash equivalents of RMB613,531,000 (2022: RMB1,116,830,000) are held in the PRC and are subject to local exchange control regulations. These regulations place restrictions on the amount of currency being exported, other than through dividends subject to the approval from relevant authorities.

(c) Liquidation of subsidiary companies

- (i) On 20 October 2023, liquidator was appointed for the purpose of winding up Herunsheng. Consequently, control over Herunsheng has been transferred to the liquidator and consolidation of Herunsheng ceased with effect from that day.
- (ii) On 16 November 2023, bankruptcy administrator was appointed for the purpose of winding up Changzhou Jiutian. Consequently, control over Changzhou Jiutian has been transferred to the bankruptcy administrator and consolidation of Changzhou Jiutian ceased with effect from that day.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

16 Investment in subsidiary companies (cont'd)

(c) Liquidation of subsidiary companies (cont'd)

At the date of deconsolidation, the assets and liabilities of the subsidiary companies comprised the following:

	Herunsheng 2023	Changzhou Jiutian 2023	Total 2023
	RMB'000	RMB'000	RMB'000
Property, plant and equipment	27,522	1,128	28,650
Trade and other receivables	657	–	657
Cash and cash equivalents	318	–	318
Trade and other payables	(27,798)	(15,335)	(43,133)
Contract liabilities	(4,199)	–	(4,199)
Deferred income	(2,000)	–	(2,000)
Net liabilities deconsolidated	(5,500)	(14,207)	(19,707)
Carrying value of net liabilities deconsolidated	(5,500)	(14,207)	(19,707)
Amounts due from subsidiary companies to the Group *	466	14,970	15,436
Non-controlling interest	3,475	–	3,475
(Gain)/loss on liquidation of subsidiary companies	(1,559)	763	(796)
Proceeds from liquidation received or receivable	–	–	–
Less: Cash and cash equivalents deconsolidated	(318)	–	(318)
Net cash outflow from liquidation of subsidiary companies	(318)	–	(318)

* Trade receivables due from Changzhou Jiutian of RMB14,970,000 and other receivables due from Herunsheng of RMB466,000 were impaired upon the commencement of winding up proceedings in the respective dates disclosed above.

The net gain on liquidation of subsidiary companies was recorded under "other income – others" in the consolidated statement of profit or loss and other comprehensive income for the financial year ended 31 December 2023.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

17 Investment in associated companies

	Group		Company	
	2023	2022	2023	2022
	RMB'000	RMB'000	RMB'000	RMB'000
Unquoted equity shares, at cost	339,709	339,709	339,709	339,709
Share of post-acquisition reserves	(290,811)	(264,312)	–	–
Allowance for impairment loss	–	–	(290,811)	(264,312)
	48,898	75,397	48,898	75,397

Movements in allowance for impairment loss during the financial year are as follows:

	Company	
	2023	2022
	RMB'000	RMB'000
At beginning of the financial year	264,312	277,451
Allowance for impairment loss	26,499	–
Reversal of allowance for impairment loss	–	(13,139)
At end of the financial year	290,811	264,312

The details of the associated companies are as follows:

Name of associated company	Principal activities (Principal place of business/ country of incorporation)	Proportion of ownership interest held	
		2023	2022
		%	%
Anyang Jiulong Chemical Co., Ltd. ("Anyang Jiulong")	Production of coal-based chemicals (PRC)	49	49
Anyang Jiujiu Chemical Technology Co., Ltd. ("Anyang Jiujiu")	Manufacturing and selling of sodium hydrosulfite (PRC)	74	74

The associated companies are audited by Baker Tilly China for the purpose of preparation of the consolidated financial statements of the Group. The activities of the associated companies are strategic to the Group's activities.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

17 Investment in associated companies (cont'd)

The Group's associated companies are Anyang Jiulong and Anyang Jiujiu. The Company's direct ownership interests in both Anyang Jiulong and Anyang Jiujiu are 49% (2022: 49%). The remaining 51% (2022: 51%) interest in Anyang Jiujiu is owned by Anyang Jiulong and accordingly, the Group's effective interests in Anyang Jiulong and Anyang Jiujiu are 49% and 74% (2022: 49% and 74%) respectively.

As disclosed in Note 3, management has assessed and concluded that the Group has no control but only significant influence over Anyang Jiujiu. Accordingly, the Group has accounted for its investment in Anyang Jiujiu as its associated company.

Anyang Jiulong Chemical Co., Ltd. ("Anyang Jiulong")

During the financial year, management performed an impairment test for the Company's investment in Anyang Jiulong as Anyang Jiulong had been making losses.

Management assessed that the recoverable amount of the Company's investment in Anyang Jiulong was lower than its carrying amount and an impairment loss of RMB26,499,000 was recognised in the Company's profit or loss for the current financial year ended 31 December 2023 accordingly (2022: recoverable amount had exceeded its carrying amount and a reversal of impairment loss of RMB13,139,000 was recognised). The recoverable amount of the investment amounting to RMB48,898,000 (2022: RMB75,397,000) was determined based on value-in-use calculations using cash flow projections from forecasts approved by management. The pre-tax discount rates applied to the cash flow projections and the forecasted gross profit margin used in the cash flow projections were 13% and -11% to 6% (2022: 15% and 2% to 10%) respectively.

Sensitivity to changes in assumptions

Management has considered the most significant assumption used in the value-in-use calculation is the gross profit margin applied. Had the gross profit margin varied from management's estimation, the estimated recoverable amount of the Company's investment in Anyang Jiulong and the impairment loss would be as follows:

	Estimated recoverable amount	Decrease/ (increase) in impairment loss in the Company's profit or loss
	RMB'000	RMB'000
Anyang Jiulong		
1% higher than the management's projection	66,367	17,469
1% lower than the management's projection	31,494	(17,404)

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

17 Investment in associated companies (cont'd)

Anyang Jiulong Chemical Co., Ltd. ("Anyang Jiulong") (cont'd)

The summarised financial information of Anyang Jiulong and its subsidiary company, Anyang Jiujiu based on their financial statements, which are prepared in accordance with International Financial Reporting Standards, not adjusted for the Group's share of those amounts and a reconciliation to the carrying amounts of the investments in the consolidated financial statements of the Group are as follows:

Summarised statement of profit or loss and other comprehensive income

	Anyang Jiulong and its subsidiary company	
	2023	2022
	RMB'000	RMB'000
Revenue	330,555	603,226
(Loss)/profit and total comprehensive (loss)/income attributable to:		
- Equity holders of the Company	(54,080)	26,814
- Non-controlling interests	(31,665)	(21,819)
	(85,745)	4,995

Summarised statement of financial position

	Anyang Jiulong and its subsidiary company	
	2023	2022
	RMB'000	RMB'000
Non-current assets	298,586	341,929
Current assets	229,747	148,234
Non-current liabilities	(5,628)	(5,809)
Current liabilities	(603,178)	(479,082)
Non-controlling interests	180,265	148,600
Total equity attributable to equity holders of the Company	99,792	153,872
Group's share of net assets based on proportion of ownership interest	48,898	75,397

The Group has not recognised its share of losses of Anyang Jiujiu amounting to RMB31,665,000 (2022: RMB21,819,000) during the current financial year because the Group's cumulative share of losses has exceeded its interest in that associated company and the Group has no obligation in respect of these losses. The Group's cumulative accumulated losses at the end of the reporting period in respect of this associated company not recognised were RMB311,149,000 (2022: RMB279,484,000).

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

17 Investment in associated companies (cont'd)

Significant restrictions

The associated companies in the PRC are subject to local exchange control regulations. These regulations place restrictions on the amount of currency being exported, other than through dividends subject to the approval from relevant authorities.

18 Deferred tax

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when the deferred income taxes relate to the same fiscal authority.

The following are the major deferred tax assets/liabilities recognised by the Group and the movements thereon during the current and prior reporting period:

	Accelerated accounting depreciation	Undistributed profits of subsidiary companies	Others	Total
	RMB'000	RMB'000	RMB'000	RMB'000
Group				
At 1 January 2023	503	(6,750)	597	(5,650)
(Charge)/credit to profit or loss (Note 9)				
- Current year	(503)	–	(597)	(1,100)
- Reversal due to utilisation	–	6,750	–	6,750
At 31 December 2023	–	–	–	–
At 1 January 2022	342	(6,750)	888	(5,520)
Credit/(charge) to profit or loss (Note 9)				
- Current year	161	(6,750)	(291)	(6,880)
- Reversal due to utilisation	–	6,750	–	6,750
At 31 December 2022	503	(6,750)	597	(5,650)

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

18 Deferred tax (cont'd)

	Group	
	2023	2022
	RMB'000	RMB'000
Representing:		
<i>Non-current</i>		
Deferred tax assets	–	1,100
Deferred tax liabilities	–	(6,750)
	–	(5,650)

The potential deferred tax assets on the following temporary differences have not been recognised in the financial statements at the end of the reporting period:

	Group	
	2023	2022
	RMB'000	RMB'000
Unabsorbed tax losses	294,244	2,282

Unabsorbed tax losses are available for carry forward up to five years from the year of loss to offset against future taxable income of the companies in which the tax losses arose subject to the agreement of the tax authorities and compliance with certain provisions of the tax legislation of the respective countries in which the companies operate. Included in unabsorbed tax losses are losses of RMB294,244,000 (2022: RMB2,282,000) that will expire in financial year 2028 (2022: financial year 2023 to 2025). The unabsorbed tax losses of RMBNil (2022: RMB2,282,000) from Changzhou Jiutian were not available for carry forward as at 31 December 2023 as consolidation of Changzhou Jiutian ceased during the financial year ended 31 December 2023 (Note 16(c)(ii)).

The potential deferred tax assets have not been recognised in the financial statements as it is not probable that the future taxable income in these companies will be sufficient to allow these temporary differences to be realised in the foreseeable future.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

19 Bank borrowings

	Group	
	2023	2022
	RMB'000	RMB'000
<i>Bank borrowings</i>		
Loan I	49,940	49,940
Loan II	–	10,000
Loan III	32,000	–
Loan IV	4,010	–
Loan V	30,000	–
	115,950	59,940
Bills payables to banks	149,934	74,702
	265,884	134,642
Representing:		
Current	199,874	84,702
Non-current	66,010	49,940
	265,884	134,642

Security for borrowings

Loan I bears interest rate of 3.70% (2022: 3.70%) per annum and is payable in 2024. Loan I is guaranteed by Anyang Chemical Industry Group Co., Ltd. ("Anhua") and Anyang Jiulong.

Loan II bore interest rate of 3.70% (2022: 3.70%) per annum and was repaid during the financial year. Loan II is unsecured.

Loans III, IV and V bear interest rate of 3.70% (2022: Nil) per annum and are payable in 2028. Loans III, IV and V are unsecured.

Bills payables to banks

Bills payables to banks are secured by certain fixed deposits held by the banks as disclosed in Note 11.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

19 Bank borrowings (cont'd)

Fair values

The carrying amounts of current bank borrowings approximate their fair values at the end of the reporting period.

Based on the discounted cash flows using market lending rate for similar borrowing which the management expects would be available to the Group at the end of the reporting period, the fair value of the non-current borrowing approximates its carrying amount as there are no significant changes in the interest rate available to the Group at the end of the reporting period. This fair value measurement is categorised within Level 3 of the fair value hierarchy.

Reconciliation of movements of liabilities to cash flows arising from financing activities

	Bank borrowings	Bills payables to banks	Total
	RMB'000	RMB'000	RMB'000
At 1 January 2022	59,940	168,241	228,181
Changes from financing cash flows:			
- Drawdown	10,000	248,412	258,412
- Repayment	(10,000)	(341,951)	(351,951)
- Interest paid	(2,299)	–	(2,299)
- Financing bank charges paid	–	(197)	(197)
Non-cash changes:			
- Interest expenses on bank borrowings	2,299	–	2,299
- Financing bank charges	–	197	197
At 31 December 2022	59,940	74,702	134,642
Changes from financing cash flows:			
- Drawdown	66,010	301,397	367,407
- Repayment	(10,000)	(226,165)	(236,165)
- Interest expenses on bank borrowings paid	(3,226)	–	(3,226)
- Financing bank charges paid	–	(632)	(632)
Non-cash changes:			
- Interest expenses on bank borrowings	1,983	–	1,983
- Financing bank charges	–	632	632
- Capitalised borrowing costs (Note 14)	1,243	–	1,243
At 31 December 2023	115,950	149,934	265,884

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

20 Trade and other payables

	Group		Company	
	2023	2022	2023	2022
	RMB'000	RMB'000	RMB'000	RMB'000
Trade payables due to:				
- Third parties	60,067	65,317	-	-
- Associated company	-	2,478	-	-
- Related parties	1,921	11,890	-	-
Trade bills payables due to: ^(a)				
- Third parties	103,954	306,295	-	-
- Associated company	-	17,842	-	-
- Related parties	-	59,128	-	-
Total trade payables	165,942	462,950	-	-
Payable for purchase of property, plant and equipment	62,608	29,415	-	-
Accrued operating expenses	5,663	1,980	670	190
Security deposits received	3,048	1,705	-	-
Value-added tax payables	1,386	2,558	-	-
Staff related costs	5,127	8,052	811	1,622
Others	1,468	4,900	-	-
Total other payables	79,300	48,610	1,481	1,812
Total trade and other payables	245,242	511,560	1,481	1,812

The average credit period on purchases of goods is 120 days (2022: 120 days).

The Group's and the Company's trade and other payables that are not denominated in the functional currencies of the respective entities are as follows:

	Group		Company	
	2023	2022	2023	2022
	RMB'000	RMB'000	RMB'000	RMB'000
Singapore dollar	1,481	1,812	1,481	1,812

(a) The Group's trade bills payables represent trade bills receivables that have been endorsed as payments made to the suppliers. These trade bills receivables have yet to mature at the end of the reporting period (Note 12).

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

21 Contract liabilities

The Group receives payments from customers based on a billing schedule as established in the contracts. Contract liabilities relate to advance consideration received from customers. Contract liabilities are recognised as revenue as (or when) the Group satisfies the performance obligations under its contracts.

The following table provides information about contract liabilities from contract with customers:

	Group		
	2023	2022	1.1.2022
	RMB'000	RMB'000	RMB'000
Trade receivables from contracts with customers	135,713	470,344	546,778
Contract liabilities	12,099	22,207	41,834

Significant changes in the contract liabilities balances during the financial year are as follows:

	Group	
	Contract liabilities	
	2023	2022
	RMB'000	RMB'000
Revenue recognised that was included in the contract liabilities balance at the beginning of the financial year (Note 4)	(18,008)	(36,765)
Increase due to advances received, excluding amounts recognised as revenue during the financial year	12,099	17,138
Deconsolidated due to liquidation of subsidiary company (Note 16(c))	(4,199)	–

22 Deferred income

	Group	
	2023	2022
	RMB'000	RMB'000
At beginning of the financial year	2,000	2,000
Deconsolidated due to liquidation of subsidiary company (Note 16(c))	(2,000)	–
At end of the financial year	–	2,000

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

23 Share capital

	Group and Company			
	2023	2022	2023	2022
	Number of ordinary shares		RMB'000	RMB'000
	'000	'000		
Issued and paid up capital				
At beginning and end of the financial year	1,988,444	1,988,444	709,977	709,977

All issued shares are fully paid ordinary shares with no par value.

The holders of ordinary shares are entitled to receive dividends as and when declared by the Company. All ordinary shares carry one vote per share without restrictions.

24 Statutory reserve fund

	Group	
	2023	2022
	RMB'000	RMB'000
At 1 January	110,706	48,142
Transferred from retained earnings	–	62,564
At 31 December	110,706	110,706

In accordance with the Foreign Enterprise Law of the PRC, the subsidiary, being a wholly foreign-owned enterprise is required to make contributions to a statutory reserve fund. At least 10% of the statutory after-tax profits as determined in accordance with the applicable PRC accounting standards and regulations is required to be allocated to the statutory reserve fund. If the cumulative total of the statutory reserve fund reaches 50% of the subsidiary's registered capital, the enterprise will not be required to make any additional contribution.

The statutory reserve fund may be used to set off against accumulated losses or to increase the registered capital of the subsidiary, subject to approval from the relevant PRC authorities and is not available for dividend distribution to the shareholders. The PRC enterprise is prohibited from distributing dividends unless the losses (if any) of previous years have been made up.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

25 Dividends

	Group and Company	
	2023	2022
	RMB'000	RMB'000
Ordinary dividends paid		
Interim exempt dividend of S\$0.0090 (approximately RMB0.0482) (2022: S\$0.0075 (approximately RMB0.0366)) per share paid in respect of the current financial year	95,877	72,748
Final exempt dividend of S\$0.0015 (approximately RMB0.0080) per share paid in respect of the previous financial year ended 31 December 2022	15,981	–
Final exempt dividend of S\$0.0012 (approximately RMB0.0058) per share paid in respect of the previous financial year ended 31 December 2021	–	11,619
	111,858	84,367

26 Related party transactions

Major shareholder

As at 31 December 2023, Anyang Longyu (HK) Development Co., Ltd. (“Anyang Longyu”) holds 502,429,900 (2022: 502,429,900) ordinary shares through its nominee, Philip Securities Pte. Ltd., representing approximately 25.27% (2022: 25.27%) of the issued share capital of the Company. Anyang Longyu is a wholly-owned subsidiary company of Anhua. Anhua is in turn a subsidiary company of HNEC. HNEC is one of the PRC’s most significant coal mining company and a significant manufacturer in the chemical industry.

Management is of the view that Anyang Longyu is able to exercise significant influence over the operations of the Group, and hence is considered as related party of the Group.

Transactions with HNEC and its subsidiary companies are considered as related party transactions.

Sales and purchases with Anhua

On 1 January 2005, Anyang Jiutian signed a 20-year raw materials and spare parts purchase agreement with Anhua. The transaction price would be mutually agreed by both parties and updated according to market price every three years. According to the supplementary agreement dated 30 July 2005, between Anyang Jiutian and Anhua, the transaction price will be reviewed every half year before October 2009 and will be reviewed every month thereafter.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

26 Related party transactions (cont'd)

Significant transactions with related parties

In addition to information disclosed elsewhere in the financial statements, the following transactions took place between the Group and related parties, who are not members of the Group during the financial year on terms agreed by the parties concerned:

	2023	2022
	RMB'000	RMB'000
Group		
<i>With associated companies (subsidiary company of HNEC)</i>		
Sales of goods	62,479	108,672
Purchases of goods, electricity and industrial steam	274,775	498,893
Rental expense	1,220	694
Advances given to, net	200	177
Impairment loss on financial assets	25,840	5,000
<i>With other subsidiary companies of HNEC</i>		
Sales of goods	10,352	13,797
Purchases of goods and industrial steam	44,586	185,777
Rental income	882	829
Rental expense	4,798	4,315
Exchange of bills for cash	–	77,141
Exchange of cash for bills	6,700	55,794

Outstanding balances with related parties at the end of the reporting period are disclosed in Note 12 and Note 20 respectively.

27 Financial instruments

a) Categories of financial instruments

Financial instruments at their carrying amounts at the end of the reporting period are as follows:

	Group		Company	
	2023	2022	2023	2022
	RMB'000	RMB'000	RMB'000	RMB'000
<i>Financial assets</i>				
At amortised cost	819,979	1,674,781	70,735	55,731
<i>Financial liabilities</i>				
At amortised cost	509,740	643,644	1,481	1,812

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

27 Financial instruments (cont'd)

b) Financial risk management

Management monitors and manages the financial risks relating to the operations of the Group and the Company to minimise adverse potential effects of financial performance. These risks include market risk (including foreign currency risk and interest rate risk), credit risk and liquidity risk.

Foreign currency risk

The principal entities in the Group transact their business significantly in RMB which is also the functional currency of the PRC entities and therefore the Group's exposure to foreign currency risk such as Singapore dollar ("SGD") is not expected to be significant.

The carrying amounts of monetary assets and monetary liabilities not denominated in the functional currency of the respective entities at the end of the reporting period are as follows:

	Group and Company					
	Assets		Liabilities		Net exposure	
	2023	2022	2023	2022	2023	2022
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
SGD	70,694	55,711	(1,481)	(1,812)	69,213	53,899

Foreign currency sensitivity analysis

The following table details the sensitivity to a reasonably possible change in the SGD exchange rate against the functional currency of the Group's entities, with all other variables held constant, of the Group's loss/profit before tax:

	Group and Company (Decrease)/increase in	
	Loss before tax	Profit before tax
	2023	2022
	RMB'000	RMB'000
SGD against RMB		
- Strengthened 5% (2022: 5%)	(3,461)	2,695
- Weakened 5% (2022: 5%)	3,461	(2,695)

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

27 Financial instruments (cont'd)

b) Financial risk management (cont'd)

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of the Group's and the Company's financial instruments will fluctuate because of changes in market interest rates. The Group's exposure to interest rate risk arises primarily from their borrowings and fixed deposits.

Borrowings and fixed deposits are at fixed rates of interest which expose the Group to fair value interest rate risk (i.e. the risk that the value of a financial instrument will fluctuate due to changes in market rates).

The Group's policy is to obtain the most favourable interest rates available and manage interest costs using a mix of fixed and floating rate debts depending on market and economic conditions. For interest income from fixed deposits, the Group manages interest rate risks by placing fixed deposits with reputable financial institutions on varying maturities and interest rate terms. The Group does not utilise derivatives to mitigate their interest rate risk.

At the end of the reporting period, the Group and the Company have no significant interest-bearing assets and liabilities at variable rates of interest, therefore the Group's and the Company's performance are substantially independent of changes in market interest rates. Accordingly, the sensitivity analysis for interest rate risk is not disclosed.

Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Group. The Group has adopted a policy of dealing only with creditworthy counterparties and obtaining sufficient collateral where appropriate, as a means of mitigating the risk of financial loss from defaults. The Group's exposure and the credit ratings of its counterparties are continuously monitored.

Concentration of credit risk exists when changes in economic, industry or geographical factors similarly affect group of counterparties whose aggregate exposure is significant in relation to the Group's total credit exposure. All the Group's customers are PRC companies. Ongoing credit evaluation is performed on the financial condition of accounts receivable and, where appropriate, credit guarantee insurance cover is purchased.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

27 Financial instruments (cont'd)

b) Financial risk management (cont'd)

Credit risk (cont'd)

The following sets out the Group's internal credit evaluation practices and basis for recognition and measurement of expected credit losses ("ECL"):

Description of evaluation of financial assets	Basis for recognition and measurement of ECL
Counterparty has a low risk of default and does not have any past due amounts	12-month ECL
Contractual payments are more than 30 days past due or where there has been a significant increase in credit risk since initial recognition	Lifetime ECL - not credit-impaired
Contractual payments are more than 90 days past due or there is evidence of credit impairment	Lifetime ECL - credit-impaired
There is evidence indicating that the Group has no reasonable expectation of recovery of payments such as when the debtor is over 720 days past due, or has been placed under liquidation or has entered into bankruptcy proceedings	Write-off

Significant increase in credit risk

In assessing whether the credit risk on a financial asset has increased significantly since initial recognition, the Group compares the risk of a default occurring on the financial asset as at the reporting date with the risk of a default occurring on the financial asset as at the date of initial recognition. In making this assessment, the Group considers both quantitative and qualitative information that is reasonable and supportable, including historical experience and forward-looking information, such as future economic and industry outlook, that is available without undue cost or effort.

In particular, the Group considers the following information when assessing whether credit risk has increased significantly since initial recognition:

- an actual or expected significant deterioration in the financial instrument's external (if available) or internal credit rating;
- existing or forecast adverse changes in business, financial or economic conditions that are expected to cause a significant decrease in the debtor's ability to meet its debt obligations;
- an actual or expected significant deterioration in the operating results/key financial performance ratios of the debtor;
- significant increases in credit risk on other financial instruments of the same debtor; and
- an actual or expected significant adverse change in the regulatory, economic, or technological environment of the debtor that results in a significant decrease in the debtor's ability to meet its debt obligations.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

27 Financial instruments (cont'd)

b) Financial risk management (cont'd)

Credit risk (cont'd)

Significant increase in credit risk (cont'd)

The Group regularly monitors the effectiveness of the criteria used to identify whether there has been a significant increase in credit risk and revises them as appropriate to ensure that the criteria are capable of identifying significant increase in credit risk before the amount becomes past due.

Regardless of the evaluation of the above factors, the Group presumes that the credit risk on a financial asset has increased significantly since initial recognition when contractual payments are more than 30 days past due, unless the Group has reasonable and supportable information that demonstrates otherwise.

The Group also assumes that the credit risk on a financial instrument has not increased significantly since initial recognition if the financial asset is determined to have low credit risk at the end of the reporting period. A financial instrument is determined to have low credit risk if it has an internal or external credit rating of "investment grade" as per globally understood definition, or the financial asset has a low risk of default; the borrower has a strong capacity to meet its contractual cash flow obligations in the near term; and adverse changes in economic and business conditions in the longer term may, but will not necessarily, reduce the ability of the borrower to fulfil its contractual cash flow obligations.

Definition of default

The Group considers the following as constituting an event of default for internal credit risk management purposes as historical experience indicates that receivables that meet either of the following criteria are generally not recoverable.

- when there is a breach of financial covenants by the counterparty; or
- information developed internally or obtained from external sources indicates that the debtor is unlikely to pay its creditors, including the Group, in full (without taking into account any collaterals held by the Group).

Irrespective of the above analysis, the Group considers that default has occurred when a financial asset is more than 90 days past due unless the Group has reasonable and supportable information to demonstrate that a more lagging default criterion is more appropriate.

Credit-impaired financial assets

A financial asset is credit-impaired when one or more events that have a detrimental impact on the estimated future cash flows of that financial asset have occurred such as evidence that the borrower is in significant financial difficulty, there is a breach of contract such as default or past due event; there is information that it is becoming probable that the borrower will enter bankruptcy or other financial reorganisation; the disappearance of an active market for that financial asset because of financial difficulties; or the purchase or origination of a financial asset at a deep discount that reflects the incurred credit losses.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

27 Financial instruments (cont'd)

b) Financial risk management (cont'd)

Credit risk (cont'd)

Estimation techniques and significant assumptions

There has been no change in the estimation techniques or significant assumptions made during the current financial year for recognition and measurement of credit loss allowances.

Maximum exposure and concentration of credit risks

The Group's trade receivables comprise 2 debtors (2022: 2 debtors) that individually represented more than 10% of the trade receivables. The Group has significant concentration of credit risk in relation to the amount due from associated company as disclosed in Note 12. The Company has no significant concentration of credit risk.

The credit risk on liquid funds is limited because the counterparties are financial institutions with high credit-ratings assigned by international credit-rating agencies. The carrying amounts of financial assets as presented on the statement of financial position represents the Group's maximum exposure to credit risk without taking account of the value of any collateral obtained.

The Company's maximum exposure to credit risk is the carrying amount of each class of financial instruments presented on the statement of financial position.

Trade receivables

The Group has applied the simplified approach to measure the lifetime expected credit loss allowance for trade receivables.

The Group estimates the expected credit loss rates for each category of past due status of the debtors based on historical credit loss experience adjusted as appropriate to reflect current conditions and forecasts of future economic conditions with consideration of the current macroeconomic conditions on the ability of the customers to settle the receivables.

There has been no change in the estimation techniques or significant assumptions made during the current financial year.

The trade bills receivables are considered integral part of trade receivables and considered in the calculation of impairment. As at 31 December 2023, 99.52% (2022: 99.74%) of the Group's trade receivables are covered by trade bills receivables. The Group assesses the concentration of risk with respect to trade receivables is low as its customers are located in several industries and operate in largely independent markets.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

27 Financial instruments (cont'd)

b) Financial risk management (cont'd)

Credit risk (cont'd)

Amount due from associated company

As disclosed in Note 12, management estimated the impairment loss on the amount due from associated company using the expected credit loss model.

The exposure to credit risk of amount due from associated company is as follows:

	Group	
	2023	2022
	RMB'000	RMB'000
Gross amount due from associated company	173,310	173,110
Less: expected cash flows for recovery of the receivable	–	(25,640)
Exposure to credit risk	173,310	147,470

Consequently, the Group has recognised an impairment loss allowance of RMB25,840,000 (2022: RMB5,000,000) during the financial year and as at 31 December 2023, cumulative impairment loss allowance totalled RMB173,310,000 (2022: RMB147,470,000) (Note 12).

Other financial assets at amortised cost

The credit loss exposure in relation to cash and cash equivalents and other receivables (excluding amounts due from former subsidiary companies) are immaterial at 31 December 2023 and 31 December 2022. As at 31 December 2023, 100% allowance for expected credit loss is provided for amounts due from former subsidiary companies which are credit-impaired.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

27 Financial instruments (cont'd)

b) Financial risk management (cont'd)

Credit risk (cont'd)

Movements in credit loss allowance are as follows:

	Trade receivables (Note 12)	Other receivables (Note 12)	Amount due from an associated company - Non-current (Note 12)	Total
	RMB'000	RMB'000	RMB'000	RMB'000
Group				
Balance at 1 January 2022	10,675	–	142,470	153,145
Loss allowance measured:				
Lifetime ECL				
- credit-impaired	97	–	5,000	5,097
Receivables written off as uncollectible	(4,520)	–	–	(4,520)
Balance at 31 December 2022	6,252	–	147,470	153,722
Loss allowance measured:				
Lifetime ECL				
- credit-impaired	14,970	466	25,840	41,276*
Balance at 31 December 2023	21,222	466	173,310	194,998

* Included is an amount totalling RMB15,436,000 arising from the liquidation of subsidiary companies (Note 16(c)).

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

27 Financial instruments (cont'd)

b) Financial risk management (cont'd)

Credit risk (cont'd)

Credit quality of financial assets

The table below details the credit quality of the Group's and the Company's financial assets at the reporting date:

		12-month or lifetime ECL	Gross carrying amount	Loss allowance	Net carrying amount
			RMB'000	RMB'000	RMB'000
Group					
2023					
Trade receivables	Lifetime ECL		21,870	(21,222)	648
Trade bills receivables	Not applicable (Exposure limited)		135,065	–	135,065
Amount due from associated company	Lifetime ECL		173,310	(173,310)	–
Refundable deposits	12-month ECL		240	–	240
Other receivables	Lifetime ECL		466	(466)	–
Cash and cash equivalents	Not applicable (Exposure limited)		684,026	–	684,026
2022					
Trade receivables	Lifetime ECL		7,477	(6,252)	1,225
Trade bills receivables	Not applicable (Exposure limited)		469,119	–	469,119
Amount due from associated company	Lifetime ECL		173,110	(147,470)	25,640
Refundable deposits	12-month ECL		236	–	236
Other receivables	12-month ECL		1,236	–	1,236
Security deposits paid to secure corporate guarantee of the bank borrowing	12-month ECL		5,000	–	5,000
Cash and cash equivalents	Not applicable (Exposure limited)		1,172,325	–	1,172,325

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

27 Financial instruments (cont'd)

b) Financial risk management (cont'd)

Credit risk (cont'd)

Credit quality of financial assets (cont'd)

The table below details the credit quality of the Group's and the Company's financial assets at the reporting date: (cont'd)

		12-month or lifetime ECL	Gross carrying amount	Loss allowance	Net carrying amount
			RMB'000	RMB'000	RMB'000
Company					
2023					
Refundable deposits	12-month ECL		240	–	240
Cash and cash equivalents	Not applicable (Exposure limited)		70,495	–	70,495
2022					
Refundable deposits	12-month ECL		236	–	236
Cash and cash equivalents	Not applicable (Exposure limited)		55,495	–	55,495

Liquidity risk

Liquidity risk is the risk that the Group and the Company will encounter difficulty in meeting financial obligations due to shortage of funds. The Group monitors and maintains a level of cash and cash equivalents deemed adequate by management to finance its operations and mitigate the effects of fluctuations in cash flows. Management monitors the utilisation of bank borrowings and ensures compliance with loan covenants, if any. This strategy has not changed from prior periods.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

27 Financial instruments (cont'd)

b) Financial risk management (cont'd)

Liquidity risk (cont'd)

The table below summarises the maturity profile of the Group's and the Company's non-derivative financial liabilities at the reporting date based on contractual undiscounted repayment obligations.

	1 year or less	1 to 5 years	Total
	RMB'000	RMB'000	RMB'000
Group			
2023			
Trade and other payables	243,856	–	243,856
Bank borrowings	201,722	68,848	270,570
	445,578	68,848	514,426
2022			
Trade and other payables	509,002	–	509,002
Bank borrowings	85,072	51,788	136,860
	594,074	51,788	645,862
Company			
2023			
Trade and other payables	1,481	–	1,481
2022			
Trade and other payables	1,812	–	1,812

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

27 Financial instruments (cont'd)

c) Fair value

i) Fair value hierarchy

The tables below analyse the fair value measurements by the levels in the fair value hierarchy based on the inputs to the valuation techniques. The different levels are defined as follows:

- Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 - inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (i.e. derived from prices); and
- Level 3 - inputs for the asset or liability that are not based on observable market data (unobservable inputs).

ii) Fair value of financial instruments by classes that are not carried at fair value and whose carrying amounts are reasonable approximation of fair value.

The carrying amounts of financial assets and financial liabilities at amortised cost are reasonable approximation of fair values, either due to their short-term nature or that they are floating rate instruments that are re-priced to market interest rates on or near the end of the reporting period.

iii) The Group and the Company have no other financial instruments.

28 Segment information

The Group is principally engaged in manufacturing and selling of chemical-based products, i.e. methylamine and DMF. All provisions are of a similar nature and subject to similar risks and returns. Accordingly, the Group's operating activities are mainly attributable to a single reportable operating segment.

Geographical information

The Group's revenue, expenses, results, assets and liabilities and capital expenditures are predominantly attributable to a single geographical region, the PRC, which is the Group's principal place of business and operations. Therefore, no analysis by geographical region is presented.

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

28 Segment information (cont'd)

Information about major customer

During the financial year, there is no external customer (2022: 1) who individually contributed 10% or more of the Group's revenue as detailed below:

	Group	
	2023	2022
	RMB'000	RMB'000
Customer A	–	342,634

29 Capital management

The Group manages its capital to ensure that entities in the Group will be able to continue as a going concern while maximising the return to shareholders through the optimisation of the debt and equity balance.

The capital structure of the Group consists of net debts, which is the borrowings less cash and cash equivalents and total equity attributable to equity holders of the Company, comprising share capital and reserves.

The Group's management reviews the capital structure on an on-going basis. As a part of this review, management considers the cost of capital and the risks associated with each class of capital. Based on recommendations of management, the Group balances its overall capital structure through the payment of dividends, new share issues and share buy-backs as well as the issuance of new debt or the redemption of existing debt.

The Group's overall strategy remains unchanged from 2022.

30 Capital commitments

Capital commitments not provided for in the financial statements:

	Group	
	2023	2022
	RMB'000	RMB'000
Capital commitments in respect of property, plant and equipment	40,812	36,573

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2023

31 Subsequent events

The Company's wholly-owned subsidiary, Anyang Jiutian Fine Chemical Co., Ltd. ("Anyang Jiutian") has, on 11 January 2024, entered into a framework agreement (the "Framework Agreement") with Anyang Chemical Industry Group Co., Ltd. ("Anhua"), a controlling shareholder of the Company having a deemed interest in approximately 25.27% of the Company's total issued and paid-up share capital, in respect of the undertaking of the Synthetic Ammonia Project (the "Investment"). The Investment involves the construction of the Synthetic Ammonia Production Facility with an estimated production capacity of 300,000 tonnes of synthetic ammonia per annum, and the lease of the Urea Production Facility with a production capacity of 200,000 tonnes of urea per annum.

Anyang Jiutian has, on 5 March 2024, entered into the definitive agreements stated in the Framework Agreement, i.e. the Synthetic Ammonia Project Transfer Agreement, Urea Facility Lease Agreement and Trademark Licensing Agreement, with Anhua, to implement the Investment. Subject to the satisfaction of the transfer agreement conditions precedent by 30 June 2024 (which may be extended by Parties' mutual agreement in writing), Anyang Jiutian agrees to take over the construction and operation of the Synthetic Ammonia Project from Anhua.

The aggregate investment amount in connection with the Investment includes the following:

- (i) Approximately RMB1.60 billion, being the estimated construction cost of the Synthetic Ammonia Production Facility and the implementation cost;
- (ii) Such amount to be paid by Anyang Jiutian for the Synthetic Ammonia Project Land Arrangement i.e. the acquisition and lease of such land parcels which comprise the Synthetic Ammonia Project Land. The amount is subject to further discussions between Anyang Jiutian and the local government of Long'an District, Anyang City; and
- (iii) The rental amount to be paid by Anyang Jiutian to Anhua for the lease of the Urea Production Facility for the initial lease term of RMB3.7 million per annum.

The investment amount will be funded using a combination of internal funds and/or bank borrowings, where at least RMB1.2 billion will be financed by loan financing.

32 Authorisation of financial statements

The consolidated financial statements of the Group and the statement of financial position and statement of changes in equity of the Company for the financial year ended 31 December 2023 were authorised for issue in accordance with a resolution of the directors dated 5 April 2024.

STATISTICS OF SHAREHOLDINGS

As at 15 March 2024

Issued and Fully Paid-up Capital	-	S\$147,792,385 comprising 1,988,444,000 ordinary shares
Class of Shares	-	Ordinary shares
Voting Rights	-	One Vote per share

There are no treasury shares and subsidiary holdings held in the issued share capital of the Company.

DISTRIBUTION OF SHAREHOLDERS BY SIZE OF SHAREHOLDINGS

Size of Shareholdings	No. of Shareholders	% of Holders	No. of Shares	% of Shares
1 – 99	–	–	–	–
100 – 1,000	103	1.74	79,045	0.00
1,001 – 10,000	1,216	20.61	9,577,800	0.48
10,001 – 1,000,000	4,414	74.80	589,164,849	29.63
1,000,001 and above	168	2.85	1,389,622,306	69.89
	5,901	100.00	1,988,444,000	100.00

LIST OF 20 LARGEST SHAREHOLDERS

	Shareholder's Name	No. of Shares	%
1	PHILLIP SECURITIES PTE LTD	561,518,800	28.24
2	RAFFLES NOMINEES (PTE) LIMITED	89,260,006	4.49
3	DBS NOMINEES PTE LTD	66,228,300	3.33
4	CITIBANK NOMINEES SINGAPORE PTE LTD	36,947,700	1.86
5	OCBC SECURITIES PRIVATE LTD	31,595,600	1.59
6	LIM YUE HENG	30,500,000	1.53
7	UOB KAY HIAN PTE LTD	24,403,100	1.23
8	LIM KIM HUAT	23,000,000	1.16
9	CGS INTERNATIONAL SECURITIES SINGAPORE PTE. LTD.	16,720,500	0.84
10	HENG SIEW ENG	15,160,000	0.76
11	MOOMOO FINANCIAL SINGAPORE PTE. LTD.	15,130,900	0.76
12	IFAST FINANCIAL PTE LTD	14,692,100	0.74
13	EL'FRED BOO HIAN YONG	13,500,000	0.68
14	TIGER BROKERS (SINGAPORE) PTE. LTD.	13,429,800	0.68
15	LEE YOW FEE	13,216,000	0.66
16	KGI SECURITIES (SINGAPORE) PTE. LTD	13,138,800	0.66
17	LIM AND TAN SECURITIES PTE LTD	11,788,300	0.59
18	LEE CHEE SENG	11,250,000	0.57
19	DBS VICKERS SECURITIES (S) PTE LTD	10,026,600	0.50
20	XU YONGSHENG	10,000,000	0.50
	TOTAL	1,021,506,506	51.37

STATISTICS OF SHAREHOLDINGS

As at 15 March 2024

SUBSTANTIAL SHAREHOLDERS

No.	Name	Direct Interest		Deemed Interests	
		No. of shares held	%	No. of shares held	%
1.	Anyang Longyu (HK) Development Co., Ltd.*	–	–	502,429,900	25.27
2.	Anyang Chemical Industry Group Co., Ltd.#	–	–	502,429,900	25.27
3.	Henan Energy And Chemical Industry Group Co., Ltd.#	–	–	502,429,900	25.27

* Anyang Longyu (HK) Development Co., Ltd. is deemed interested in 502,429,900 shares held through its nominee, Phillip Securities Pte. Ltd.

Anyang Chemical Industry Group Co., Ltd. and Henan Energy And Chemical Industry Group Co., Ltd. are deemed to be interested in the shares held by Anyang Longyu (HK) Development Co., Ltd. by virtue of Section 6 of the Companies Act 1967.

COMPLIANCE WITH RULE 723 OF THE SGX-ST LISTING MANUAL SECTION B: RULES OF CATALIST

Based on information available and to the best knowledge of the Directors, as at 15 March 2024, approximately 73.02% of the ordinary shares of the Company are held by the public. The Company is therefore in compliance with Rule 723 of the SGX-ST Listing Manual Section B: Rules of Catalist of Singapore Exchange Securities Trading Limited.

APPENDIX I

APPENDIX I DATED 09 APRIL 2024

THIS APPENDIX I IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.

This Appendix I is circulated to shareholders of Jiutian Chemical Group Limited (the “**Company**”) together with the Company’s Annual Report for its financial year ended 31 December 2023 (the “**Annual Report**”). Its purpose is to provide shareholders of the Company with information relating to the proposed renewal of shareholders’ general mandate for interested person transactions to be tabled at the Annual General Meeting of the Company to be held at Royal Plaza on Scotts, Balmoral Hall, Level 5, 25 Scotts Road, Singapore 228220 on 25 April 2024 at 10.30 a.m..

IF YOU ARE IN ANY DOUBT ABOUT ITS CONTENTS OR THE ACTION YOU SHOULD TAKE, YOU SHOULD CONSULT YOUR STOCKBROKER, BANK MANAGER, SOLICITOR, ACCOUNTANT, TAX ADVISER OR OTHER PROFESSIONAL ADVISER IMMEDIATELY.

If you have sold or transferred all your shares in the capital of the Company, you should immediately inform the purchaser or transferee or bank, stockbroker or agent through whom the sale or transfer was effected for onward notification to the purchaser or transferee, that this Appendix I, together with the Notice of AGM, the accompanying Proxy Form and Request Form (all as defined herein), may be accessed on the website of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) at <https://www.sgx.com/securities/company-announcements>. A printed copy of this Appendix I will NOT be despatched to Shareholders as the Company’s constitution provides for the use of electronic communications pursuant to the Catalist Rules (as defined herein). Accordingly, only hardcopies of the Notice of AGM, Proxy Form and Request Form will be sent to Shareholders. Shareholders who wish to obtain a printed copy of the Appendix I should complete the Request Form and return it to the Company by post to the business office of the Company at 350 Orchard Road, #21-03 Shaw House, Singapore 238868 or via email to nghankiat@jiutianchemical.com, no later than 18 April 2024.

The Ordinary Resolution proposed to be passed in respect of the proposed renewal of the shareholders’ general mandate for interested person transactions is set out in the Notice of Annual General Meeting, of which is contained together with the Proxy Form in the Annual Report.

This Appendix I has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”). It has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this Appendix I, including the correctness of any of the statements or opinions made or reports contained in this Appendix I.

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318 and sponsorship@ppcf.com.sg.



APPENDIX IN RELATION TO

THE PROPOSED RENEWAL OF THE SHAREHOLDERS’ GENERAL MANDATE FOR INTERESTED PERSON TRANSACTIONS

APPENDIX I

CONTENTS

DEFINITION	119
LETTER TO SHAREHOLDERS	123
1. INTRODUCTION	123
2. PROPOSED RENEWAL OF THE IPT MANDATE	124
3. THE CATALIST RULES	124
4. PROPOSED RENEWAL OF THE IPT MANDATE	126
5. INTERESTS OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS	139
6. SHAREHOLDING INTERESTS OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS	140
7. ANNUAL GENERAL MEETING	140
8. NON-INTERESTED DIRECTORS' RECOMMENDATION	141
9. ACTION TO BE TAKEN BY SHAREHOLDERS	141
10. ABSTENTION FROM VOTING IN CONNECTION WITH THE PROPOSED RENEWAL OF THE IPT MANDATE	142
11. DIRECTORS' RESPONSIBILITY STATEMENT	143
12. DOCUMENTS AVAILABLE FOR INSPECTION	143

APPENDIX I

DEFINITION

In this Appendix I, the following definitions shall apply throughout unless the context otherwise requires:-

Companies, Organisations and Agencies

"Anhua"	:	Anyang Chemical Industry Group Co., Ltd., a subsidiary of HNEC
"Anhua Group"	:	Anhua and its subsidiaries and associates
"Anyang Jiulong"	:	Anyang Jiulong Chemical Co., Ltd., a subsidiary of HNEC and an associated company of Jiutian
"Anyang Jiutian"	:	Anyang Jiutian Fine Chemical Co., Ltd., a wholly-owned subsidiary of Jiutian
"Anyang Longyu"	:	Anyang Longyu (HK) Development Co., Ltd., a wholly-owned subsidiary of Anhua
"Anyang Yongjin"	:	Anyang Yongjin Chemical Co., Ltd., a wholly-owned direct subsidiary of HNEC
"CDP"	:	The Central Depository (Pte) Limited
"Company" or "Jiutian"	:	Jiutian Chemical Group Limited
"Henan Electric"	:	Henan Electric Power Corporation, a state-owned electricity utility company, independent from both Anhua Group and Jiutian Group
"HNEC"	:	Henan Energy and Chemical Industry Group Co., Ltd. (formerly known as Henan Coal and Chemical Group Co., Ltd.) is the parent of Anhua
"Guolong Logistics"	:	Anyang Guolong Logistics Co., Ltd., a wholly-owned direct subsidiary of Anhua
"Jiutian Group"	:	For the purposes of this Appendix I, comprises the Company, its subsidiaries and its associated companies and are also Entities at Risk
"SGX-ST"	:	Singapore Exchange Securities Trading Limited

General

"Act"	:	The Companies Act 1967 of Singapore, as amended or modified or supplemented from time to time
"AGM"	:	The annual general meeting of the Company to be held at Royal Plaza on Scotts, Balmoral Hall, Level 5, 25 Scotts Road, Singapore 228220 on 25 April 2024 at 10.30 a.m.
"Annual Report"	:	The annual report of the Company for FY2023
"Appendix I"	:	This Appendix I dated 9 April 2024

APPENDIX I

“associated company”	:	A company in which at least 20% but not more than 50% of its shares are held by the Company or Jiutian Group and that it is not listed on the SGX-ST or an approved exchange. This definition shall include Anyang Jiujiu and Anyang Jiulong, both of which are as defined above) in which the Group holds
“associate”	:	<p>(a) in relation to any director, chief executive officer, substantial shareholder or controlling shareholder (being an individual) means:-</p> <p>(i) his immediate family;</p> <p>(ii) the trustees of any trust of which he or his immediate family is a beneficiary or, in the case of a discretionary trust, is a discretionary object; and</p> <p>(iii) any company in which he and his immediate family together (directly or indirectly) have an interest of 30% or more;</p> <p>(b) in relation to a substantial shareholder or a controlling shareholder (being a company) means any other company which is its subsidiary or holding company or is a subsidiary of such holding company or one in the equity of which it and/or such other company or companies taken together (directly or indirectly) have an interest of 30% or more</p>
“Audited Accounts”	:	The audited financial statements of Jiutian Group
“Audit Committee”	:	The audit committee of the Board
“Board” or “Directors”	:	The board of directors of the Company for the time being
“Catalist”	:	The sponsor-supervised listing platform of the SGX-ST
“Catalist Rules”	:	The SGX-ST Listing Manual (Section B: Rule of Catalist), as amended, modified or supplemented from time to time
“controlling shareholder”	:	<p>A person who:-</p> <p>(a) holds directly or indirectly 15% or more of the nominal amount of all voting shares (excluding treasury shares and subsidiary holdings) in the company (unless the SGX-ST determines that such a person is not a controlling shareholder); or</p> <p>(b) in fact exercises control over a company</p>
“Dimethylamine”	:	A type of raw material used in the manufacturing of certain pharmaceutical products, agricultural chemicals and other organic chemicals
“Entities at Risk”	:	The entities at risk who fall within the IPT Mandate, as set out in section 4.2 of this Appendix I
“FY”	:	Financial year ended 31 December

APPENDIX I

- “Interested Persons” : (a) a director, chief executive officer, or controlling shareholder of the issuer; or
- (b) an associate of any such director, chief executive officer, or controlling shareholder.

The interested persons of the Company who fall within the IPT Mandate are set out in section 4.2 of this Appendix I

- “IPT” : Means a Transaction between an Entity at Risk and an Interested Person
- “IPT Mandate” : The general mandate that was first approved by Shareholders at the extraordinary general meeting of the Company held on 16 November 2012, amended at the annual general meeting of the Company held on 29 April 2014; and last renewed at the annual general meetings of the Company held on 26 April 2023.
- “Latest Practicable Date” : 28 March 2024, being the latest practicable date prior to the printing of this Appendix I on SGXNET
- “Non-interested Directors” : The Directors who are deemed to be non-conflicted in respect of and for the purpose of the IPT Mandate, namely, Mr Lee Chee Seng, Mr Wu Yu Liang, Mr Chan Kam Loon, Mr Gao Guoan, Mr Chen Mingjin, and Mr Koh Eng Kheng Victor
- “Notice of AGM” : The notice of AGM dated 09 April 2024
- “NTA” : Net tangible assets
- “Proxy Form” : The proxy form in respect of the AGM as set out in this Annual Report
- “Request Form” : The request form for Shareholders to request for physical copy of annual report
- “Raw Materials Type I” : Includes liquid ammonia, methanol, nitrogen and carbon dioxide
- “Raw Materials Type II” : Includes liquid coal gas, oxygen, clean water, desalinated water, recycled water and instrument air
- “Recurrent IPTs” : The categories of transactions with the Interested Persons which fall within the IPT Mandate, as set out in sections 4.2.2(b) and 4.3 of this Appendix I
- “Shares” : Ordinary shares in the capital of the Company

Currencies, Units and Others

- “RMB” : Renminbi, the lawful currency of the PRC
- “S\$” : Singapore dollars, the lawful currency of the Republic of Singapore
- “%” : Per centum or percentage

APPENDIX I

The terms "Depositor", "Depository Agent" and "Depository Register" shall have the meanings ascribed to them respectively in Section 81F of the Securities and Future Act (Chapter 289) of Singapore ("**SFA**").

Words importing the singular shall, where applicable, include the plural and vice versa, and words importing the masculine gender shall, where applicable, include the feminine and neuter genders and vice versa. Words importing persons shall, where applicable, include corporations.

Any reference in this Appendix I to any statute or enactment is a reference to that statute or enactment as for the time being amended or re-enacted. Any word defined under the Act, the SFA, the Catalist Rules or any statutory modification thereof and used in this Appendix I shall, where applicable, have the same meaning ascribed to it under the Act, the SFA, the Catalist Rules or any statutory modification thereof, as the case may be, unless otherwise provided.

Any reference to dates and time of day in this Appendix I shall be a reference to Singapore dates and time unless otherwise stated.

APPENDIX I

LETTER TO SHAREHOLDERS

JIUTIAN CHEMICAL GROUP LIMITED

(Company Registration Number 200415416H)
(Incorporated in the Republic of Singapore)

Board of Directors:

Mr Xu Aijun (*Non-Executive and Non-Independent Chairman*)
Mr Lee Chee Seng (*Executive Director*)
Mr Wu Yu Liang (*Non-Executive and Lead Independent Director*)
Mr Chan Kam Loon (*Non-Executive and Independent Director*)
Mr Gao Guoan (*Non- Executive and Independent Director*)
Mr Wang Gang (*Non-Executive and Non-Independent Director*)
Mr Chen Mingjin (*Non-Executive and Independent Director*)
Mr Koh Eng Kheng Victor (*Non-Executive and Independent Director*)
Mr Song Fudong (*Non-Executive and Non-Independent Director*)

Registered Office:

9 Raffles Place #26-01
Republic Plaza
Singapore 048619

09 April 2024

To: The Shareholders of Jiutian Chemical Group Limited

Dear Sir/Madam

THE PROPOSED RENEWAL OF THE SHAREHOLDERS' GENERAL MANDATE FOR INTERESTED PERSON TRANSACTIONS

1. INTRODUCTION

The Company proposes to seek the approval of its Shareholders at the AGM to be held on 25 April 2024 for the proposed renewal of the IPT Mandate.

The Company refers to the Notice of AGM accompanying the Annual Report for FY2023 and Resolution 7 in relation to the proposed renewal of the IPT Mandate under the heading "Special Business" set out in the Notice of AGM.

The purpose of this Appendix I is to provide Shareholders with information relating to the IPT Mandate.

The proposed renewal of the IPT Mandate will authorise Jiutian Group as "entities at risk" within the meaning of Chapter 9 of the Catalist Rules, to enter in the ordinary course of business any of the mandated transactions with specific classes of the Company's interested persons, provided that such transactions are made on normal commercial terms and are not prejudicial to the interests of the Company and its minority Shareholders, and are entered into in accordance with the review procedures for such transactions.

General information relating to Chapter 9 of the Catalist Rules is set out in Section 3 of this Appendix I.

APPENDIX I

2. PROPOSED RENEWAL OF AN IPT MANDATE

Under Chapter 9 of the Catalist Rules, a general mandate for transactions with interested persons is subject to annual renewal. The IPT Mandate was previously approved and adopted at the extraordinary general meeting of the Company held on 16 November 2012, amended at an annual general meeting of the Company held on 29 April 2014; and last renewed at the annual general meeting of the Company held on 26 April 2023.

The existing IPT Mandate will continue to be in force until the conclusion of the AGM. Accordingly, it is proposed that the IPT Mandate be renewed at the AGM and to take effect, unless revoked or varied by the Company in general meeting, until the next annual general meeting of the Company. The nature of the Recurrent IPTs and the classes of Interested Persons in respect of which the IPT Mandate is sought to be renewed remain unchanged.

3. THE CATALIST RULES

3.1 Chapter 9 of the Catalist Rules

Chapter 9 of the Catalist Rules governs transactions in which a listed company or any of its subsidiaries or associated companies (known as an “**entity at risk**”) enters into or proposes to enter into with a person who is an interested person of the listed company. The purpose is to guard against the risk that an interested person could influence the listed company, its subsidiaries or associated companies to enter into transactions with it that may adversely affect the interests of the listed company or its shareholders.

For the purposes of Chapter 9 of the Catalist Rules:-

3.1.1 an “**entity at risk**” means:-

- (a) the listed company;
- (b) a subsidiary of the listed company that is not listed on the SGX-ST or an approved exchange; or
- (c) an associated company of the listed company that is not listed on the SGX-ST or an approved exchange, provided that the listed group, or the listed group and its interested person(s), has control over the associated company;

3.1.2 an “**interested person**” means a director, chief executive officer or controlling shareholder of the listed company or an associate of any such director, chief executive officer or controlling shareholder. The SGX-ST may deem any person or entity to be an interested person if the person or entity has entered into, or proposes to enter into: (i) a transaction with an entity at risk and (ii) an agreement or arrangement with an interested person in connection with that transaction.

3.1.3 an “**associate**”:-

- (a) in relation to any director, chief executive officer, substantial shareholder or controlling shareholder (being an individual) means:-
 - (i) his immediate family (i.e. spouse, children, adopted children, step-children, siblings and parents);

APPENDIX I

- (ii) the trustees of any trust of which he or his immediate family is a beneficiary or, in the case of a discretionary trust, is a discretionary object; and
 - (iii) any company in which he and his immediate family together (directly or indirectly) have an interest of 30% or more;
- (b) in relation to a substantial shareholder or a controlling shareholder (being a company) means any other company which is its subsidiary or holding company or is a subsidiary of such holding company or one in the equity of which it and/or such other company or companies taken together (directly or indirectly) have an interest of 30% or more;
- 3.1.4 an “**approved exchange**” means a stock exchange that has rules which safeguard the interests of shareholders against interested person transactions according to similar principles to Chapter 9 of the Catalist Rules; and
- 3.1.5 an “**interested person transaction**” means a transaction between an entity at risk and an interested person, and includes the provision or receipt of financial assistance, the acquisition, disposal or leasing of assets, the provision or receipt of goods or services, the issuance or subscription of securities, the granting of or being granted options, and the establishment of joint ventures or joint investments, whether or not in the ordinary course of business, and whether or not entered into directly or indirectly.

3.2 Chapter 9 of the Catalist Rules

Transactions conducted under a IPT Mandate are not separately subject to Catalist Rules 905 and 906.

An immediate announcement and/or shareholders’ approval is required in respect of transactions with interested persons if the value of the transaction is equal to or exceeds certain financial thresholds.

In particular, an immediate announcement is required where:-

- (a) the transaction is of a value equal to, or more than, 3% of the Group’s latest audited NTA; or
- (b) the aggregate value of all transactions entered into with the same interested person during the same financial year amounts to 3% or more of the Group’s latest audited NTA and as set out under Rule 905(2) of the Catalist Rules.

Further, shareholders’ approval (in addition to an immediate announcement) is required where:-

- (a) the transaction is of a value equal to, or more than, 5% of the Group’s latest audited NTA; or
- (b) the transaction, when aggregated with other transactions entered into with the same interested person during the same financial year, is of a value equal to, or more than, 5% of the Group’s latest audited NTA. However, a transaction which has been approved by shareholders, or is the subject of aggregation with another transaction that has been approved by shareholders, need not be included in any subsequent aggregation as set out under Rule 906(1)(b) of the Catalist Rules.

The above requirements for immediate announcement and/or for shareholders’ approval do not apply to any transaction below S\$100,000, and certain transactions which, by reason of the nature of such transactions, are not considered to put the listed company at risk to its interested person and hence excluded from the ambit of Chapter 9 of the Catalist Rules.

APPENDIX I

The SGX-ST should be consulted on the appropriate benchmark to calculate the relevant thresholds as set out above if the group's latest audited net tangible assets is negative, which may be based on its market capitalisation. In addition, while transactions below S\$100,000 entered into with the same interested person during the same financial year are not normally aggregated, the SGX-ST may aggregate any such transaction entered into during the same financial year and treat them as if they were one transaction in accordance with Rule 902 of the Catalist Rules.

For the purpose of aggregation in Rules 905, 906 and 907, reference is to be made to Rule 908 of the Catalist Rules in the interpretation of the term "same interested person" as abovementioned.

The value of a transaction is the amount at risk to the listed company is illustrated pursuant to Rule 909 of the Catalist Rules.

3.3 Illustration

For illustration purposes, based on Jiutian Group's latest Audited Accounts for FY2023, Jiutian Group's latest audited NTA as at 31 December 2023 was approximately RMB764.43 million. Accordingly, in relation to Jiutian Group, for the purposes of Chapter 9 of the Catalist Rules, 3% and 5% of the latest audited consolidated NTA of the Group for FY2023 would be RMB 22.93 million and RMB38.22 million respectively. Shareholders' approval is required where:-

- (a) the transaction is of a value equal to, or more than, RMB38.22 million, being 5% of Jiutian Group's latest audited NTA as at 31 December 2023; or
- (b) the transaction, when aggregated with other transactions entered into with the same interested person during the same financial year, is of a value equal to, or more than, RMB38.22 million, being 5% of the Group's latest audited NTA as at 31 December 2023. The aggregation will exclude any transaction that has been approved by shareholders previously or is the subject of aggregation with another transaction that has been approved by shareholders.

3.4 General Mandate

Part VIII of Chapter 9 of the Catalist Rules allows a listed company to seek a general mandate from its shareholders for recurrent transactions with interested persons where such transactions are of a revenue or trading nature or those necessary for its day-to-day operations such as the purchase and sale of supplies and materials, but not in respect of the purchase or sale of assets, undertakings or businesses. A general mandate granted by shareholders is subject to annual renewal.

4. PROPOSED RENEWAL OF THE IPT MANDATE

4.1 Scope of the IPT Mandate

Jiutian Group and the Interested Persons are in related businesses. It is envisaged that in the ordinary course of their respective businesses, certain recurrent transactions (as more particularly set out in sections 4.2.2(b) and 4.3 of this Appendix I) between Jiutian Group, and the Interested Persons will continue to occur from time to time. The Recurrent IPTs are transactions in the ordinary course of business of Jiutian Group.


APPENDIX I

Given that the Recurrent IPTs are of a trading nature and are expected to recur and occur at any time, and due to the time-sensitive nature of these transactions, in order for Jiutian Group to undertake such transactions in a more expeditious manner, the Company is seeking the approval of its shareholders for the proposed renewal of the IPT Mandate in respect of the Recurrent IPTs provided that such transactions are made on normal commercial terms and are not prejudicial to the interests of the Company and its minority shareholders.

4.2 Information on the Entities at Risk and the Interested Persons

4.2.1 Relationships between the Entities at Risk and the Interested Persons

As at the Latest Practicable Date, the corporate structure of Jiutian Group, Anhua Group and the relationships among them were as follows:-



Notes:-

- (1) Anhua is the holding company of Anyang Longyu, a controlling shareholder of the Company.
- (2) Anyang Jiulong is a joint venture pursuant to 15.9% is held by Anhua, 35.1% is held by HNEC and Jiutian holds 49% of the registered capital of Anyang Jiulong. Accordingly, Anyang Jiulong is a subsidiary of HNEC and an associated company of Jiutian. Therefore, in certain circumstances, Anyang Jiulong would be deemed to be an Entity at Risk when it enters into transactions with the Interested Persons as part of Jiutian Group. It would also be deemed to be an Interested Person as being part of Anhua Group when it enters into transactions with Jiutian Group.
- (3) Anyang Jiujiu is a joint venture between Jiutian and Anyang Jiulong pursuant to which Anyang Jiulong holds 51% and Jiutian holds 49% of the registered capital of Anyang Jiujiu. The effective interest of Jiutian Group in Anyang Jiujiu is therefore approximately 74%. However, it was assessed and concluded that Jiutian Group has no control but only significant influence over Anyang Jiujiu as the majority voting rights and representative of the board of the directors in Anyang Jiujiu are held by Anyang Jiulong. Accordingly, Anyang Jiujiu is an associated company of Jiutian. HNEC would have control over Anyang Jiujiu through its subsidiary, Anyang Jiulong.

Therefore, in certain circumstances, Anyang Jiujiu would be deemed to be an Entity at Risk when it enters into transactions with the Interested Persons as part of Jiutian Group. It would also be deemed to be an Interested Person as being part of Anhua Group when it enters into transactions with Jiutian Group.

4.2.2 Classes of the Entities at Risk and the Interested Persons

(a) Background

As at the Latest Practicable Date, Anyang Longyu holds 502,429,900 Shares through its nominee, Philip Securities Pte. Ltd., representing approximately 25.27% of the issued share capital of the Company.

APPENDIX I

Anyang Longyu is a wholly-owned subsidiary of Anhua, a state-owned enterprise incorporated in Anyang, Henan Province, PRC. Anhua is in turn a subsidiary of HNEC. HNEC is one of the PRC's most significant coal mining companies and a significant manufacturer in the chemical industry. As such, all transactions entered into by Anhua Group (which includes Anyang Jiulong as subsidiary of HNEC), Guolong Logistics (subsidiary of Anhua) and Anyang Yongjin (subsidiary of HNEC) (as interested person are associates of controlling shareholder, Anyang Longyu) with Jiutian Group (which includes Anyang Jiutian, Anyang Jiulong and Anyang Jiujiu as Entities at Risk) are interested person transactions under Chapter 9 of the Catalist Rules.

Anhua has been a key supplier of raw materials to Jiutian Group since 2005 pursuant to a 20-year supply agreement that was entered into between Anyang Jiutian and Anhua commencing on 1 January 2005 and expiring on 31 December 2024 (the "**Supply Agreement**"). The term of the Supply Agreement is renewable on the 18th year for a further period of 20 years through negotiations between Jiutian Group and Anhua. As at the Latest Practicable Date, Jiutian Group and Anhua are in discussions on the renewal of the Supply Agreement.

Pursuant to the Supply Agreement, Anhua has been supplying

- (a) liquid coal gas, liquid ammonia, water, electricity, meter running gas, industrial steam and nitrogen to Jiutian Group's dimethylformamide and methylamine workshops;
- (b) liquid coal gas, water, electricity, industrial steam, meter gas and nitrogen to Jiutian Group's methanol workshop; and
- (c) carbon dioxide, oxygen, production water, electricity and industrial steam to Jiutian Group's gas workshop.

The prices for all the raw materials and services to be supplied by Anhua under the Supply Agreement are not fixed and are subject to negotiations between Jiutian Group and Anhua. Anyang Jiutian also has the rights, under the Supply Agreement, to purchase raw materials directly from other third parties.

With the Supply Agreement, Jiutian Group can be assured of a stable supply of its essential raw materials in accordance with its standards and specifications. Another advantage of the Supply Agreement is that Jiutian Group will not be charged by Anhua for any transportation costs for the raw materials supplied due to the close proximity of the factories of Anhua and Jiutian Group.

(b) *List of Entities at Risk and Interested Persons*

Pursuant to Chapter 9 of the Catalist Rules, the list of the Entities at Risk and the Interested Persons and the types of transactions which are covered under the IPT Mandate are as follows:

- (i) Entities at Risk

Jiutian Group

- (ii) Interested Persons

Anhua, Anyang Yongjin, Guolong Logistics and/or Anyang Jiulong

APPENDIX I

4.3 Categories of the Recurrent IPTs

The IPT Mandate will include all transactions set out in section 4.2.2(b) of this Appendix I which are recurrent transactions of revenue or trading nature or those which are necessary for the day-to-day operations of Jiutian Group. The categories of the Recurrent IPTs which are covered by the IPT Mandate include the following:-

4.3.1 (i) Transactions A – Purchase of Raw Materials Type I

Jiutian Group currently purchases Raw Materials Type I from Interested Persons to produce its chemical products. Due to the close proximity of the factories of Jiutian Group and Interested Persons, these raw materials are being delivered to the factories of Jiutian Group via pipelines without any transportation costs being incurred by Jiutian Group.

Jiutian Group is able to purchase Raw Materials Type I from unrelated third parties. However, purchasing such raw materials from unrelated third parties will be much higher as transportation costs will be incurred to store these raw materials in either storage bottles or tanks and transporting them to the factories of Jiutian Group via trucks.

The prices of raw materials under Raw Materials Type I purchased from Interested Persons are not less favourable than the terms offered by the Interested Persons to third parties and those purchased by Jiutian Group from unrelated third parties taking into account industry norms such as transportation costs and the payment terms that may include cash or credit or bills receivable.

(ii) Transactions A – Purchase of Raw Materials Type II

Jiutian Group is unable to either obtain quotes or purchase Raw Materials Type II from unrelated third parties. It is usual for most factories in the PRC to produce such raw materials for their own use.

Since 2005, Jiutian Group has been purchasing Raw Materials Type II from Interested Persons under the Supply Agreement. If these raw materials are not supplied by Interested Persons, Jiutian Group would incur heavy capital expenditures to produce the same using its own facilities. It is also cost efficient for Jiutian Group to obtain these raw materials from Interested Persons as opposed to factories from neighbouring towns as the said raw materials would be transported to the factories of Jiutian Group through pipelines without any transportation costs being incurred if such purchases were made. There are also no other factories which are in the vicinity of the factories of Jiutian Group for such raw materials to be supplied via pipelines. Jiutian Group will incur transportation costs for purchasing the same from unrelated third parties.

Jiutian Group purchases liquid coal gas, oxygen and instrument air from Interested Persons based on the prices computed by Jiutian Group using the Technical Cost Conversion Formulae.

The prices of such raw materials are determined based on the unit production costs of Interested Persons for the said raw materials with a mark-up of 5% (the "**Production Cost Method**") to cover the 5% sales tax that is payable by Interested Persons to the PRC authorities for such sale of raw materials to Jiutian Group.

APPENDIX I

4.3.2 Transactions B – Purchase of electricity and industrial steam

Jiutian Group purchases electricity from Interested Persons which is delivered to Jiutian Group's factories via power lines without incurring delivery costs.

The only other vendor in the vicinity which supplies electricity is Henan Electric, a state-owned electricity utility company which supplies electricity to the public in the Henan province of the PRC.

The unit price of electricity purchased by Jiutian Group from Interested Persons will not be higher than the unit price of electricity quoted by Henan Electric.

In addition, the purchase of electricity from Interested Persons is comparatively more cost effective than to incur costs to build an electricity substation and to install new power lines so as to receive electricity from Henan Electric.

Due to the close proximity of the factories of Jiutian Group with that of the Interested Persons. Jiutian Group is able to purchase industrial steam from Interested Persons which is delivered via pipelines and without incurring transportation costs.

In addition, the purchase of industrial steam from Interested Persons is comparatively more cost effective compared to investing heavy capital expenditure for the building of steam boilers to produce industrial steam internally.

There are no other factories which are in the vicinity of Jiutian Group's factories for industrial steam to be supplied via pipelines and Jiutian Group will incur transportation costs for purchasing the same from unrelated third parties. It is not practicable for industrial steam to be transported via trucks or long distance pipes.

Jiutian Group uses the relevant Technical Cost Conversion Formulae in arriving at the purchase price of industrial steam.

It is not practicable for Jiutian Group to obtain quotations from unrelated third parties for the purchase of industrial steam as typically, chemical companies would have their own steam boilers to produce for their own use.

4.3.3 Transactions A and C – Purchase and/or sale of Repair Materials

Jiutian Group purchases repair materials from Interested Persons which are necessary for carrying out repairs and maintenance work on its factories in the PRC (the "**Repair Materials**"). These Repair Materials include steel materials, cement and related materials. Taking into account of the industry norms such as the prevailing market conditions, the nature of the Repair Materials, the order quantity, the discount or rebates for bulk purchases, transportation cost and credit terms, the prices paid for the Repair Materials which are purchased from Interested Persons are not less favourable than those purchased from unrelated third parties.

Interested Persons may also purchase these Repair Materials from Jiutian Group when Interested Persons are in need of such materials and Jiutian Group have excess stock of the same. These materials will be sold to Interested Persons at prevailing market prices which are determined by comparing the sale price of such materials against the quotations which Jiutian Group obtain from at least two unrelated third parties. The terms offered by Jiutian Group to the Interested Persons for the sale of Repair Materials would not be less favorable compared to the terms offered by Jiutian Group to third parties.

APPENDIX I

4.3.4 Transaction D – Sale of electricity and industrial steam

Jiutian Group has been selling electricity and industrial steam to Interested Persons since September 2010.

The unit price of electricity sold to Interested Persons by Jiutian Group shall not be lower than the unit price of electricity offered by Henan Electric.

The selling price for the industrial steam is determined by Jiutian Group using the Technical Cost Conversion Formulae.

Electricity and industrial steam are respectively delivered to the factories of Interested Persons via power lines and pipelines without any transportation costs being imposed.

4.3.5 Transactions E – Sale of Dimethylamine

Dimethylamine is one of the products which Jiutian Group produces and sells to third parties in its ordinary course of business. Jiutian Group started selling Dimethylamine to Interested Persons since 28 February 2013.

When selling Dimethylamine to Interested Persons, the sale price and terms of the sale will be comparable and not more favourable to prevailing prices which Jiutian Group sells to third parties.

4.3.6 Transactions F and G – Rental and/or lease of equipment

Jiutian Group and Interested Persons, from time to time, lease and/or rent equipment from each other whenever the need arises. Additional equipment may be required by the parties due to higher production requirements as a result of an increase in their purchase orders or where certain equipment is under maintenance.

Jiutian Group leased part of its facilities in the methanol workshop to Interested Persons who uses the said facilities to process certain gases for their own use.

Other examples of equipment which were leased by Jiutian Group rented from Interested Persons include compressors and storage tanks which are necessary and critical in the chemical industry. Each of Jiutian Group and Interested Persons have their own compressors and storage tanks and whenever there is a shortage of capacity due to higher production requirements or maintenance issues, Jiutian Group and Interested Persons will lease to and/or rent such equipment from each other.

The equipment for rental is usually bulky in size, customised for the production of chemicals and there is no market for the rental of such equipment. The rental rate shall be the depreciation rate of the equipment with a markup of 10% which consists of maintenance related administrative expenses (7.5%) and taxes (2.5%) that is to be borne by the lessor in connection therewith.

4.4 The Technical Cost Conversion Formulae

Jiutian Group had, from March 2012, adopted the Technical Cost Conversion Formulae for the purposes of determining the prices of certain raw materials and to ensure the reasonableness of the

- (i) purchase prices of liquid coal gas, oxygen and instrument air from Interested Persons; and
- (ii) price of industrial steam when it purchases or sells industrial steam from or to Interested Persons.

APPENDIX I

The Technical Cost Conversion Formulae takes into account factors such as the component cost of the raw materials and the quantity of each component that is required to produce every unit of the raw material. The Directors of Jiutian are of the view that the Technical Cost Conversion Formulae will ensure that the purchase price of the aforesaid raw materials are reasonable and are not prejudicial to the interests of the Company and its minority Shareholders as the Technical Cost Conversion Formulae do not favour Jiutian Group or its Interested Persons. The purchase of raw materials from the Interested Persons also results in cost savings to the Entities at Risk as no transportation costs is incurred by the Entities at Risk when it purchases raw materials from the Interested Persons.

Each of the Technical Cost Conversion Formulae was formulated by Wuhuan Engineering Co., Ltd. ("**Wuhuan Engineering**"), an independent technical consultant in the PRC, not related in any way to Jiutian Group or its Interested Persons. Wuhuan Engineering is an engineering consulting, design and contracting enterprise of chemical petrochemical and medical industries with all class A certificates in the PRC. Further information about Wuhuan Engineering and the services provided by them can be found at their website at www.cwcec.com.

4.5 The Production Cost Method

Jiutian Group uses the Production Cost Method in arriving at the prices of clean water, desalinated water and recycled water.

The Production Cost Method uses the unit production cost of Interested Persons for the said raw materials with a mark up of 5% to cover the tax that is payable by the Interested Persons to the PRC authorities on the sale of raw materials to Jiutian Group.

In order to ensure that the prices of the raw materials, whereby the Production Cost Method is used, are fair and reasonable, the local finance team (which includes the Group Financial Controller) of Jiutian Group will request for the costing report of such raw materials from Interested Persons and reviews the key component costs of the raw materials. As all of Jiutian Group and Interested Persons are in related businesses, Jiutian Group is able to review and determine whether the production costs for the aforesaid raw materials are reasonable.

Jiutian Group has and will continue to use the Production Cost Method in arriving at the prices of clean water, desalinated water and recycled water as Wuhuan Engineering does not have the requisite expertise to formulate the technical formulae for arriving at the prices of such materials.

The Directors of Jiutian are of the view that the Production Cost Method will continue to ensure that the purchase price of the aforesaid raw materials are reasonable and are not prejudicial to the interests of the Company and its minority Shareholders. Moreover, when Jiutian Group purchases such raw materials from Interested Persons, it does not incur any transportation costs and that results a cost saving to Jiutian Group.

Any inefficiencies in the production of the aforesaid raw materials such as temporary shutdowns due to maintenance by Interested Persons will invariably add to the cost of production for which Jiutian Group will have to bear. Notwithstanding such cost increase, Jiutian Group still has to purchase the aforesaid raw materials from Interested Persons because it is not possible for Jiutian Group to purchase them from unrelated third parties that are in the vicinity of their factories. To purchase the aforesaid raw materials from the nearest neighbouring town will require Jiutian Group to install 3 waterlines to receive the aforesaid raw materials.

The management of the Company, together with the Audit Committee, will constantly monitor the volume of purchases of the aforesaid raw materials from Interested Persons, and consider accordingly if the installation of the 3 waterlines to receive the aforesaid raw materials is commercially justifiable.

APPENDIX I

4.6 Rationale for and benefits of the IPT Mandate

The Directors believe that the IPT Mandate is in the best interests of Jiutian Group for the following reasons:-

- (a) the Directors are of the view that it is beneficial to Jiutian Group to continue to transact with Interested Persons as they do not incur any transportation costs if they purchase the raw materials from Interested Persons as opposed to purchasing the same from unrelated third parties;
- (b) there are certain raw materials such as industrial steam, clean water, desalinated water and recycled water which are to be procured from facilities that are near to the factories of Jiutian Group and there are no other nearby facilities which offers such an option;
- (c) timely delivery is an essential element in the businesses of Jiutian Group. If the Company is required to seek shareholders' approval on each occasion it deals with the Interested Persons, it would not be commercially viable for the Interested Persons to transact with Jiutian Group. The IPT Mandate would facilitate such transactions with the Interested Persons being carried out in a timely manner; and
- (d) the Recurrent IPTs will occur from time to time at differing intervals. The IPT Mandate and the subsequent renewals on an annual basis will eliminate the need to prepare and make announcements and/or convene separate general meetings on a continual basis to seek prior shareholders' approval for the entry into these transactions. This will reduce the time and expenses which would otherwise be incurred to convene general meetings on an ad hoc basis and allow such resources and time to be channelled towards the Company's other corporate and business objectives.

4.7 Guidelines and Review Procedures for the Recurrent IPTs under the IPT Mandate

- 4.7.1 The Company has established the following procedures to ensure that the Recurrent IPTs are undertaken on an arm's length basis and on normal commercial terms and are not prejudicial to the interests of the Company and its minority shareholders. In general, these are procedures established by the Company to ensure that the Recurrent IPTs are undertaken on normal commercial terms that are consistent with the usual business practices and policies of Jiutian Group, which are generally not more favourable to the Interested Persons than those extended to unrelated third parties.

The guidelines and review procedures for each type of the Recurrent IPTs are as follows:-

(a) Transactions A and B

(i) *Purchase of Raw Materials Type I and/or Repair Materials*

When Jiutian Group purchases Raw Materials Type I which are readily available in the market and/or Repair Materials from Interested Persons, two other quotations from unrelated third parties will be obtained for comparison to ensure that such Recurrent IPTs are conducted on normal commercial terms and are not prejudicial to the interests of the Company and its minority shareholders. The purchase price for Raw Materials Type I and/or the Repair Materials shall not be higher than the most competitive price offered by two other unrelated third parties, and all pertinent factors, including but not limited to quality, specifications and requirements, duration of contracts, reliability in delivery and track record will be taken into consideration.

APPENDIX I

In addition, the credit terms obtained from Interested Persons shall not be less favourable than those obtained from unrelated third parties. The payment terms to Interested Persons can range from advance payment of up to two months before delivery to payment due in 7-days after the invoice date. The advance payment terms are provided in order for Jiutian Group to secure its purchase of Raw Materials Type I to ensure no interruption to the continuous operation of its production plants. The advance payment amount is limited up to 2 months of prior year average monthly value of purchases of Raw Materials Type I from Interested Persons.

(ii) *Purchase of Raw Materials Type II*

When Jiutian Group purchases Raw Materials Type II from Interested Persons whereby it is not practicable to transact with unrelated third parties, Jiutian Group uses the Technical Cost Conversion Formulae or the Production Cost Method to ensure that the prices of Raw Materials Type II are reasonable and are not prejudicial to the interests of the Company and its minority shareholders.

When purchasing liquid coal gas, oxygen and instrument air from Interested Persons, Jiutian Group uses the relevant Technical Cost Conversion Formula in arriving at the prices of such raw materials.

When purchasing clean water, desalinated water and recycled water from Interested Persons, Jiutian Group uses the Production Cost Method to arrive at the prices of such raw materials.

In purchasing raw materials which involves the use of the Production Cost Method, the Group Financial Controller of Jiutian Group will request for the costing report from Interested Persons and reviews the key component costs of the raw materials. As all of Jiutian Group and Interested Persons are in related businesses, Jiutian Group is able to review and determine whether the production cost of Interested Persons for the aforesaid raw materials are reasonable. This ensures that the prices quoted by Interested Persons are reasonable and are of a markup of up to 5% of the unit production cost of Interested Persons. Interested Persons pay up to 5% tax on sale of raw materials to Jiutian Group and up to 5% markup is to cover the tax that is payable by Interested Persons to the PRC authorities.

The payment terms to Interested Persons can range from advance payment of up to two months before delivery to payment due in 7days after the invoice date. The advance payment terms are provided in order for Jiutian Group to secure its purchase of Raw Materials Type II to ensure no interruption to the continuous operation of its production plants. The advance payment amount is limited up to 2 months of prior year average monthly value of purchases of Raw Materials Type II from Interested Persons.

Monthly reports are prepared by (i) the local team of each of the subsidiaries of the Company and (ii) the local finance team of Anyang Jiulong and the Group Financial Controller of the Company will review the costing and the setting of the prices for such raw materials. Thereafter, a report containing details of the transaction and the prices of the raw materials is provided to the Audit Committee for its approval.

APPENDIX I

(iii) *Purchase of electricity and industrial steam*

When purchasing electricity from Interested Persons, Jiutian Group will compare the unit price of electricity quoted against the unit price of electricity as quoted by Henan Electric to ensure that such Recurrent IPTs are conducted on normal commercial terms and are not prejudicial to the interests of the Company and its minority Shareholders.

The unit price of electricity when purchases are made by Jiutian Group shall not be higher than the unit price of electricity offered by Henan Electric. In addition, the credit terms obtained for the purchase of electricity shall not be less favourable than those obtained from Henan Electric.

When purchasing industrial steam from Interested Persons, Jiutian Group uses the Technical Cost Conversion Formula in arriving at the price of industrial steam.

The payment terms to Interested Persons can range from advance payment of 2 months before delivery to payment due in 7-days after the invoice date. The advance payment terms are provided in order for Jiutian Group to secure its purchase of electricity and industrial steam to ensure no interruption to the continuous operation of its production plants. The advance payment amount is limited up to 2 months of prior year average monthly value of purchases of electricity and industrial steam from Interested Persons.

(b) Transactions C and D

(i) *Sale of Repair Materials*

When selling the Repair Materials which are in excess of the needs of Jiutian Group to Interested Persons, the sale price and terms of the sale will not be lower or less favourable to prevailing market prices quoted by unrelated third parties.

Jiutian Group will obtain quotations from at least two unrelated third parties selling such materials for comparison to ensure that such Recurrent IPTs are conducted on normal commercial terms and are not prejudicial to the interests of the Company and its minority shareholders.

(ii) *Sale of electricity and industrial steam*

When selling electricity to Interested Persons, Jiutian Group will compare its unit selling price of electricity against the unit price of electricity as quoted by Henan Electric to ensure that such Recurrent IPTs are conducted on normal commercial terms and are not prejudicial to the interests of the Company and its minority shareholders.

The unit price of electricity sold to Interested Persons from Jiutian Group shall not be lower than the unit price of electricity offered by Henan Electric.

When selling industrial steam to Interested Persons, the price of the industrial steam shall be determined by Jiutian Group using the Technical Cost Conversion Formula.

APPENDIX I

The credit terms offered to Interested Persons can range from advance payment to payment due in 7 days after the invoice date. The advance payment amount is limited up to 2 months of prior year average monthly sales of electricity and industrial steam to Interested Persons.

(c) Transaction E - Sale of Dimethylamine

When selling Dimethylamine to Interested Persons, Jiutian Group will compare the sale price and terms of the sale against its sale, in the same month, of Dimethylamine to unrelated third parties to ensure that the sale price and terms of the sale will not be lower or less favourable compared to prevailing prices which Jiutian Group sells to unrelated third parties.

This seeks to ensure that the sale of Dimethylamine to Interested Persons are conducted on normal commercial terms and are not prejudicial to the interests of the Company and its minority shareholders.

(d) Transaction F and G - Rental and/or lease of equipment

When renting and/or leasing of equipment from/to Interested Persons, the rental rate of the equipment shall be based on the depreciation rate of the equipment with a mark-up of 10% consisting of maintenance related administrative expenses (7.5%) and taxes (2.5%) to be borne by the lessor in connection therewith.

The depreciation policy of the subsidiaries of Jiutian Group in the PRC and that of the Interested Persons are similar as tax allowance for capital assets are unified in the PRC.

There is currently no market for the rental of such equipment and the Audit Committee is of the view that the formula for computing the rate for rental or lease of equipment from/to Interested Persons is fair and reasonable.

4.7.2 All Recurrent IPTs must be consistent with the usual business practices and policies of Jiutian Group. The following additional guidelines and review procedures are also undertaken by Jiutian Group to ensure that the Recurrent IPTs are carried out on normal commercial terms and in accordance with the procedures of the IPT Mandate:-

- (a) any single transaction or the aggregate value of all transactions entered into with the same Interested Person in the same financial year is of a value less than RMB500,000 will be reviewed and approved by the Group Financial Controller of the Company and/or Acting CEO and general manager of the subsidiaries (who shall not be interested in respect of the particular transaction) as designated by the Audit Committee prior to entering into the transaction;
- (b) any single transaction or the aggregate value of all transactions entered into with the same Interested Person in the same financial year is of a value between RMB500,000 but less than RMB20 million will be reviewed and approved jointly by the Acting Chief Executive Officer and the Group Financial Controller of the Company prior to entering into the transaction. In the event that any of the said persons is not available, an appropriate senior executive approved by the Audit Committee will be appointed in the interim;

APPENDIX I

- (c) where any single transaction or the aggregate value of all transactions entered into with the same Interested Person in the same financial year is equal to or more than RMB20 million, such transactions will be reviewed by the Audit Committee of the Company prior to entering into the transaction;
- (d) in the event that a person is interested in any transaction to be entered into with an Interested Person, he shall abstain from participating in the review and/or approval of that particular transaction;
- (e) the Company maintains a register for all transactions (including those less than S\$100,000) entered into with the Interested Persons (the "Register") recording the basis, aggregation of transaction with the same interested person pursuant to Rule 908 of the Catalist Rules, including, if applicable, the quotations obtained to support such basis, on which they were entered into and the person who has approved the transaction;
- (f) the Company shall, on a quarterly basis, report and forward the Register to the Audit Committee on all transactions entered into with the Interested Persons during the preceding quarter. The Audit Committee shall review such Recurrent IPTs at its quarterly meetings, save for those transactions which have been previously approved by the Audit Committee during the financial year, to ensure that the Recurrent IPTs are carried out on normal commercial terms and in accordance with the guidelines and review procedures of the IPT Mandate. All relevant non-quantitative factors will also be taken into account. Such review includes the examination of the transaction and its supporting documents or such other data deemed necessary by the Audit Committee. The Audit Committee shall, when it deems fit, have the right to require the appointment of independent sources, advisers and/or valuers to provide additional information pertaining to the transaction under review;
- (g) the Company's annual internal audit plan shall incorporate a review of all Recurrent IPTs including the established review procedures for the monitoring of such transactions entered into during the same financial year pursuant to the IPT Mandate;
- (h) the Audit Committee shall also, on a yearly basis, review the internal audit report to ascertain whether the guidelines and review procedures established to monitor the Recurrent IPTs have been complied with and whether the established guidelines and review procedures continue to be adequate and/or commercially practicable in ensuring that the Recurrent IPTs are conducted on normal commercial terms and will not be prejudicial to the interests of the Company and its minority shareholders; and
- (i) a new general mandate from shareholders shall be sought if the periodic reviews by the Audit Committee indicate that the existing guidelines and review procedures have become inappropriate or insufficient to ensure that the Recurrent IPTs will be conducted on normal commercial terms and will not be prejudicial to the interests of the Company and its minority shareholders.

APPENDIX I

- 4.7.3 Most of the Recurrent IPTs with the Interested Persons are expected to be in the range of RMB500,000 and RMB20 million. As such, it is prudent that the Recurrent IPTs within the said range are reviewed and approved jointly by the Acting Chief Executive Officer and the Group Financial Controller of the Company. As a further control element, the Recurrent IPTs are subject to further review by the Audit Committee in the event that the value of a transaction or aggregate value of all transactions entered into with the same Interested Person in the same financial year is equal to or exceeds RMB20 million. In such a situation, the Group Financial Controller of the Company shall forward the list of the Recurrent IPTs and the basis of the transactions to the Audit Committee for its review prior to entering into such transactions.
- 4.7.4 The Audit Committee believes that the above guidelines and review procedures are sufficient to ensure that the Recurrent IPTs will be conducted on normal commercial terms and will not be prejudicial to the interests of the Company and its minority shareholders. The Audit Committee will obtain a fresh mandate from shareholders if the above guidelines and review procedures become inappropriate.
- 4.7.5 In the event that the Audit Committee is of the view that a new general mandate shall be sought from the shareholders, all transactions to be entered into with the Interested Persons during the interim shall be subject to the review and approval of the Audit Committee, to ensure that such transactions will be conducted on normal commercial terms and will not be prejudicial to the interests of the Company and its minority shareholders.

4.8 Statement of the Audit Committee

Pursuant to Rule 920(1)(c) of the Catalist Rules, the Audit Committee confirms that:-

- (a) the methods and review procedures for determining the transaction prices of the Recurrent IPTs in the IPT Mandate have not changed since the last Shareholders' approval on 26 April 2023; and
- (b) the methods and review procedures in section 4.8(a), are sufficient to ensure that the Recurrent IPTs will be carried out on normal commercial terms and will not be prejudicial to the interests of the Company and its minority shareholders.

4.9 Validity Period of the Proposed IPT Mandate

If approved at the AGM, the Proposed IPT Mandate will take effect from the date of the passing of the ordinary resolution approving the renewal of the IPT Mandate and will (unless revoked or varied by the Company in a general meeting) continue to be in force until the next annual general meeting of the Company.

Approval from the shareholders will be sought for the renewal of the IPT Mandate at each subsequent annual general meeting of the Company subject to satisfactory review by the Audit Committee of its continued application to the transactions with the Interested Persons.

APPENDIX I

4.10 Disclosure in the annual report

The Company will announce the aggregate value of transactions conducted with the Interested Persons pursuant to the IPT Mandate for the relevant financial periods which the Company is required to report on pursuant to the Catalist Rules and within the time frame required for the announcement of such reports.

Disclosure will also be made in the Company's annual report of the aggregate value of transactions conducted with the Interested Persons pursuant to the IPT Mandate during the current financial year, and in the annual reports for subsequent financial years that the proposed IPT Mandate continues to be in force, in accordance with the requirements of Chapter 9 of the Catalist Rules.

The names of each Interested Person and the corresponding aggregate value of the transactions entered with the same Interested Person during the financial year under review will be presented in the following format:-

Name of interested person	Nature of relationship	Aggregate value of all interested person transactions entered during the financial year under review (excluding transactions less than S\$100,000 and transactions conducted under the shareholders' mandate pursuant to Rule 920 of the Catalist Rules)	Aggregate value of all interested person transactions conducted under the shareholders' mandate pursuant to Rule 920 of the Catalist Rules (excluding transactions less than S\$100,000)
---------------------------	------------------------	--	--

5. INTERESTS OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

Save as disclosed in this Appendix I, none of the Directors or substantial shareholders of the Company has any interest, direct or indirect, in the proposed renewal of the IPT Mandate other than through their respective shareholdings and/or directorships in the Company.

APPENDIX I

6. SHAREHOLDING INTERESTS OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

The interests of the Directors and substantial shareholders of the Company in the Shares as at the Latest Practicable Date, as recorded in the Register of Directors' Shareholdings and the Register of Substantial Shareholders maintained under the provisions of the Act, were as follows:-

	Direct Interest		Deemed Interest	
	Number of Shares	% ⁽¹⁾	Number of Shares	% ⁽¹⁾
<u>Directors</u>				
Xu Aijun	–	–	–	–
Lee Chee Seng ⁽²⁾	11,250,000	0.57	22,419,000	1.13
Wu Yu Liang	300,000	0.02	–	–
Chan Kam Loon	–	–	–	–
Gao Guoan	–	–	–	–
Wang Gang	–	–	–	–
Chen Mingjin	–	–	–	–
Koh Eng Kheng Victor	–	–	–	–
Song Fudong	–	–	–	–
<u>Substantial Shareholders</u>				
Anyang Longyu ⁽³⁾	–	–	502,429,900	25.27
Anhua ⁽⁴⁾	–	–	502,429,900	25.27
HNEC ⁽⁴⁾	–	–	502,429,900	25.27

Notes:

- (1) Based on the issued share capital of 1,988,444,000 Shares as at the Latest Practicable Date.
- (2) Lee Chee Seng is deemed interested in 19,419,000 Shares held through his indirect nominee, Credit Suisse AG, Singapore Branch and 3,000,000 Shares held through his nominee KGI Securities (Singapore) Pte. Ltd.
- (3) Anyang Longyu is deemed interested in 502,429,900 Shares held through its nominee, Phillip Securities Pte Ltd.
- (4) Anhua and HNEC is deemed to be interested in the shares held by Anyang Longyu by virtue of Section 6 of the Companies Act 1967.

7. ANNUAL GENERAL MEETING

The AGM, notice of which is contained in the Annual Report of the Company, will be held at Royal Plaza on Scotts, Balmoral Hall, Level 5, 25 Scotts Road, Singapore 228220 on 25 April 2024 at 10.30 a.m. for the purpose of considering and, if thought fit, passing with or without modifications, Resolution 7 relating to the proposed renewal of the IPT Mandate.

APPENDIX I

8. NON-INTERESTED DIRECTORS' RECOMMENDATION

As Mr Xu Aijun, Mr Song Fu Dong and Mr Wang Gang are the nominee directors of HNEC and Anhua on the Board of the Company, each of them will abstain from making any recommendation to the shareholders on Resolution 7 relating to the proposed renewal of the IPT Mandate. Accordingly, the Non-interested Directors (who are considered to be independent for the purposes of making a recommendation to the shareholders in respect of the proposed renewal of the IPT Mandate) are Mr Lee Chee Seng, Mr Wu Yu Liang, Mr Chan Kam Loon, Mr Gao Guoan, Mr Chen Mingjin and Mr Koh Eng Kheng Victor. Save as disclosed herein, none of the Directors has any interest, direct or indirect, in the proposed renewal of the IPT Mandate other than through their respective Shareholdings and/or directorships in the Company.

Having fully considered, among others, the terms, rationale and the benefits of the IPT Mandate to Jiutian Group as set out in this Appendix I, the Non-Interested Directors are of the view that the proposed renewal of the IPT Mandate is in the best interests of the Company and, accordingly, they recommend that Shareholders vote in favour of Resolution 7 relating to the proposed renewal of the IPT Mandate at the AGM.

9. ACTION TO BE TAKEN BY SHAREHOLDERS

9.1 Submission of Proxy Forms to vote

The AGM will be being convened at Royal Plaza on Scotts, Balmoral Hall, Level 5, 25 Scotts Road, Singapore 228220 on 25 April 2024 at 10.30 a.m..

The AGM will be convened in a physical format only and there will be no option for Shareholders to participate virtually. Shareholders who are unable to attend the AGM and who wish to appoint a proxy to attend and vote at the AGM on their behalf are requested to complete, sign and return the Proxy Form attached to the Notice of AGM in accordance with the instructions printed thereon as soon as possible and by completing and submitting the duly completed Proxy Form to the Company's Share Registrar, Tricor Barbinder Share Registration Services, at 9 Raffles Place, #26-01, Republic Plaza, Singapore 048619, by 10.30 a.m. (Singapore time) on 22 April 2024, and in default the Proxy Form shall not be treated as valid. Hardcopies of the Notice of AGM, Proxy Form and Request Form will be sent by post to Shareholders. Alternatively, Shareholders may access the Proxy Form on the website of the SGX-ST at <https://www.sgx.com/securities/company-announcements> and the Company's website at <http://www.jiutianchemical.com.sg/>, and thereafter download, complete and sign the Proxy Form, before submitting it by post to the address provided above. The completion and return of the Proxy Form by such Shareholder will not prevent him from attending and voting at the AGM in person if he so wishes.

A Depositor shall not be regarded as a member of the Company entitled to attend the AGM and to speak and vote thereat unless his name appears on the Depository Register at least 72 hours before the time appointed for holding the AGM.

Shareholders should refer to the Notice of AGM for further information, including the steps to be taken by Shareholders to participate at the AGM.

APPENDIX I

9.2 Submission of Questions in Advance

Shareholders can submit substantial and relevant questions relating to the Resolutions to be tabled for approval at the AGM, in advance of the AGM, to the Company in the following manner:

- (i) Shareholders may submit their questions by post, to be deposited at the registered office of the Company at 9 Raffles Place, #26-01, Republic Plaza, Singapore 048619; or
- (ii) Shareholders may submit their questions electronically via email to nghankiat@jiutianchemical.com,

in each case, by 18 April 2024 on 10.30a.m. (the “Cut-Off Time”).

When submitting substantial and relevant questions electronically via email or by post, Shareholders must provide the Company with the following details to enable the Company to verify their status as Shareholders: (a) status: individual shareholder or corporate representative; (b) full name/full company name (as per CDP/CPF/SRS/Scrip-based records); (c) NRIC/FIN/ Passport number/ Registration number; (d) email address; and (e) contact number (optional).

Persons who hold Shares through Relevant Intermediaries (as defined under Section 181(6) of the Companies Act) (other than CPF/SRS investors) should contact their respective Relevant Intermediaries through which they hold such Shares to submit their questions relating to the Resolutions to be tabled for approval at the AGM based on the abovementioned instructions.

The Company will endeavour to address all substantial and relevant questions received from Shareholders prior to the AGM, before or during the AGM. The responses to substantial and relevant questions received from Shareholders by the Cut-Off Time will be posted on SGXNet and the Company's corporate website at <http://www.jiutianchemical.com.sg/> before 10.30a.m. on 20 April 2024, being at least forty-eight (48) hours prior to the closing date and time for the lodgement of the Proxy Form. The Company will address any subsequent clarifications sought, or substantial and relevant follow-up questions (relating to the Resolutions to be tabled for approval at the AGM) received after the Cut-Off Time which have not already been addressed prior to the AGM, as well as those substantial and relevant questions received at the AGM, during the AGM. Where substantially similar questions are received, the Company will consolidate such questions and consequently not all questions may be individually addressed.

10. ABSTENTION FROM VOTING IN CONNECTION WITH THE PROPOSED RENEWAL OF THE IPT MANDATE

Rule 919 of the Catalist Rules provides that interested persons and their associates must not vote on any shareholders' resolution approving any mandate in respect of any interested person transactions nor accept appointments as proxies unless specific instructions as to voting are given.

Accordingly, Anyang Longyu will abstain from voting its shareholding, and undertakes to ensure that its associates will abstain from voting, in respect of Resolution 7 relating to the proposed renewal of the IPT Mandate at the AGM. Further, Anyang Longyu undertakes to decline, and shall ensure that its associates shall decline, to accept appointment as proxies to vote in respect of Resolution 7 unless the shareholder concerned shall have given specific instructions as to the manner in which his votes are to be cast at the AGM for the said resolution. In addition, Mr Xu Aijun, Mr Song Fu Dong and Mr Wang Gang have also undertaken to decline to accept appointment as proxies to vote in respect of Resolution 7 unless the Shareholder concerned shall have given specific instructions as to the manner in which his votes are to be cast at the AGM in respect of the said resolution.

APPENDIX I

11. DIRECTORS' RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this Appendix I and confirm after making all reasonable enquiries that, to the best of their knowledge and belief, this Appendix I constitutes full and true disclosure of all material facts about the proposed renewal of the IPT Mandate as set out herein, the Company and its subsidiaries, and the Directors are not aware of any facts the omission of which would make any statement in this Appendix I misleading.

Where information in this Appendix I has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from these sources and/or reproduced in this Appendix I in its proper form and context.

12. DOCUMENTS AVAILABLE FOR INSPECTION

The following documents may be inspected at the registered office of the Company at 9 Raffles Place, #26-01 Republic Plaza, Singapore 048619 during normal business hours from the date hereof up to and including the date of the AGM:-

- (a) the Constitution of the Company;
- (b) the annual report of the Company for FY2023; and
- (c) the Technical Cost Conversion Formulae.

Yours faithfully
for and on behalf of the Board of Directors of
Jiutian Chemical Group Limited

Lee Chee Seng
Executive Director

APPENDIX II

APPENDIX II DATED 09 APRIL 2024

THIS APPENDIX II IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.

This Appendix II is circulated to shareholders of Jiutian Chemical Group Limited (the “**Company**”) together with the Company’s Annual Report for its financial year ended 31 December 2023 (the “**Annual Report**”). Its purpose is to provide shareholders of the Company with information relating to, and to seek their approval for the proposed renewal of the share buyback mandate to be tabled at the Annual General Meeting of the Company to be held at Royal Plaza on Scotts, Balmoral Hall, Level 5, 25 Scotts Road, Singapore 228220 on 25 April 2024 at 10.30a.m..

IF YOU ARE IN ANY DOUBT ABOUT ITS CONTENTS OR THE ACTION YOU SHOULD TAKE, YOU SHOULD CONSULT YOUR STOCKBROKER, BANK MANAGER, SOLICITOR, ACCOUNTANT, TAX ADVISER OR OTHER PROFESSIONAL ADVISER IMMEDIATELY.

If you have sold or transferred all your shares in the capital of the Company, you should immediately inform the purchaser or transferee or bank, stockbroker or agent through whom the sale or transfer was effected for onward notification to the purchaser or transferee, that this Appendix II, together with the Notice of AGM, the accompanying Proxy Form and Request Form (all as defined herein), may be accessed on the website of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) at <https://www.sgx.com/securities/company-announcements>. A printed copy of this Appendix II will NOT be despatched to Shareholders as the Company’s constitution provides for the use of electronic communications pursuant to the Catalist Rules (as defined herein). Accordingly, only hardcopies of the Notice of AGM, Proxy Form and Request Form will be sent to Shareholders. Shareholders who wish to obtain a printed copy of the Appendix II should complete the Request Form and return it to the Company by post to the business office of the Company at 350 Orchard Road, #21-03 Shaw House, Singapore 238868 or via email to nghankiat@jiutianchemical.com, no later than 18 April 2024.

The Ordinary Resolution proposed to be passed in respect of the proposed renewal of the share buyback mandate is set out in the Notice of Annual General Meeting. The Notice of Annual General Meeting and the Proxy Form are contained in the Annual Report.

This Appendix II has been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”). It has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this Appendix II, including the correctness of any of the statements or opinions made or reports contained in this Appendix II.

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318 and sponsorship@ppcf.com.sg.



JIUTIAN CHEMICAL GROUP LIMITED

(Company Registration Number 200415416H)

(Incorporated in the Republic of Singapore)

APPENDIX IN RELATION TO

THE PROPOSED RENEWAL OF THE SHARE BUYBACK MANDATE

APPENDIX II

CONTENTS

DEFINITIONS	146
LETTER TO SHAREHOLDERS	149
1. INTRODUCTION	149
2. PROPOSED RENEWAL OF THE SHARE BUYBACK MANDATE	149
3. DIRECTORS' AND SUBSTANTIAL SHAREHOLDERS' INTERESTS	164
4. ANNUAL GENERAL MEETING	165
5. ACTION TO BE TAKEN BY SHAREHOLDERS	165
6. DIRECTORS' RECOMMENDATION	166
7. DIRECTORS' RESPONSIBILITY STATEMENT	166
8. DOCUMENTS FOR INSPECTION	166

APPENDIX II

DEFINITIONS

In this Appendix II, the following definitions shall apply throughout unless the context otherwise requires:-

"ACRA"	:	Accounting and Corporate Regulatory Authority of Singapore
"AGM"	:	The annual general meeting of the Company to be held at Royal Plaza on Scotts, Balmoral Hall, Level 5, 25 Scotts Road, Singapore 228220 on 25 April 2024 at 10.30a.m.
"Anyang Longyu"	:	Anyang Longyu (HK) Development Co., Ltd.
"Annual Report"	:	The annual report of the Company for the financial year ended 31 December 2023
"Appendix II"	:	This Appendix II dated 09 April 2024
"associated company"	:	A company in which at least 20% but not more than 50% of its shares are held by the Company or the Group and shall include Anyang Jiujiu Chemical Technology Co., Ltd. in which the Group holds 74% of its registered capital (direct interest of 49% and indirect interest of 25%) but over which the Company has significant influence but not control or joint control over the financial and operating policies of the said company.
"Board" or "Directors"	:	The board of directors of the Company as at the Latest Practicable Date
"Catalist"	:	The sponsor-supervised listing platform of the SGX-ST
"Catalist Rules"	:	The SGX-ST Listing Manual (Section B: Rules of Catalist), as amended, modified or supplemented from time to time
"CDP"	:	The Central Depository (Pte) Limited
"Companies Act"	:	The Companies Act 1967 of Singapore, as amended or modified or supplemented from time to time
"Company"	:	Jiutian Chemical Group Limited
"Constitution"	:	The Constitution of the Company, as amended or modified or supplemented from time to time
"Controlling Shareholder"	:	A person who: <ul style="list-style-type: none"> (a) holds directly or indirectly 15% or more of the nominal amount of all voting Shares in the Company; or (b) in fact exercise control of the Company
"EPS"	:	Earnings per Share
"Group"	:	The Company, its subsidiaries and its associated companies

APPENDIX II

“HNEC”	:	Henan Energy and Chemical Industry Group Co., Ltd.
“Latest Practicable Date”	:	28 March 2024 being the latest practicable date prior to the printing of this Appendix II
“Market Day(s)”	:	A day or days on which the SGX-ST is open for trading in securities
“Notice of AGM”	:	The notice of AGM dated 09 April 2024
“NTA”	:	Net tangible assets
“Proxy Form”	:	The proxy form in respect of the AGM as set out in this Annual Report
“Request Form”	:	The request form for Shareholders to request for physical copy of this Annual Report
“Relevant Period”	:	The period commencing from the date of AGM on which the ordinary resolution relating to the proposed renewal of the Share Buyback Mandate is passed and expiring on the date on which the next annual general meeting of the Company is held or required by law or the Constitution to be held, or the date on which the share buybacks are carried out to the full extent mandated or the date the said mandate is revoked or varied by the Company in a general meeting, whichever is the earliest.
“SGX-ST”	:	Singapore Exchange Securities Trading Limited
“SFA”	:	Securities and Futures Act, Chapter 289 of Singapore, as amended or modified or supplemented from time to time
“Share Buyback”	:	The purchase or acquisition of issued Share(s) by the Company pursuant to the terms of the Share Buyback Mandate
“Share Buyback Mandate”	:	The general and unconditional mandate given by the Shareholders to authorise the Directors to exercise all powers of the Company to purchase or otherwise acquire, on behalf of the Company, issued Shares in accordance with the terms of the Share Buyback Mandate set out in this Appendix II as well as the rules and regulations set forth in the Companies Act and the Catalist Rules
“Shareholders”	:	Registered holders of Shares, except that where the registered holder is CDP, the term “Shareholders” shall, in relation to such Shares and where the context so admits, mean the persons named as Depositors in the Depository Register maintained by CDP whose Securities Accounts are credited with those Shares
“Shares”	:	Ordinary shares in the capital of the Company
“SIC”	:	The Securities Industry Council of Singapore
“Sponsor”	:	PrimePartners Corporate Finance Pte. Ltd.
“subsidiary”	:	A company being a subsidiary of the Company, as defined by Section 5 of the Companies Act

APPENDIX II

“Subsidiary Holdings”	:	Shares referred to in Sections 21(4), 21(4B), 21(6A) and 21(6C) of the Companies Act
“Substantial Shareholder”	:	A person who has an interest in voting Shares of the Company and the total votes attached to that Share, or those Shares, are not less than 5% of the total votes attached to all voting Shares in the Company
“Take-over Code”	:	The Singapore Code on Take-overs and Mergers as may be amended or modified or supplemented from time to time
“Treasury Shares”	:	Shares purchased by the Company pursuant to the Share Buyback Mandate and held by the Company in accordance with Section 76H of the Companies Act and have since purchase been continuously held by the Company
“RMB” and “RMB cents”	:	Renminbi dollars and cents, the lawful currency of the People’s Republic of China (“PRC”)
“S\$” and “cents”	:	Singapore dollars and cents, the lawful currency of Singapore
“%” or “per cent.”	:	Per centum or percentage

The terms “Depositor”, “Depository Agent” and “Depository Register” shall have the meanings ascribed to them respectively in Section 81SF of the SFA.

Words importing the singular shall, where applicable, include the plural and vice versa, and words importing the masculine gender shall, where applicable, include the feminine and neuter genders. Words importing persons shall, where applicable, include corporations.

Any reference in this Appendix II to any enactment is a reference to that enactment as for the time being amended or re-enacted. Any word defined under the Companies Act, the Catalist Rules or the Take-over Code or any modification thereof and not otherwise defined in this Appendix II shall, where applicable, have the same meaning ascribed to it under the Companies Act, the Catalist Rules or the Take-over Code or such modification thereof, as the case may be, unless the context otherwise requires.

Any reference to date and time of day in this Appendix II shall be a reference to Singapore date and time unless otherwise stated.

All discrepancies in figures in tables included in this Appendix II between the listed amounts and the totals thereof are due to rounding. Accordingly, figures shown as totals in certain tables may not be an arithmetic aggregation of the figures which precede them.

In this Appendix II, unless otherwise stated, the exchange rate of S\$1.00 to RMB5.356 being the rate as at the Latest Practicable Date, has been used to convert Singapore dollars to Renminbi dollars and vice versa. The said exchange rate has been presented solely for information only and should not be construed as a representation that the said exchange rate could have been, or could be, converted into the respective currencies, at any particular rates, the rate stated, or at all.

APPENDIX II

LETTER TO SHAREHOLDERS

JIUTIAN CHEMICAL GROUP LIMITED

(Company Registration Number 200415416H)
(Incorporated in the Republic of Singapore)

Board of Directors:

Mr Xu Aijun (*Non-Executive and Non-Independent Chairman*)
Mr Lee Chee Seng (*Executive Director*)
Mr Wu Yu Liang (*Non- Executive and Lead Independent Director*)
Mr Chan Kam Loon (*Non-Executive and Independent Director*)
Mr Gao Guoan (*Non-Executive and Independent Director*)
Mr Wang Gang (*Non-Executive and Non-Independent Director*)
Mr Chen Mingjin (*Non-Executive and Independent Director*)
Mr Koh Eng Kheng Victor (*Non-Executive and Independent Director*)
Mr Song Fudong (*Non-Executive and Non-Independent Director*)

Registered Office:

9 Raffles Place #26-01
Republic Plaza
Singapore 048619

09 April 2024

To: The Shareholders of Jiutian Chemical Group Limited

Dear Sir/Madam

THE PROPOSED RENEWAL OF THE SHARE BUYBACK MANDATE

1. INTRODUCTION

The Company proposes to seek the approval of its Shareholders at the AGM to be held on 25 April 2024 for the proposed renewal of the Share Buyback Mandate.

The Company refers to the summary of resolutions to be passed in the upcoming AGM accompanying the Annual Report for the financial year ended 31 December 2023 and Resolution 8 in relation to the proposed renewal of the Share Buyback Mandate under the heading "Special Business" set out in the Notice of AGM.

The purpose of this Appendix II is to provide Shareholders with information relating to the Share Buyback Mandate.

2. PROPOSED RENEWAL OF THE SHARE BUYBACK MANDATE

2.1 Background

The Share Buyback Mandate was originally approved by Shareholders at an extraordinary general meeting of the Company held on 13 January 2014 and was last renewed at the annual general meeting of the Company held on 26 April 2023.

The Share Buyback Mandate will expire on 25 April 2024, being the date of the forthcoming AGM.

APPENDIX II

Shareholders' approval is thus being sought at the AGM for the renewal of the Share Buyback Mandate for the Share Buyback by the Company of its issued Shares. If approved, the Share Buyback Mandate will take effect from the date of the AGM at which the renewal of the Share Buyback Mandate is approved by the Shareholders and continue in force for the duration of the Relevant Period, which is until the earlier of the date of the next AGM of the Company or such date as the next AGM is required by law or by the Constitution to be held (whereupon it will lapse, unless renewed at such meeting), or the date when Share Buybacks pursuant to a Share Buyback Mandate are carried out to the full extent mandated or the date the Share Buyback Mandate is revoked or varied by the Company in general meeting.

Any Share Buyback by the Company will have to be made in accordance with, and in the manner prescribed by, the Companies Act, the Constitution, the Catalist Rules, and such other laws and regulations as may for the time being be applicable. It is also a requirement that a company which wishes to purchase or acquire its own shares should obtain approval from its shareholders to do so at a general meeting of its shareholders.

2.2 Rationale

The Share Buyback Mandate will give the Company the flexibility to undertake purchases of its issued Shares up to the ten per cent. (10%) limit described in paragraph 2.3.1 below, at any time, subject to market conditions, during the period that the Share Buyback Mandate is in force.

Share Buyback is one of the methods by which return on equity may be enhanced. Share Buybacks also provide the Company with a mechanism to return surplus cash (if any) which is in excess of the Group's financial needs and/or ordinary capital requirements in an expedient and cost-effective manner. The Directors believe that the Share Buybacks may help to mitigate short-term market or price volatility, off-set the effects of short-term share speculation and bolster Shareholders' confidence and employees' morale. Share Buybacks will also allow the Directors have greater control over the Company's share capital structure, dividend policy and cash reserves with a view to enhance the EPS and/or NTA per Share of the Company and the Group.

Whilst the Share Buyback Mandate would authorise Share Buybacks up to the said ten per cent. (10%) limit during the duration referred to in paragraph 2.3.2 below, Shareholders should note that purchases of Shares pursuant to the Share Buyback Mandate may not be carried out to the full ten per cent. (10%) limit as authorised and the purchases of Shares pursuant to the Share Buyback Mandate would be made only as and when the Directors consider it to be in the best interest of the Company and/or Shareholders and in circumstances which they believe will not result in any material adverse effect to the financial position of the Company or the Group, or result in the Company being delisted from the SGX-ST. The Directors will use their best efforts to ensure that after a Share Buyback pursuant to the Share Buyback Mandate, the number of Shares remaining in the hands of the public will not fall to such a level as to cause market illiquidity or adversely affect the orderly trading and listing status of the Shares on the SGX-ST.

2.3 Authority and Limits on the Share Buyback Mandate

The authority and limits of the Share Buyback Mandate, if renewed at the AGM, are the same as were first approved by Shareholders at the extraordinary general meeting of the Company held on 13 January 2014. The authority and limitations placed on purchases of Shares by the Company under the Share Buyback Mandate are summarised below:-

APPENDIX II

2.3.1 *Maximum Number of Shares*

Only Shares which are issued and fully paid-up may be purchased by the Company. The total number of Shares that may be purchased by the Company during the Relevant Period shall not exceed ten per cent. (10%) of the total number of issued Shares of the Company as at the date of the AGM at which the renewal of the Share Buyback Mandate is approved, unless the Company has, at any time during the Relevant Period, effected a reduction of its share capital in accordance with the applicable provisions of the Companies Act, in which event the total number of issued Shares of the Company shall be taken to be the total number of issued Shares of the Company as altered (the "**Maximum Limit**"). Any Shares which are held as Treasury Shares and Subsidiary Holdings will be disregarded for purposes of computing the ten per cent. (10%) limit.

For illustrative purposes only, based on the existing issued and paid-up share capital of the Company as at the Latest Practicable Date, comprising 1,988,444,000 Shares, excluding Treasury Shares and Subsidiary Holdings, and assuming that no further Shares are issued and no further Shares are purchased or acquired and held by the Company as Treasury Shares on or prior to the AGM, not more than 198,844,400 Shares (representing ten per cent. (10%) of the total number of issued Shares (excluding Treasury Shares and Subsidiary Holdings) as at that date) may be purchased or acquired by the Company pursuant to the Share Buyback Mandate.

As at the Latest Practicable Date, the Company does not hold any Treasury Shares and does not have any Subsidiary Holdings.

(a) Where Shares purchased or acquired are held as Treasury Shares

The number of Shares held as Treasury Shares cannot at any time exceed 10% of the total number of issued Shares. On the basis of the aforesaid limit and that the Company does not hold Treasury Shares as at the Latest Practicable Date, the maximum number of Shares which can be purchased or acquired by the Company and be held as Treasury Shares is 198,844,400 Shares, representing 10% of the total number of Shares in issue (excluding Treasury Shares and Subsidiary Holdings) as at the Latest Practicable Date.

(b) Where Shares purchased or acquired are cancelled

The maximum number of Shares which can be purchased or acquired by the Company and cancelled is 198,844,400 Shares, representing 10% of the total number of Shares in issue (excluding Treasury Shares and Subsidiary Holdings) as at the Latest Practicable Date.

While the Share Buyback Mandate would authorise a purchase or acquisition of Shares up to the 10% limit, Shareholders should note that purchases or acquisitions of Shares pursuant to the Share Buyback Mandate may not be carried out up to the full 10% limit as authorised, or at all. In particular, no purchase or acquisition of the Shares would be made in circumstances which would have or may have a material adverse effect on the float, liquidity, orderly trading of the Shares and/or financial position of the Group.

APPENDIX II

2.3.2 Duration of Authority

Purchases of Shares may be made, at any time and from time to time, by the Company on and from the date of the AGM at which the renewal of the Share Buyback Mandate is approved, up to the earliest of:-

- (a) the date on which the next AGM of the Company is held or required by law to be held;
- (b) the date on which the purchases or acquisitions of Shares pursuant to the Share Buybacks are carried out to the full extent mandated; or
- (c) the date on which the authority conferred by the Share Buyback Mandate is revoked or varied by the Shareholders in a general meeting.

(the "**Relevant Period**")

The authority conferred on the Directors by the Share Buyback Mandate to purchase or acquire Shares may be renewed by the Shareholders in a general meeting of the Company, such as at the next AGM or at an extraordinary general meeting to be convened immediately after the conclusion or adjournment of the next AGM. When seeking the approval of the Shareholders for the renewal of the Share Buyback Mandate, the Company is required to disclose details pertaining to purchases or acquisitions of Shares pursuant to the Share Buyback Mandate made during the previous twelve (12) months (whether by way of Market Purchases (as defined below) or Off-Market Purchases (as defined below)), including the total number of Shares purchased or acquired, the purchase price per Share or the highest and lowest prices paid for such purchases or acquisitions of Shares, where relevant, and the total consideration paid for such purchases or acquisitions.

2.3.3 Manner of Share Buyback

Purchases of Shares by the Company may be effected by way of:-

- (a) on-market purchases transacted on the SGX-ST through the SGX-ST's trading system, and which may be transacted through one or more duly licensed stockbrokers appointed by the Company for the purpose of Share Buyback ("**Market Purchases**"); and/or
- (b) off-market purchases (if effected otherwise than on the SGX-ST) in accordance with an "equal access scheme" as defined in Section 76C of the Companies Act ("**Off-Market Purchases**") as may be determined or formulated by the Directors as they may consider fit, which scheme(s) shall satisfy all the conditions prescribed by the Companies Act and the Catalist Rules.

In an Off-Market Purchase, the Directors may impose such terms and conditions which are consistent with the Share Buyback Mandate, the Catalist Rules, the Companies Act, the Constitution of the Company and other applicable laws and regulations, as they consider fit in the interests of the Company and/or Shareholders in connection with or in relation to any equal access scheme or schemes.

Under the Companies Act, an Off-Market Purchase must satisfy all the following conditions:-

- (i) offers for the Share Buyback shall be made to every person who holds Shares to purchase or acquire the same percentage of their Shares;

APPENDIX II

- (ii) all of the aforementioned persons shall be given a reasonable opportunity to accept the offers made to them; and
- (iii) the terms of all the offers shall be the same, except that there shall be disregarded, where applicable:-
 - (a) differences in consideration attributable to the fact that the offers relate to shares with different accrued dividends entitlements;
 - (b) differences in consideration attributable to the fact that the offers relate to shares with different amounts remaining unpaid; and
 - (c) differences in the offers introduced solely to ensure that each person is left with a whole number of shares.

Pursuant to Rule 870 of the Catalist Rules, if the Company wishes to make an Off-Market Purchase in accordance with an equal access scheme, it must issue an offer document to all Shareholders containing at least the following information:-

- (i) the terms and conditions of the offer;
- (ii) the period and procedures for acceptances;
- (iii) the reasons for the proposed Share Buyback;
- (iv) the consequences, if any, of the Share Buyback by the Company that will arise under the Take-over Code or other applicable take-over rules;
- (v) whether the Share Buyback, if made, would have any effect on the listing of the Shares on the Catalist;
- (vi) details of any Share Buyback made by the Company in the previous twelve (12) months (whether by way of Market Purchases or Off-Market Purchases), giving the total number of Shares purchased or acquired, the purchase price per Share or the highest and lowest prices paid for the purchases or acquisitions of Shares, where relevant, and the total consideration paid for the Share Buyback; and
- (vii) whether the Shares purchased by the Company would be cancelled or kept as Treasury Shares.

2.3.4 *Maximum Purchase Price*

The purchase price per Share (excluding brokerage, stamp duties, applicable goods and services tax and other related expenses) to be paid for the Shares purchased pursuant to the Share Buyback Mandate will be determined by the Directors, provided that such purchase price to be paid for a Share must not exceed:-

- (i) in the case of a Market Purchase, one hundred and five per cent. (105%) of the Average Closing Price (as defined hereinafter); and
- (ii) in the case of an Off-Market Purchase pursuant to an equal access scheme, one hundred and twenty per cent. (120%) of the Average Closing Price (as defined hereinafter),

(the "**Maximum Price**") in either case, excluding related expenses of the purchase or acquisition.

APPENDIX II

For the above purposes of determining the Maximum Price:-

“Average Closing Price” means the average of the closing market prices of the Shares over the last five (5) Market Days on which transactions in the Shares were recorded, before the day on which the purchase or acquisition of Shares was made, or as the case may be, the date of the making of the offer (as defined below) pursuant to the Off-Market Purchase, and deemed to be adjusted for any corporate action that occurs during the relevant five (5) Market Days period and the day on which the purchases are made; and

“date of the making of the offer” means the date on which the Company announces its intention to make an offer for an Off-Market Purchase, stating therein the purchase price (which shall not be more than the Maximum Price for an Off-Market Purchase calculated on the foregoing basis) for each Share and the relevant terms of the equal access scheme for effecting the Off-Market Purchase.

2.4 Status of Purchased Shares

Any Share purchased by the Company is deemed cancelled immediately on purchase or acquisition (and all rights and privileges attached to that Share will expire on such cancellation) unless such Shares are held by the Company as Treasury Shares to the extent permitted under the Companies Act. Accordingly, the total number of issued Shares will be diminished by the number of Shares purchased or acquired by the Company and which are not held as Treasury Shares.

All Shares purchased by the Company (other than Treasury Shares held by the Company to the extent permitted under the Companies Act) will be automatically delisted by the SGX-ST, and (where applicable) all share certificates in respect thereof will be cancelled and destroyed by the Company as soon as reasonably practicable following settlement of any such purchase or acquisition.

At the time of each purchase of Shares by the Company, the Directors may decide to cancel Shares which have been purchased by the Company or hold such Shares as Treasury Shares, depending on whether it is in the interests of the Company to do so.

2.5 Treasury Shares

Under the Companies Act, Shares purchased or acquired by the Company may be held or dealt with as Treasury Shares. Some of the provisions on Treasury Shares under the Companies Act are summarised below:-

2.5.1 *Maximum Holdings*

The aggregate number of Shares held as Treasury Shares cannot at any time exceed ten per cent. (10%) of the total number of issued Shares. In the event that the aggregate number of Treasury Shares held by the Company exceeds the aforesaid limit, the Company shall dispose of or cancel the excess Treasury Shares in accordance with Section 76K of the Companies Act within six (6) months from the day the aforesaid limit is first exceeded or such further periods as ACRA may allow.

2.5.2 *Voting and Other Rights*

For the purposes of the Companies Act, the Company cannot exercise any right to attend or vote at meetings in respect of Treasury Shares.

APPENDIX II

In addition, no dividend may be paid, and no other distribution (whether in cash or otherwise) of the Company's assets (including any distribution of assets to members of the Company on a winding up) may be made, to the Company in respect of Treasury Shares. However, the allotment of Shares as fully paid bonus shares in respect of Treasury Shares is allowed.

The Treasury Shares may be sub-divided or consolidated, so long as the total value of the Treasury Shares after such sub-division or consolidation is the same as the total value of the Treasury Shares before the sub-division or consolidation, as the case may be.

2.5.3 *Disposal and Cancellation*

Where Shares are held as Treasury Shares, the Company may at any time:-

- (a) sell the Treasury Shares (or any of them) for cash;
- (b) transfer the Treasury Shares (or any of them) for the purposes of any share scheme, whether for its employees, Directors or other person;
- (c) transfer the Treasury Shares (or any of them) as consideration for the acquisition of shares in or assets of another company or assets of a person;
- (d) cancel the Treasury Shares (or any of them); or
- (e) sell, transfer or otherwise use the Treasury Shares for such purposes as may be prescribed by the Minister of Finance of Singapore.

Under Rule 704(31) of the Catalist Rules, an immediate announcement must be made of any sale, transfer, cancellation and/or use of Treasury Shares (in each case, the "usage"). Such announcement must include details such as the date of the usage, the purpose of the usage, the number of Treasury Shares comprised in the usage, the number of Treasury Shares before and after the usage, the percentage of the number of Treasury Shares comprised in the usage against the total number of issued Shares (of the same class as the treasury shares) which are listed on the SGX-ST before and after the usage and the value of the Treasury Shares comprised in the usage.

2.6 Reporting Requirements

Within thirty (30) days of the passing of the Shareholders' resolution to approve the proposed renewal of the Share Buyback Mandate, the Company shall lodge a copy of such resolution with ACRA.

The Company shall notify ACRA in the prescribed form within thirty (30) days of a Share Buyback on the Catalist or otherwise. Such notification shall include, inter alia, details of the purchase, the total number of Shares purchased or acquired by the Company, the number of Shares cancelled, the number of Shares held as Treasury Shares, the Company's issued share capital before and after the Share Buyback and the amount of consideration paid by the Company for the purchases or acquisitions, whether the Shares were purchased out of profits or the capital of the Company and such other particulars as may be required by ACRA.

Within thirty (30) days of the cancellation or disposal of Treasury Shares in accordance with the provisions of the Companies Act, the Directors shall lodge with ACRA the notice of cancellation or disposal of Treasury Shares in the prescribed form as required by ACRA.

APPENDIX II

Pursuant to the Catalist Rules, a listed company shall announce all purchases or acquisitions of its Shares via SGXNet not later than 9.00 a.m.:-

- (a) in the case of a Market Purchase, on the Market Day following the day on which the Market Purchase was made; or
- (b) in the case of an Off-Market Purchase under an equal access scheme, on the second Market Day after the close of acceptance of the offer.

The notification of such purchases of Shares to the SGX-ST shall be in such form and shall include such details that the SGX-ST may prescribe (which must be in the form of Appendix 8D to the Catalist Rules). The Company shall make arrangements with its stockbrokers to ensure that they provide to the Company in a timely fashion of the necessary information which will enable the Company to make the notifications to the SGX-ST.

2.7 Source of Funds

The Company may only apply funds legally available for such purchase or acquisition as provided in the Constitution, Catalist Rules and the applicable laws in Singapore. The Company may not purchase or acquire its Shares for a consideration other than in cash or, in the case of a Market Purchase, for settlement otherwise than in accordance with the trading rules of the SGX-ST.

Pursuant to the Companies Act, any payment made by the Company in consideration of the Share Buyback by the Company may be made out of the Company's capital or profits, so long as the Company is solvent.

It is an offence for a Director or an officer of the Company to approve or authorise the Share Buyback or the release of obligations, knowing that the Company is not solvent. For this purpose, pursuant to the Section 76F(4) of the Companies Act, a company is solvent if at the date of payment of purchase or acquisition of its shares, the following conditions are satisfied:

- (a) there is no ground on which the company could be found to be unable to pay its debts;
- (b) if:
 - (1) it is intended to commence winding up of the company within the period of 12 months immediately after the date of payment, the company will be able to pay its debts in full within the period of 12 months after the date of commencement of the winding up; or
 - (2) it is not intended to commence winding up, the company will be able to pay its debts as they fall due within the period of 12 months immediately after the date of the payment; and
- (c) the value of the company's assets is not less than the value of its liabilities (including contingent liabilities) and such value of its assets will not, after the proposed purchase, acquisition, variation or release (as the case may be), become less than the value of its liabilities (including contingent liabilities).

In determining whether the Company is solvent, the Directors must have regard to the most recent audited financial statements, other relevant circumstances, and may rely on valuations of assets or estimates of liabilities. In determining the value of contingent liabilities, the Directors may take into account the likelihood of the contingency occurring, as well as any counter-claims by the Company.

APPENDIX II

The Company intends to use internal sources of funds or external borrowings or a combination of both to finance the purchases or acquisition of its Shares pursuant to the Share Buyback Mandate. The amount of funding required for the Company purchases or acquisition of its Shares and the financial impact on the Company and the Group arising from such purchases of Shares pursuant to the Share Buyback Mandate will depend on, inter alia, the aggregate number of Shares purchased, the consideration paid at the relevant time, and the amount (if any) borrowed by the Company to fund the purchases of Shares. However, in considering the option of external financing, the Board will consider particularly the prevailing gearing level of the Group and the costs of such financing. The Board will only make purchases or acquisitions of Shares pursuant to the Share Buyback Mandate in circumstances which they believe will not result in any material adverse effect to the financial position of the Company or the Group.

2.8 Financial Effects

It is not possible for the Company to realistically calculate or quantify the impact of purchases or acquisitions of Shares that may be made pursuant to the Share Buyback Mandate on the Company and the Group's EPS and NTA per Share as the resultant effect would depend on, inter alia, the aggregate number of Shares purchased, whether the Share Buyback is made out of capital and/or profits, the purchase price paid for such Shares, the amount (if any) borrowed by the Company to fund such purchases or acquisitions of Shares and whether the Shares purchased or acquired are cancelled or held as Treasury Shares.

Under the Companies Act, purchases or acquisitions of Shares by the Company may be made out of the Company's capital or profits so long as the Company is solvent.

Where the consideration paid by the Company for the Share Buyback is made out of profits, such consideration (including brokerage, stamp duties, applicable goods and services tax and other related expenses) will correspondingly reduce the amount available for the distribution of cash dividends by the Company.

Where the consideration (including brokerage, stamp duties, applicable goods and services tax and other related expenses) paid by the Company for the Share Buyback is made out of capital, the amount available for distribution of cash dividends by the Company will not be reduced.

The Directors do not propose to exercise the Share Buyback Mandate to such an extent that it would have a material adverse effect on the working capital requirements of the Group or on the financial position of the Company or the Group. The Share Buyback will only be effected after considering relevant factors such as the working capital requirements, the availability of financial resources, the expansion and investment plans of the Group and the prevailing market conditions. The Share Buyback Mandate will be exercised with a view to enhance the EPS and/or NTA per Share of the Group.

APPENDIX II

For illustrative purposes only, the financial effects of the Share Buyback Mandate on the Group, based on the audited financial statements of the Group for the financial year ended 31 December 2023, are based on the following assumptions as set out below:-

(a) Details of the assumed Share Buybacks

Share Buybacks					Maximum Number of Shares to be Purchased	Equivalent Percentage of issued Shares ⁽²⁾
Scenario	Out Of Capital	Type	Whether held as Treasury Shares or cancelled	Maximum Price per Share (\$\$/RMB) ⁽¹⁾		
(A)	Capital	Market Purchase	Held as Treasury Shares	S\$0.0233/ RMB0.1248	198,844,400	10.0%
(B)	Capital	Market Purchase	Cancelled	S\$0.0233/ RMB0.1248	198,844,400	10.0%
(C)	Capital	Off-Market Purchase	Held as Treasury Shares	S\$0.0266/ RMB0.1427	198,844,400	10.0%
(D)	Capital	Off-Market Purchase	Cancelled	S\$0.0266/ RMB0.1427	198,844,400	10.0%

Notes:-

- (1) The Maximum Price per Share for a Market Purchase or an Off-Market Purchase is computed based on respectively one hundred and five per cent. (105%) and one hundred and twenty per cent. (120%) of the average of the closing market prices of the Shares over the last (5) Market Days immediately preceding the Latest Practicable Date on which transactions in the Shares were recorded on the SGX-ST of S\$0.0222.
- (2) Based on 1,988,444,000 issued Shares as at the Latest Practicable Date.
- (b) internal funding of RMB24,825,000 and RMB28,372,000 were undertaken to fund the Market Purchases and Off-Market Purchases respectively;
- (c) transaction costs incurred for the Share Buyback pursuant to the Share Buyback Mandate are assumed to be insignificant and have been ignored for the purposes of computing the financial effects; and
- (d) the Share Buyback by the Company took place on 1 January 2023.

APPENDIX II

(A) Pro-forma financial effects on the Group for scenarios of Share Buybacks by the Company out of capital

As at 31 December 2023 (RMB'000)	As per the audited consolidated financial statements of the Company	Pro-forma financial effects as at 31 December 2023			
		Scenario (A)	Scenario (B)	Scenario (C)	Scenario (D)
Share capital	709,977	709,977	685,152	709,977	681,605
Statutory reserve fund	110,706	110,706	110,706	110,706	110,706
Accumulated losses	(54,846)	(54,846)	(54,846)	(54,846)	(54,846)
Treasury shares	–	(24,825)	–	28,372	–
Total Shareholders' equity	765,837	741,012	741,012	737,465	737,465
NTA ⁽¹⁾	764,432	739,607	739,607	736,060	736,060
Current assets	923,183	898,358	898,358	894,811	894,811
Current liabilities	457,215	457,215	457,215	457,215	457,215
External borrowings	265,884	265,884	265,884	265,884	265,884
Cash and cash equivalents	684,026	659,201	659,201	655,654	655,654
Loss attributable to Shareholders	(344,643)	(344,643)	(344,643)	(344,643)	(344,643)
Total issued no. of Shares ⁽²⁾ ('000)	1,988,444	1,789,600	1,789,600	1,789,600	1,789,600
Financial Ratios					
NTA per Share (RMB cents)	38.44	41.33	41.33	41.13	41.13
LPS ⁽³⁾ (RMB cents)	(17.33)	(19.26)	(19.26)	(19.26)	(19.26)
Gearing ratio ⁽⁴⁾ (times)	0.35	0.36	0.36	0.36	0.36
Current ratio ⁽⁵⁾ (times)	2.02	1.96	1.96	1.96	1.96

Note:-

- (1) NTA per Share equals to NTA (excludes land use rights) divided by the number of Shares outstanding adjusted for the effect of the Share Buyback as at 31 December 2023.
- (2) Excludes Treasury Shares and Subsidiary Holdings, where applicable.
- (3) LPS is calculated based on loss attributable to Shareholders and aggregated weighted average number of issued and paid-up Shares (excluding Treasury Shares and Subsidiary Holdings) adjusted for the effect of the Share Buyback based on the audited financial statements of the Company and the Group for FY2023.
- (4) Gearing ratio represents total borrowings divided by Shareholders' equity.
- (5) Current ratio equals to current assets divided by current liabilities.

Shareholders should note that the financial effects illustrated above are based on the respective aforesaid assumptions and purely for illustrative purposes only. In particular, it is important to note that the above analysis is based on the audited financial statements of the Group for the financial year ended 31 December 2023 and is not necessarily representative of the future financial performance of the Company or the Group.

APPENDIX II

The Company will take into account both financial (such as cash surplus, debt position and working capital requirements) and non-financial factors (such as stock market conditions and performance of the Shares) in assessing the relative impact of the Share Buyback before execution. Although the Share Buyback Mandate would authorise the Company to purchase or acquire up to ten per cent. (10%) of the total number of issued Shares of the Company, ascertained as at the date of the AGM, the Company may not necessarily purchase the entire ten per cent. (10%) of the total number of its issued Shares. In addition, the Company may cancel all or part of the Shares repurchased or hold all or part of the Shares repurchased as Treasury Shares.

2.9 Interested Persons

The Company is prohibited from knowingly buying Shares on the Catalist from an interested person, that is, a Director, the chief executive officer of the Company or Controlling Shareholder of the Company or any of their Associates, and any interested person is prohibited from knowingly selling his Shares to the Company.

2.10 Taxation

Shareholders who are in doubt as to their respective tax positions or any tax implications arising from the Share Buyback by the Company, or who may be subject to tax in a jurisdiction should consult their own professional advisers.

2.11 Take-over implications arising from Share Buybacks

Appendix 2 of the Take-over Code ("Appendix 2") contains the Share Buy-Back Guidance Note applicable as at the Latest Practicable Date. The take-over implications arising from any purchase or acquisition by the Company of its Shares are set out below.

2.11.1 *Obligation to make a Take-over Offer*

If, as a result of any purchase by the Company of its Shares, the proportionate interest in the voting capital of the Company of a Shareholder and persons acting in concert with him increases, such increase will be treated as an acquisition for the purposes of Rule 14 of the Take-over Code ("**Rule 14**"). Consequently, a Shareholder or a group of Shareholders acting in concert with a Director could obtain or consolidate effective control of the Company and become obliged to make an offer under Rule 14.

Shareholders are advised to consult their professional advisers and/or the SIC and/or other relevant authorities at the earliest opportunity as to whether an obligation on their part, if any, to make a mandatory take-over offer under the Take-over Code would arise by reason of any Share Buyback by the Company.

2.11.2 *Persons acting in concert*

Under the Take-over Code, persons acting in concert comprise individuals or companies who, pursuant to an agreement or understanding (whether formal or informal), co-operate, through the acquisition by any of them of shares in a company to obtain or consolidate effective control of that company.

APPENDIX II

Unless the contrary is established, the Take-over Code presumes, inter alia, the following individuals and companies to be persons acting in concert with each other:-

- (i) a company with its parent company, subsidiaries, fellow subsidiaries, any associated companies of the foregoing companies, any company whose associated companies include any of the foregoing companies, and any person who has provided financial assistance (other than a bank in the ordinary course of business) to any of the foregoing for the purchase of voting rights;
- (ii) a company with any of its directors, together with their close relatives, related trusts and any companies controlled by any of the directors, their close relatives and related trusts;
- (iii) a company with any of its pension funds and employee share schemes;
- (iv) a person with any investment company, unit trust or other fund whose investment such person manages on a discretionary basis, but only in respect of the investment account which such person manages;
- (v) a financial or other professional adviser, including a stockbroker, with its client in respect of the shareholdings of the adviser and the persons controlling, controlled by or under the same control as the adviser and all the funds which the adviser manages on a discretionary basis, where the shareholdings of the adviser and any of those funds in the client total ten per cent. (10%) or more of the client's equity share capital;
- (vi) directors of a company, together with their close relatives, related trusts and companies controlled by any of them, which is subject to an offer or where they have reason to believe a bona fide offer for their company may be imminent;
- (vii) partners; and
- (viii) an individual, his close relatives, his related trusts, any person who is accustomed to act according to his instructions, companies controlled by any of the foregoing persons, and any person who has provided financial assistance (other than a bank in the ordinary course of business) to any of the foregoing persons and/or entities for the purchase of voting rights.

For this purpose, ownership or control of at least twenty per cent. (20%) but not more than fifty per cent. (50%) of the voting rights of a company will be regarded as the test of associated company status.

The circumstances under which Shareholders, including Directors and persons acting in concert with them respectively, will incur an obligation to make a take-over offer under Rule 14 after a Share Buyback by the Company are set out in Appendix 2.

2.11.3 Effect of Rule 14 and Appendix 2 of the Take-over Code

In general terms, the effect of Rule 14 and Appendix 2 of the Take-over Code is that, unless exempted, Directors and persons acting in concert with them will incur an obligation to make a take-over offer under Rule 14 if, as a result of the Company purchasing or acquiring Shares, the voting rights of such Directors and their concert parties would increase to thirty per cent. (30%) or more, or in the event that such Directors and their concert parties hold between thirty per cent. (30%) and fifty per cent. (50%) of the Company's voting rights, if the voting

APPENDIX II

rights of such Directors and their concert parties would increase by more than one per cent. (1%) in any period of six (6) months. In calculating the percentages of voting rights of such Directors and their concert parties, Treasury Shares and Subsidiary Holdings shall be excluded.

Under Appendix 2, a Shareholder not acting in concert with the Directors will not be required to make a take-over offer under Rule 14 if, as a result of the Company purchasing or acquiring its Shares, the voting rights of such Shareholder would increase to thirty per cent. (30%) or more, or, if such Shareholder holds between thirty per cent. (30%) and fifty per cent. (50%) of the Company's voting rights, the voting rights of such Shareholder would increase by more than one per cent. (1%) in any period of six (6) months. Such Shareholder need not abstain from voting in respect of the resolution authorising the Share Buyback Mandate.

2.11.4 Application of the Take-over Code

As at the Latest Practicable Date, Mr Xu Aijun, the Company's Non-Executive and Non-Independent Chairman, Mr Wang Gang and Mr Song Fu Dong, the Company's Non-Executive and Non-Independent Directors, were appointed to the Board as nominees of HNEC and Anhua ("Nominee Directors"). HNEC is the ultimate holding company of Anyang Longyu, a Controlling Shareholder of the Company and Anhua is the parent company of Anyang Longyu. Accordingly, under the Take-over Code, the Nominee Directors, HNEC, Anhua and Anyang Longyu are deemed to be persons acting in concert with each other (the "**Concert Party Group**").

The details of the shareholdings of the Directors and Substantial Shareholders of the Company as at the Latest Practicable Date are set out in Section 3 below.

Accordingly, the Concert Party Group would not be obliged to make a general offer to other Shareholders under Rule 14 and Appendix 2 of the Take-over Code as a result of a purchase or acquisition of the Shares by the Company pursuant to the Share Buyback Mandate. The Directors are not aware of any potential Shareholder(s) who may have to make a general offer to the other Shareholders as a result of a purchase or acquisition of the Shares by the Company pursuant to the Share Buyback Mandate.

Anyang Longyu has undertaken to the Company that it will not acquire any Shares and/or sell, transfer or otherwise dispose any of its Shares for the period commencing from the Latest Practicable Date to the date of the AGM. Based on the said undertaking, the interest of Anyang Longyu in the Company as at the date of the AGM will be as per illustrated in the ensuing section 3 of this Appendix II.

The Nominee Directors have undertaken to the Company that none of them will acquire any Shares for the period commencing from the Latest Practicable Date to the date of the AGM. Based on the said undertaking, as at the date of the AGM, none of the Nominee Directors will hold Shares of the Company.

The statements herein do not purport to be a comprehensive or exhaustive description of all implications that may arise under the Take-over Code. Shareholders who are in doubt as to whether they would incur any obligation to make a take-over offer under the Take-over Code as a result of Share Buybacks by the Company pursuant to the Share Buyback Mandate are advised to consult their professional advisers and/or the SIC at the earliest opportunity.

APPENDIX II

2.12 The Catalyst Rules

While the Catalyst Rules do not expressly prohibit any purchase of shares by a listed company during any particular time or times, because the listed company would be considered to be an “insider” in relation to any proposed purchase or acquisition of its issued shares, the Company will not undertake any Share Buyback pursuant to the Share Buyback Mandate at any time after a price sensitive development has occurred or has been the subject of a consideration and/or a decision of the Board until such time as the price-sensitive information has been publicly announced. In particular, in line with the Company’s internal guide on securities dealings, the Company will not purchase any Shares through Market Purchases during the period of two (2) weeks and one (1) month immediately preceding the announcement of the Company’s quarterly (1st and 3rd quarter) and half/full year results respectively, as the case may be, and ending on the date of announcement of the relevant results.

The Company is required under Rule 723 of the Catalyst Rules to ensure that at least ten per cent. (10%) of its issued Shares (excluding Treasury Shares, preference shares and convertible equity securities) are in the hands of the public. The term “public” is defined under the Catalyst Rules as persons other than (a) the directors, chief executive officer, Substantial Shareholders or Controlling Shareholders of the listed company and its subsidiary companies and (b) the associates (as defined in the Catalyst Rules) of the persons described in paragraph (a).

As at the Latest Practicable Date, 1,452,045,100 Shares (excluding nil Treasury Shares and Subsidiary Holdings), representing approximately 73.02% of the issued Shares of the Company, are in the hands of the public. Assuming that the Company purchases or acquires its Shares through Market Purchases up to the full ten per cent. (10%) limit pursuant to the Share Buyback Mandate from the public, the number of Shares in the hands of the public would be reduced to 1,253,200,700 Shares (excluding nil Treasury Shares and Subsidiary Holdings), representing approximately 70.03% of the issued Shares of the Company. Accordingly, the Company is of the view that there is a sufficient number of Shares held in the hands of the public which would permit the Company to undertake purchases of its Shares up to the full ten per cent. (10%) limit pursuant to the Share Buyback Mandate without affecting the listing status of the Shares on the SGX-ST, and that the number of Shares remaining in the hands of the public will not fall to such a level as to cause market illiquidity or to affect orderly trading.

In undertaking any purchases or acquisitions of Shares pursuant to the Share Buyback Mandate, the Directors will use their best efforts to ensure that, notwithstanding such purchases, a sufficient float in the hands of the public will be maintained so that the purchases of Shares will not adversely affect the listing status of the Shares on the SGX-ST, cause market illiquidity or adversely affect the orderly trading of the Shares.

2.13 Share Buybacks in the previous twelve (12) months

The Company has not purchased or acquired any Shares during the twelve (12) month period immediately preceding the Latest Practicable Date.

APPENDIX II

3. DIRECTORS' AND SUBSTANTIAL SHAREHOLDERS' INTERESTS

Based on the Register of Director's Shareholdings and the Register of Substantial Shareholders maintained pursuant to Sections 164 and 88 of the Companies Act respectively, as at the Latest Practicable Date, the shareholdings of the Directors and Substantial Shareholders before and after the Share Buyback pursuant to the Share Buyback Mandate, assuming (a) the Company purchases or acquired the maximum limit of ten per cent. (10%) of the issued share capital of the Company as at the Latest Practicable Date; and (b) there is no change in the number of Shares held or deemed to be held by the Directors and Substantial Shareholders of the Company, will be as follows:

	Before the Share Buyback (Number of Shares)			Before the Share Buyback	After the Share Buyback
	Direct Interest	Deemed Interest	Total Interest	% ⁽¹⁾	% ⁽²⁾
Directors					
Xu Aijun	–	–	–	–	–
Lee Chee Seng ⁽³⁾	11,250,000	22,419,000 ⁽²⁾	33,669,000	1.69	1.88
Wu Yu Liang	300,000	–	300,000	0.02	0.02
Chan Kam Loon	–	–	–	–	–
Gao Guoan	–	–	–	–	–
Song Fudong	–	–	–	–	–
Wang Gang	–	–	–	–	–
Chen Mingjin	–	–	–	–	–
Koh Eng Kheng Victor	–	–	–	–	–
Substantial Shareholders					
Anyang Longyu (HK) Development Co., Ltd. ⁽⁴⁾	–	502,429,900 ⁽³⁾	502,429,900	25.27	28.07
Anyang Chemical Industry Group Co., Ltd. ⁽⁵⁾	–	502,429,900 ⁽³⁾	502,429,900	25.27	28.07
HNEC ⁽⁵⁾	–	502,429,900 ⁽³⁾	502,429,900	25.27	28.07

Notes:

- (1) Based on the issued share capital of 1,988,444,000 Shares as at the Latest Practicable Date.
- (2) Calculated based on 1,789,599,600 Shares assuming the purchase of the maximum of 198,844,400 Shares pursuant to the Share Buyback Mandate.
- (3) Lee Chee Seng is deemed interested in 19,419,000 Shares held through his indirect nominee, Credit Suisse AG, Singapore Branch; and 3,000,000 Shares held through his direct nominee, KGI Securities (Singapore) Pte. Ltd.
- (4) Anyang Longyu is deemed interested in 502,429,900 Shares through its nominee, Philip Securities Pte. Ltd.
- (5) Anhua and HNEC is deemed to be interested in the shares held by Anyang Longyu by virtue of Section 6 of the Companies Act 1967.

APPENDIX II

4. ANNUAL GENERAL MEETING

The AGM, notice of which is contained in the Annual Report of the Company, will be held at at Royal Plaza on Scotts, Balmoral Hall, Level 5, 25 Scotts Road, Singapore 228220 on 25 April 2024 at 10.30 a.m. for the purpose of considering and, if thought fit, passing with or without modifications, Resolution 8 relating to the proposed renewal of the Share Buyback Mandate.

5. ACTION TO BE TAKEN BY SHAREHOLDERS

5.1 Submission of Proxy Forms to vote

The AGM will be being convened at Royal Plaza on Scotts, Balmoral Hall, Level 5, 25 Scotts Road, Singapore 228220 on 25 April 2024 at 10.30 a.m..

The AGM will be convened in a physical format only and there will be no option for Shareholders to participate virtually. Shareholders who are unable to attend the AGM and who wish to appoint a proxy to attend and vote at the AGM on their behalf are requested to complete, sign and return the Proxy Form attached to the Notice of AGM in accordance with the instructions printed thereon as soon as possible and by completing and submitting the duly completed Proxy Form to the Company's Share Registrar, Tricor Barbinder Share Registration Services, at 9 Raffles Place, #26-01, Republic Plaza, Singapore 048619, by 10.30 a.m. (Singapore time) on 22 April 2024, and in default the Proxy Form shall not be treated as valid. Hardcopies of the Notice of AGM, Proxy Form and Request Form will be sent by post to Shareholders. Alternatively, Shareholders may access the Proxy Form on the website of the SGX-ST at <https://www.sgx.com/securities/company-announcements> and the Company's website at <http://www.jiutianchemical.com.sg/>, and thereafter download, complete and sign the Proxy Form, before submitting it by post to the address provided above. The completion and return of the Proxy Form by such Shareholder will not prevent him from attending and voting at the AGM in person if he so wishes.

A Depositor shall not be regarded as a member of the Company entitled to attend the AGM and to speak and vote thereat unless his name appears on the Depository Register at least 72 hours before the time appointed for holding the AGM.

Shareholders should refer to the Notice of AGM for further information, including the steps to be taken by Shareholders to participate at the AGM.

5.2 Submission of Questions in Advance

Shareholders can submit substantial and relevant questions relating to the Resolutions to be tabled for approval at the AGM, in advance of the AGM, to the Company in the following manner:

1. Shareholders may submit their questions by post, to be deposited at the registered office of the Company at 9 Raffles Place, #26-01, Republic Plaza, Singapore 048619; or
2. Shareholders may submit their questions electronically via email to nghankiat@jiutianchemical.com,

in each case, by 18 April 2024 on 10.30a.m. (the "**Cut-Off Time**").

When submitting substantial and relevant questions electronically via email or by post, Shareholders must provide the Company with the following details to enable the Company to verify their status as Shareholders: (a) status: individual shareholder or corporate representative; (b) full name/full company name (as per CDP/CPF/SRS/Scrip-based records); (c) NRIC/FIN/ Passport number/ Registration number; (d) email address; and (e) contact number (optional).

APPENDIX II

Persons who hold Shares through Relevant Intermediaries (as defined under Section 181(6) of the Companies Act) (other than CPF/SRS investors) should contact their respective Relevant Intermediaries through which they hold such Shares to submit their questions relating to the Resolutions to be tabled for approval at the AGM based on the abovementioned instructions.

The Company will endeavour to address all substantial and relevant questions received from Shareholders prior to the AGM, before or during the AGM. The responses to substantial and relevant questions received from Shareholders by the Cut-Off Time will be posted on SGXNet and the Company's corporate website at <http://www.jiutianchemical.com.sg/> before 10.30 a.m. on 20 April 2024, being at least forty-eight (48) hours prior to the closing date and time for the lodgement of the Proxy Form. The Company will address any subsequent clarifications sought, or substantial and relevant follow-up questions (relating to the Resolutions to be tabled for approval at the AGM) received after the Cut-Off Time which have not already been addressed prior to the AGM, as well as those substantial and relevant questions received at the AGM, during the AGM.

6. DIRECTORS' RECOMMENDATION

Having fully considered, inter alia, the rationale and benefit of the Share Buyback Mandate, the Directors are of the view that the proposed renewal of the Share Buyback Mandate is in the best interests of the Company. They accordingly recommend that Shareholders vote in favour of Resolution 8 relating to the proposed renewal of the Share Buyback Mandate at the AGM.

7. DIRECTORS' RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this Appendix II and confirm after making all reasonable enquiries that, to the best of their knowledge and belief, this Appendix II constitutes full and true disclosure of all material facts about the proposed renewal of the Share Buyback Mandate, the Company and its subsidiaries, and the Directors are not aware of any facts the omission of which would make any statement in this Appendix II misleading. Where information in this Appendix II has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in this Appendix II in its proper form and context.

8. DOCUMENTS FOR INSPECTION

The Constitution and the Annual Report of the Company are available for inspection during normal office hours at the registered office of the Company at 9 Raffles Place, #26-01 Republic Plaza, Singapore 048619 from the date of this Appendix II up to date of the AGM.

Yours faithfully
for and on behalf of the Board of Directors of
JIUTIAN CHEMICAL GROUP LIMITED

Lee Chee Seng
Executive Director

NOTICE OF THE NINETEENTH ANNUAL GENERAL MEETING



NOTICE IS HEREBY GIVEN THAT the Nineteenth Annual General Meeting of Jiutian Chemical Group Limited ("**Company**") will be held at Royal Plaza on Scotts, Balmoral Hall, Level 5, 25 Scotts Road, Singapore 228220 on Thursday, 25 April 2024 at 10:30 a.m. for the purpose of transacting the following businesses:

ORDINARY BUSINESS

1. To receive and adopt the Directors' Statement and the Audited Financial Statements for the financial year ended 31 December 2023 together with the Auditors' Report thereon. **(Resolution 1)**

2. To approve the payment of Directors' fee of S\$209,000 for the financial year ending 31 December 2024, to be paid quarterly in arrears (FY2023: S\$209,000). **(Resolution 2)**

3. To re-elect Mr Koh Eng Kheng Victor who is retiring in accordance with the Regulation 91 of the Constitution of the Company and has offered himself for re-election. **(Resolution 3)**

[See Explanatory Note 1]

4. To re-elect Mr Xu Aijun who is retiring in accordance with the Regulation 97 of the Constitution of the Company and has offered himself for re-election. **(Resolution 4)**

[See Explanatory Note 2]

5. To note the retirement/voluntary retirement of the following Directors of the Company upon the conclusion of this AGM:-

a. Mr Chan Kam Loon

Upon the retirement of Mr Chan Kam Loon as Director of the Company, he will be relinquishing his position as the Chairman of the Audit Committee as well as a member of the Remuneration Committee.

b. Mr Wu Yu Liang

Upon the retirement of Mr Wu Yu Liang as Director of the Company, he will be relinquishing his position as the Chairman of the Remuneration Committee as well as a member of the Audit Committee.

c. Mr Gao Guoan

Upon the retirement of Mr Gao Guoan as Director of the Company, he will be relinquishing his position as the Chairman of the Nominating Committee as well as a member of the Remuneration Committee.

d. Mr Chen Mingjin

NOTICE OF THE NINETEENTH ANNUAL GENERAL MEETING

6. To re-appoint Messrs Baker Tilly TFW LLP as Auditors of the Company and to authorise the Directors to fix their remuneration. **(Resolution 5)**
7. To transact any other ordinary business which may properly be transacted at an Annual General Meeting .

SPECIAL BUSINESS

To consider and, if thought fit, to pass the following as Ordinary Resolutions, with or without modifications:

8. **Authority to allot and issue shares** **(Resolution 6)**

That, pursuant to Section 161 of the Companies Act 1967 of Singapore (the "**Companies Act**") and Rule 806 of Section B: Rules of Catalist of the Listing Manual of the Singapore Exchange Securities Trading Limited ("**SGX-ST**"), ("**Catalist Rules**"), authority be and is hereby given to the Directors of the Company to:

- (a) (i) allot and issue shares in the capital of the Company ("**Shares**") (whether by way of rights, bonus or otherwise); and/or
- (ii) make or grant offers, agreements or options (collectively, "**Instruments**") that might or would require Shares to be issued, including but not limited to the creation and issue of (as well as adjustments to) options, warrants, debentures or other instruments convertible into Shares,

at any time and upon such terms and conditions and for such purposes and to such persons as the Directors may in their absolute discretion deem fit; and

- (b) notwithstanding the authority conferred by this Resolution may have ceased to be in force, issue Shares in pursuance of any Instrument made or granted by the Directors while this Resolution was in force, provided that:
- (1) the aggregate number of Shares (including shares to be issued in pursuance of Instruments made or granted pursuant to this Resolution) to be issued pursuant to this Resolution does not exceed one hundred per cent (100%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) in the capital of the Company (as calculated in accordance with sub-paragraph (2) below), of which the aggregate number of Shares to be issued other than on a pro-rata basis to existing shareholders of the Company (including Shares to be issued in pursuance of Instruments made or granted pursuant to this Resolution) does not exceed fifty per cent (50%) of the total number of issued Shares (excluding treasury shares and subsidiary holdings) (as calculated in accordance with sub-paragraph (2) below);

NOTICE OF THE NINETEENTH ANNUAL GENERAL MEETING

- (2) (subject to such manner of calculation as may be prescribed by the SGX-ST), for the purpose of determining the aggregate number of Shares that may be issued under sub-paragraph (1) above, the total number of issued shares (excluding treasury shares and subsidiary holdings) shall be based on the total number of issued shares (excluding treasury shares and subsidiary holdings) in the capital of the Company at the time this Resolution is passed, after adjusting for:
- (i) new Shares arising from the conversion or exercise of Instruments or any convertible securities;
 - (ii) new Shares arising from exercising share options or vesting of share awards, provided that the options or awards were granted in compliance with Part VIII of Chapter 8 of the Catalist Rules; and
 - (iii) any subsequent bonus issue, consolidation or subdivision of Shares.

Adjustments in accordance with Rule 806(3)(a) or Rule 806(3)(b) are only to be made in respect of new shares arising from convertible securities, share options or share awards which were issued and outstanding or subsisting at the time of the passing of the resolution approving the mandate.

- (3) in exercising the authority conferred by this Resolution, the Company shall comply with the provisions of the Catalist Rules for the time being in force (unless such compliance has been waived by the SGX-ST), and all applicable legal requirements under the Companies Act, and otherwise, the Company's Constitution for the time being; and
- (4) unless revoked or varied by the Company in general meeting, the authority conferred by this Resolution shall continue in force until the conclusion of the next annual general meeting of the Company or the date by which the next annual general meeting of the Company is required by law to be held, whichever is the earlier.

[See Explanatory Note 3]

9. **Proposed Renewal of the General Mandate for Interested Person Transactions** **(Resolution 7)**

That :

- (a) approval be and is hereby given, for the purposes of Chapter 9 of the Catalist Rules, for the Entities at Risk (as defined in Appendix I to the Company's Annual Report for its financial year ended 31 December 2023 dated 9 April 2024 (the "**Appendix I**")), or any of them, to enter into any of the transactions falling within the types of Recurrent IPTs (as defined in Appendix I) with any Interested Person (as defined in Appendix I), provided that such transactions are made on normal commercial terms, will not be prejudicial to the interests of the Company and its minority shareholders and are in accordance with the guidelines and review procedures for such Recurrent IPTs (the "**IPT Mandate**");

NOTICE OF THE NINETEENTH ANNUAL GENERAL MEETING

- (b) the IPT Mandate shall, unless revoked or varied by the Company in general meeting, continue in force until the conclusion of the next annual general meeting of the Company;
- (c) the Audit Committee of the Company be and is hereby authorised to take such action as it deems proper in respect of the procedures and/or to modify or implement such procedures as may be necessary to take into consideration any amendment to Chapter 9 of the Catalist Rules which may be prescribed by the SGX-ST from time to time; and
- (d) the Directors or any one of them be and are hereby authorised to complete and do all such acts and things as they or he may consider necessary or expedient for the purposes of or in connection with and to give effect to the transactions contemplated and/or authorised by the IPT Mandate and/or this Resolution (including but not limited to the execution of other ancillary documents, procurement of third party consents and making of amendments to the Recurrent IPTs) as they or he shall think fit and in the interests of the Company.

[See Explanatory Note 4]

10. Proposed Renewal of the Share Buyback Mandate

(Resolution 8)

That :

- (a) for the purposes of Sections 76C and 76E of the Companies Act and Catalist Rules, the exercise by the Directors of the Company of all the powers of the Company to purchase or otherwise acquire issued ordinary shares fully paid in the capital of the Company not exceeding in aggregate the Maximum Limit (as hereinafter defined), at such price or prices as may be determined by the Directors of the Company from time to time up to the Maximum Price (as hereafter defined), whether by way of:

- (i) market purchase(s) (each a "**Market Purchase**") on the SGX-ST; and/or
- (ii) off-market purchase(s) (each an "**Off-Market Purchase**") effected otherwise than on the SGX-ST in accordance with any equal access scheme(s) as may be determined or formulated by the Directors of the Company as they consider fit, which scheme(s) shall satisfy all conditions prescribed by the Companies Act;

and otherwise in accordance with all other laws and regulations, including but not limited to, the provisions of the Companies Act and the Catalist Rules as may for the time being be applicable, be and is hereby authorised and approved generally and unconditionally (the "**Share Buyback Mandate**");

- (b) unless varied or revoked by the members of the Company in a general meeting, the authority conferred on the Directors of the Company pursuant to the Share Buyback Mandate may be exercised by the Directors at any time and from time to time during the period commencing from the date of the passing of this Resolution and expiring on the earlier of:

NOTICE OF THE NINETEENTH ANNUAL GENERAL MEETING

- (i) the date on which the next annual general meeting of the Company is held or required by law to be held;
 - (ii) the date on which purchases or acquisitions of Shares by the Company pursuant to the Share Buyback Mandate are carried out to the full extent mandated; or
 - (iii) the date on which the authority conferred by the Share Buyback Mandate is varied or revoked;
- (c) in this Resolution:

"Maximum Limit" means that number of issued Shares representing ten per cent (10%) of the total number of issued Shares as at the date of the passing of this Resolution unless the Company has effected a reduction of the total number of issued Shares of the Company in accordance with the applicable provisions of the Companies Act, at any time during the Relevant Period (as hereafter defined), in which event the total number of issued Shares shall be taken to be the total number of issued Shares as altered.

Any Shares which are held as treasury shares and subsidiary holdings will be disregarded for purposes of computing the 10% limit; and

"Relevant Period" means the period commencing from the date of the annual general meeting at which the renewal of the Share Buyback Mandate is approved and thereafter, expiring on the date on which the next annual general meeting of the Company is held or is required by law to be held, whichever is the earlier, after the date of this Resolution is passed; and

"Maximum Price", in relation to a share to be purchased or acquired pursuant to the Share Buyback Mandate means an amount (excluding brokerage, stamp duties, commission, applicable goods and services tax and other related expenses) not exceeding:

- (i) in the case of a Market Purchase, one hundred and five per cent (105%) of the Average Closing Price (as hereinafter defined); and
- (ii) in the case of an Off-Market Purchase, one hundred and twenty per cent (120%) of the Average Closing Price (as hereinafter defined),

where:

"Average Closing Price" means the average of the closing market prices of a Share over the last five (5) market days on which transactions in the Shares were recorded on the SGX-ST immediately preceding the date of the Market Purchase by the Company or, as the case may be, the date of the making of the offer (as hereinafter defined) pursuant to Off-Market Purchase, and deemed to be adjusted for any corporate action which occurs after the relevant five (5) market day period and the day on which the purchases are made; and

NOTICE OF THE NINETEENTH ANNUAL GENERAL MEETING

“date of the making of the offer” means the date on which the Company announces its intention to make an offer for an Off-Market Purchase, stating therein the purchase price (which shall not be more than the Maximum Price for an Off-Market Purchase calculated on the foregoing basis) for each Share and the relevant terms of the equal access scheme for effecting the Off-Market Purchase;

- (d) the Directors of the Company and/or any of them be and are hereby authorised to deal with the Shares purchased or acquired by the Company, pursuant to the Share Buyback Mandate, in any manner as they think fit, which is permissible under the Companies Act; and
- (e) the Directors of the Company and/or any of them be and are hereby authorised to complete and do all such acts and things (including executing such documents as may be required) as they and/or he may consider expedient and necessary to give effect to the transactions contemplated and/or authorised by this Resolution.

[See Explanatory Note 5]

BY ORDER OF THE BOARD

Pan Mi Keay
Company Secretary

Singapore, 9 April 2024

Explanatory Notes:

1. Mr Koh Eng Kheng Victor, upon re-election as a director of the Company, will remain as a Non-Executive and Independent Director as well as a member of Audit Committee and Nominating Committee. Upon the retirement of Mr Wu Yu Liang as Director of the Company, he will serve as the Chairman of Remuneration Committee. He is considered independent for the purposes of Rule 704(7) of the Catalist Rules. Pursuant to Rule 720(5) of the Catalist Rules, further information on Mr Koh Eng Kheng Victor is set out on the pages 29 to 34 of the Company's Annual Report.
2. Mr Xu Aijun, upon re-election as a director of the Company, will remain as a Non-Executive and Non-Independent Chairman and member of Nominating Committee. Pursuant to Rule 720(5) of the Catalist Rules, further information on Mr Xu Aijun is set out on the pages 29 to 34 of the Company's Annual Report.
3. Resolution 6 in item 8 above, if passed, will authorise and empower the Directors of the Company from the date of the above meeting until the next annual general meeting to allot and issue shares and/or convertible securities in the Company. The aggregate number of Shares (including any Shares issued pursuant to Instruments made or granted) which the Directors may allot and issue under this Resolution, shall not exceed one hundred per cent (100%) of the Company's total number of issued Shares (excluding treasury shares and subsidiary holdings). For issues of Shares other than a pro-rata basis to all shareholders, the aggregate number of Shares to be issued will not exceed fifty per cent (50%) of Company's total number of issued Shares (excluding treasury shares and subsidiary holdings). This authority will, unless revoked or varied at a general meeting, expire at the next annual general meeting of the Company or the date by which the next annual general meeting of the Company is required by law to be held, whichever is earlier. However, notwithstanding the cessation of this authority, the Directors are empowered to issue Shares pursuant to any instruments made or granted under this authority.

NOTICE OF THE NINETEENTH ANNUAL GENERAL MEETING

4. Resolution 7 in item 9 above, if passed, will renew the IPT Mandate initially approved by shareholders on 16 November 2012 to allow the Entities at Risk (as defined in Appendix I to the Company's Annual Report for its financial year ended 31 December 2023 dated 9 April 2024 (the "**Appendix I**")), or any of them, to enter into transactions with any Interested Person (as defined in Appendix I). Please refer to Appendix I for details relating to the said IPT Mandate.
5. Resolution 8 in item 10 above, if passed, will empower the Directors of the Company to buyback issued Shares from time to time (whether by way of market purchases or off-market purchases on an equal access scheme) of up to ten per cent (10%) of the total number of issued Shares of the Company (excluding treasury shares and subsidiary holdings) at the prices of up to but not exceeding the Maximum Price (as defined in Appendix II to the Company's Annual Report for its financial year ended 31 December 2023 dated 9 April 2024 (the "**Appendix II**")) and in accordance with the terms and subject to the conditions of the Share Buyback Mandate (as defined in Appendix II), the Companies Act, and the Catalist Rules. This authority will, unless revoked or varied at general meeting, continue in force until the earlier of (a) the date that the next annual general meeting of the Company is held or required by law to be held and (b) the date on which purchases or acquisitions of Shares pursuant to the Share Buyback Mandate are carried out in full to the prescribed limit mandated.

The Company intends to use internal sources of funds or external borrowings or a combination of both to finance the purchase or acquisition of its Shares pursuant to the Share Buyback Mandate. The amount of financing required for the Company to purchase or acquire its Shares, and the impact on the Company's financial position, cannot be ascertained as at the date of this Notice as these will depend on the number of Shares purchased or acquired, the price at which such Shares were purchased or acquired and whether the Shares purchased or acquired are cancelled or held as treasury shares.

The financial effects of the purchase or acquisition of Shares by the Company pursuant to the proposed Share Buyback Mandate on the audited financial statements of the Company and its subsidiaries and associated companies for the financial year ended 31 December 2023, based on certain assumptions, are set out in paragraph 2.8 of Appendix II.

IMPORTANT NOTES:

Physical Meeting

1. The Annual General Meeting of the Company (the "**AGM**") will be held physically with no option for members to participate virtually. Printed copies of the Annual Report 2023 will not be sent to members. Instead, the Annual Report 2023 will be sent to members by electronic means via an announcement on the SGX website at the URL <https://www.sgx.com/securities/company-announcements>.
2. Printed copies of this Notice of AGM, the Proxy Form and Request Form will be sent to members by post. The Proxy Form and Request Form may be downloaded from the SGXNet. For Shareholders who prefer to receive a printed copy of the Annual Report 2023, please refer to the Request Form on how to make a request.
3. Members (including investors under the Central Provident Fund and the Supplementary Retirement Scheme ("**CPF and SRS Investors**")) may participate in the AGM by:
 - (a) attending the AGM in person;
 - (b) raising questions at the AGM or submitting questions in advance of the AGM; and/or
 - (c) voting at the AGM
 - (i) themselves personally; or
 - (ii) through their duly appointed proxy(ies).
4. Investors who hold shares through relevant intermediaries as defined in Section 181 of the Companies Act, including CPF and SRS Investors, who wish to participate in the AGM should approach their respective agents at least (7) seven working days before the AGM, so that the necessary arrangements can be made by the relevant agents for their participating in the AGM.

NOTICE OF THE NINETEENTH ANNUAL GENERAL MEETING

Voting

5. A member of the Company who is not a relevant intermediary entitled to appoint not more than (2) two proxies to attend, speak and vote on his/her behalf at the meeting. Where such member appoints more than (1) one proxy, the proportion of his shareholding concerned to be represented by each proxy shall be specified in the form of proxy. A proxy need not be a Member of the Company.
6. A member of the Company who is a relevant intermediary entitled to appoint more than two proxies to attend, speak and vote at the meeting, but each proxy must be appointed to exercise the rights attached to a different share or shares held by such member. Where such member appoints more than two proxies, the number of shares in relation to which each proxy has been appointed shall be specified in the form of proxy.

“**Relevant Intermediary**” has the meaning ascribed to it in Section 181 of the Companies Act 1967 of Singapore.

7. A member can appoint the Chairman of the Meeting as his/her/its proxy but this is not mandatory.
8. If a member wishes to appoint the Chairman of the Meeting as proxy, such member (whether individual or corporate) must give specific instructions as to voting for, voting against, or abstentions from voting on, each resolution in the instrument appointing the Chairman of the Meeting as proxy. If no specific direction as to voting or abstentions from voting in respect of a resolution in the form of proxy, the appointment of the Chairman of the AGM as proxy for that resolution will be treated as invalid.
9. The instrument appointing a proxy or proxies, duly completed and signed, must be submitted to the Company in the following manner:
 - (a) by post to the Company’s Share Registrar, Tricor Barbinder Share Registration Services, at 9 Raffles Place, #26-01 Republic Plaza, Singapore 048619; or
 - (b) email to sg.is.proxy@sg.tricorglobal.com,

in either case, by no later than 10:30 a.m. on 22 April 2024, being 72 hours before the time fixed for the AGM.

A member who wishes to submit a proxy form must complete and sign the proxy form, before submitting it by post to the address provided above, or before scanning and sending it by email to the email address provided above.

10. Investors who hold shares through relevant intermediaries as defined in Section 181 of the Companies Act, including CPF and SRS investors, who wish to appoint a proxy or proxies (including the Chairman), should approach their respective agents to submit their votes at least seven (7) working days before the AGM in order to allow sufficient time for their respective relevant intermediaries to in turn submit a proxy form to vote on their behalf.
11. The instrument appointing a proxy or proxies must be under the hand of the appointor or by his/her attorney duly authorised in writing. Where the instrument appointing a proxy or proxies is executed by a corporation, it must be executed either under its common seal or under the hand of its attorney or a duly authorised officer.
12. A corporation which is a member may authorise by resolution of its directors or other governing body such person as it thinks fit to act as its representative at the AGM in accordance with Section 179 of the Companies Act 1967.

NOTICE OF THE NINETEENTH ANNUAL GENERAL MEETING

13. A depository's name must appear on the Depository Register maintained by The Central Depository (Pte) Limited as at 72 hours before the time fixed for holding the annual general meeting in order for the Depositor to be entitled to attend and vote at the annual general meeting.

Submission of Questions in Advance

1. Members may also submit questions relating to the resolutions to be tabled for approval at the AGM in advance of the AGM in the following manner by 10:30 a.m. on 18 April 2024:
 - (a) via email to: nghankiat@jiutianchemical.com; and/or
 - (b) by post to the Company's Share Registrar, Tricor Barbinder Share Registration Services, at 9 Raffles Place, #26-01 Republic Plaza, Singapore 048619.
2. For verification purpose, when submitting any questions via email or by post, members MUST provide the Company with their particulars (comprising full name (for individuals)/company name (for corporates), email address, contact number, NRIC/passport number/company registration number, shareholding type and number of shares held).
3. The Board and Management will endeavour to address the substantial and relevant questions from members at least 48 hours prior to the closing date and time of the lodgement of the proxy forms by uploading the responses to questions from members on the SGXNet. After the cut-off time for the submission of questions, if there are substantial and relevant questions received, the Board may address them at the AGM. Minutes of the AGM which will be published on the SGXNet within one (1) month after the date of the AGM.

Personal Data Privacy

By submitting an instrument appointing a proxy(ies) and/or representative(s) to attend, speak and vote at the annual general meeting and/or any adjournment thereof, a member of the Company (i) consents to the collection, use and disclosure of the member's personal data by the Company (or its agents) for the purpose of the processing and administration by the Company (or its agents) of proxies and representatives appointed for the annual general meeting (including any adjournment thereof) and the preparation and compilation of the attendance lists, minutes and other documents relating to the annual general meeting (including any adjournment thereof), and in order for the Company (or its agents) to comply with any applicable laws, listing rules, regulations and/or guidelines (collectively, the "Purposes"), (ii) warrants that where the member discloses the personal data of the member's proxy(ies) and/or representative(s) to the Company (or its agents), the member has obtained the prior consent of such proxy(ies) and/or representative(s) for the collection, use and disclosure by the Company (or its agents) of the personal data of such proxy(ies) and/or representative(s) for the Purposes, and (iii) agrees that the member will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the member's breach of warranty.

This page has been intentionally left blank.

IMPORTANT

- The Annual General Meeting of the Company (the "AGM") will be held physically with no option for members to participate virtually. Printed copies of this Proxy Form and accompanying Notice of AGM and Request Form will be sent to members by post.
- This proxy form is not valid for use by investors holding shares in the Company through relevant intermediaries (as defined in Section 181 of the Companies Act 1967 ("Investor") (including investors, holding through Central Provident Fund Investment Scheme ("CPF") or Supplementary Retirement Scheme ("SRS") ("CPF/SRS Investors") and shall be ineffective for all intents and purposes if used or purported to be used by them. An Investor who wishes to vote should instead approach his/her relevant intermediary as soon as possible to specify voting instructions. A CPF/SRS Investor who wishes to vote should approach his/her CPF Agent Banks or SRS Operator by 10.30 a.m. on 16 April 2024, being seven (7) working days before the AGM to submit his/her voting instructions.
- By submitting this Proxy Form, the member accepts and agrees to the personal data privacy terms set out in the Notice of AGM dated 9 April 2024.
- Please read the notes overleaf which contain instructions on, inter alia, the appointment of a proxy(ies).

I/We _____ (Name)

of _____ (Address)

being a member/members of **Jiutian Chemical Group Limited** (the "Company") hereby appoint:

Name	Address	NRIC/ Passport No.	Proportion of Shareholding (%)

*and/or (delete when appropriate)

Name	Address	NRIC/ Passport No.	Proportion of Shareholding (%)

or failing *him/her/them, the Chairman of the Nineteenth Annual General Meeting ("19th AGM") of the Company as *my/our *proxy/proxies to vote for *me/us on *my/our behalf at the 19th AGM of the Company, to be held at Royal Plaza on Scotts, Balmoral Hall, Level 5, 25 Scotts Road, Singapore 228220 on Thursday, 25 April 2024 at 10:30 a.m. and at any adjournment thereof.

*I/We direct *my/our *proxy/proxies to vote for, against and/or to abstain from voting on the Ordinary Resolutions to be proposed at the 19th AGM as indicated hereunder with an "x" in the spaces provided hereunder. If no specific directions as to voting are given, the *proxy/proxies will vote or abstain from voting at *his/her/their discretion.

(Voting will be conducted by poll manually. If you wish to exercise all your votes "For" or "Against", please indicate with a tick (✓) in the "For" or "Against" box. Alternatively, please indicate the number of votes "For" or "Against" as appropriate in the resolution. If you wish to "Abstain" from voting on the resolution, please indicate with a tick (✓) in the "Abstain" box. Alternatively, please indicate the number of shares which you wish to abstain from voting. In the absence of directions for the resolution, the appointment of Chairman of the Meeting as your proxy for the resolution will be treated as invalid. If no specific direction as to voting is given, the proxy/proxies will vote or abstain from voting at his/her/their discretion.)

No.	Resolutions	For*	Against*
Ordinary Business			
1.	To receive and adopt the Directors' Statement and the Audited Financial Statements for the financial year ended 31 December 2023 together with the Auditors' Report thereon.		
2.	To approve the payment of Directors' fee of S\$209,000 for the financial year ending 31 December 2024, to be paid quarterly in arrears. (FY2023: S\$209,000).		
3.	To re-elect Mr Koh Eng Kheng Victor as a Director.		
4.	To re-elect Mr Xu Aijun as a Director.		
5.	To re-appoint Messrs Baker Tilly TFW LLP as Auditors of the Company and authorise the Directors to fix their remuneration.		
Special Business			
6.	To authorise Directors to allot and issue Shares.		
7.	To approve the Proposed Renewal of the General Mandate for Interested Person Transactions.		
8.	To approve the Proposed Renewal of the Share Buyback Mandate.		

* Delete as appropriate

Dated this _____ day of _____ 2024

Total No. of Shares in	No. of Shares
CDP Register	
Register of Members	

Signature of Shareholder(s)
Or, Common Seal of Corporate Shareholder

IMPORTANT: PLEASE READ NOTES OVERLEAF BEFORE COMPLETING THIS PROXY FORM

1st fold along this line

Notes:

1. Please insert the total number of Shares held by you. If you have Shares entered against your name in the Depository Register (as defined in section 81SF of the Securities and Futures Act 2001 of Singapore), you should insert that number of Shares. If you have Shares registered in your name in the Register of Members, you should insert that number of Shares. If you have Shares entered against your name in the Depository Register and Shares registered in your name in the Register of Members, you should insert the aggregate number of Shares entered against your name in the Depository Register and registered in your name in the Register of Members. If no number is inserted, the instrument appointing a proxy or proxies shall be deemed to relate to all the Shares held by you.
2. A member of the Company who is not a relevant intermediary is entitled to appoint not more than two (2) proxies to attend, speak and vote on his/her behalf at the AGM. Such proxy need not be a Member of the Company. Where a Member appoints two proxies, the appointments shall be invalid unless he specifies the proportion of his shareholding (expressed as a percentage of the whole) to be represented by each proxy.
3. A member of the Company who is a relevant intermediary is entitled to appoint more than two (2) proxies to attend, speak and vote at the AGM, but each proxy must be appointed to exercise the rights attached to a different share or shares held by such member. Where such member appoints more than two (2) proxies, the number of shares to be represented by each proxy must be stated.
"Relevant Intermediary" has the meaning ascribed to it in Section 181 of the Companies Act 1967 of Singapore.
4. The instrument appointing a proxy or proxies, duly completed and signed, must be submitted to the Company in the following manner:-
 - (a) by post to the Company's Share Registrar, Tricor Barbinder Share Registration Services, at 9 Raffles Place, #26-01 Republic Plaza, Singapore 048619; or
 - (b) email to sg.is.proxy@sg.tricorglobal.comin either case, by no later than 10:30 a.m. on 22 April 2024, being 72 hours before the time fixed for the AGM.
A member who wishes to submit an instrument of proxy must complete and sign the proxy form, before submitting it by post to the address provided above, or before scanning and sending it by email to the email address provided above.
5. The instrument appointing a proxy or proxies must be under the hand of the appointor or by his/her attorney duly authorised in writing. Where the instrument appointing a proxy or proxies is executed by a corporation, it must be executed either under its common seal or under the hand of its attorney or a duly authorised officer.
6. Where an instrument appointing a proxy or proxies is signed and authorised on behalf of the appointor by an attorney, the letter of power of attorney (or other authority) or a duly certified copy thereof must (failing previous registration with the Company) be lodged with the instrument of proxy, failing which the instrument may be treated as invalid.
7. A corporation which is a member may authorise by resolution of its directors or other governing body such person as it thinks fit to act as its representative at the meeting, in accordance with Section 179 of the Companies Act 1967 of Singapore.
8. The submission of an instrument or form appointing a proxy by a shareholder does not preclude him from attending and voting in person at the AGM if he so wishes, in which case the appointment of the proxy will be deemed revoked and the Company reserves the right to refuse to admit any person appointed under the relevant instrument appointing the proxy to the AGM.
9. An investor who holds shares under the Central Provident Fund Investment Scheme ("CPF Investor") and/or the Supplementary Retirement Scheme ("SRS") (as may be applicable) may attend and cast his vote(s) at the AGM in person. CPF and SRS investors who are unable to attend the AGM but would like to vote, may inform their CPF and/or SRS Approved Nominees to appoint the Chairman of the AGM to act as their proxy, in which case, the CPF and SRS Investors shall be precluded from attending the AGM.
10. The Company shall be entitled to reject an instrument appointing a proxy or proxies which is incomplete, improperly completed, illegible or where the true intentions of the appointor are not ascertainable from the instructions of the appointor specified in the instrument appointing a proxy or proxies. In addition, in the case of a member whose shares are entered against his name in the Depository Register, the Company may reject any instrument appointing a proxy or proxies lodged if the member, being the appointor, is not shown to have shares entered against his name in the Depository Register as at seventy-two (72) hours before the time appointed for holding the AGM, as certified by The Central Depository (Pte) Ltd to the Company.

2nd fold along this line

Affix
Postage
Stamp

Jiutian Chemical Group Limited
350 Orchard Road
#21-03 Shaw House
Singapore 238868

Sealed here



九天化工集团有限公司
JIUTIAN CHEMICAL GROUP LIMITED

350 Orchard Road
#21-03 Shaw house
Singapore 238868
Main Line: (65) 6536 3738
Faxline: (65) 6536 3898